Pharmaceutical composition for preventing and / or treating hearing loss

A pharmaceutical composition targeting TRPC3 and TRPC6 channels addresses the need for effective treatments for hearing loss by inhibiting these channels, offering preventive and therapeutic benefits.

JP7594274B2Active Publication Date: 2024-12-04OSAKA UNIVERSITY
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020177736
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-24
Filing Date
2020-10-23
Publication Date
2024-12-04
Estimated Expiration
2040-10-23

AI Technical Summary

Technical Problem

There is a need for effective therapeutic drugs to prevent and treat hearing loss caused by factors such as exposure to loud sounds, genetics, aging, and the side effects of anticancer drugs like cisplatin, as existing treatments like steroid hormones, vitamin B12, and vasodilators lack sufficient evidence for their effectiveness.

Method used

Development of a pharmaceutical composition containing TRPC3 and/or TRPC6 channel inhibitors, represented by specific compounds or their salts and prodrugs, to prevent and treat hearing loss by modulating these channels.

Benefits of technology

The composition effectively inhibits TRPC3 and/or TRPC6 channels, providing preventive and therapeutic benefits for hearing loss, particularly sensorineural and drug-induced hearing loss.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594274000082
    Figure 0007594274000082
  • Figure 0007594274000083
    Figure 0007594274000083
  • Figure 0007594274000084
    Figure 0007594274000084
Patent Text Reader

Abstract

To provide a pharmaceutical composition for prevention / treatment of hearing loss.SOLUTION: The composition contains a compound represented by formula (1) in the figure, a salt thereof, or a prodrug thereof. [In the formula, A is a benzene ring; B is aryl or heteroaryl; X is an oxygen atom or a sulfur atom; Y is a nitrogen atom or a carbon atom; the double line consisting of a solid line and a broken line is a single or double bond when Y is a carbon atom, and is a single bond when Y is a nitrogen atom; and R1 is lower alkyl or the like and p is 0, 1 or 2, or (R1)p is oxo.]SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition for preventing and / or treating hearing loss. [Background technology]

[0002] Hearing is made up of a series of sensory perception systems consisting of the outer ear, middle ear, cochlea, and nervous system. Sound, which is vibration of air, passes through the ear canal, vibrates the eardrum, and is mechanically amplified by the middle ear bones before reaching the cochlea. In the cochlea, the mechanical signal of sound vibration is converted into an electrical signal by the hair cells, which are sensory cells, and the information is finally transmitted to the auditory cortex of the brain via nerve transmission. Damage to any component of this pathway causes a decrease in the ability to perceive sound, i.e., hearing loss. Hearing loss is classified into conductive hearing loss caused by damage to the inner ear and outer ear transmission system, and sensorineural hearing loss caused by damage from the cochlea to the nervous system. Hearing loss can be caused not only by exposure to loud noise, genetics, and aging, but also by side effects of anticancer drugs, especially platinum-based drugs (cisplatin, carboplatin, nedaplatin, oxaliplatin, etc.), and antibiotics. Cisplatin (CDDP; cis-diamminedichloroplatinum(II)) is used to treat cancer, especially childhood cancer, but it is known to cause hearing loss as a side effect. Generally, drugs such as steroid hormones, vitamin B12, ATP, and vasodilators are used to treat hearing loss, but there is insufficient evidence on their effectiveness and there is still room for debate. Therefore, the development of an effective treatment is eagerly awaited.

[0003] The TRP (Transient receptor potential) gene was identified in 1989 as the causative gene for photoreceptor response mutants in Drosophila. Subsequent research has revealed that many mammalian proteins have homology to the proteins encoded by the TRP gene, and they basically function as cation channels in the cell membrane. TRP channels form a superfamily with enormous functional diversity and are classified into groups such as TRPA, TRPV, TRPM, and TRPC. The TRPC (TRP classic or TRP canonical) group is further classified into subgroups TRPC1-C7.

[0004] It is known that TRPC3-deficient mice are resistant to pressure overload-induced cardiac fibrosis, and that administration of the TRPC3 channel inhibitor Pyr3 strongly suppresses pressure overload-induced cardiac fibrosis in mice (Non-Patent Documents 1 and 2). In addition, TRPC6-deficient mice are resistant to bleomycin-induced pulmonary fibrosis and renal interstitial fibrosis caused by unilateral ureteral obstruction (Non-Patent Documents 3 and 4), and administration of Pyr2 (BTP2), an inhibitor of TRPC3 and TRPC6 channels, suppresses renal interstitial fibrosis caused by unilateral ureteral obstruction in mice.

[0005] Compounds exhibiting TRPC3 inhibitory activity and / or TRPC6 inhibitory activity have been reported, such as Pyr2 (BTP2), Pyr3, Pyr4, GSK2332255B, GSK2833503A, SAR7334, and BI-749327 (Non-Patent Documents 5 to 11). In addition, US2019 / 0169168 (Patent Document 1) describes compounds exhibiting an inhibitory activity against the TRPC6 channel, and WO2019 / 215268 (Patent Document 2) describes compounds exhibiting an inhibitory activity against the TRPC3 channel and the TRPC6 channel. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] US2019 / 0169168A1

Patent document 2

Non-licensed literature

[0007] [Non-licensed document 1] Numaga-Tomita, T. et al. TRPC3-GEF-H1 axis mediates pressure overload-induced cardiac fibrosis. Sci. Rep. 6, 39383; doi: 10.1038 / srep39383 (2016).

Non-licensed Document 2

Non-licensed Document 4

Non-licensed Document 5

[0008] The objective of the present invention is to provide a pharmaceutical composition for preventing and / or treating hearing loss. [Means for solving the problem]

[0009] As a result of intensive research conducted by the present inventors to solve the above problems, it has been found that a substance having inhibitory activity against at least one TRPC channel selected from the group consisting of TRPC3 channel and TRPC6 channel (hereinafter, sometimes referred to as a "TRPC3 / 6 channel inhibitor"), such as a compound represented by the general formula (1) described below, a compound represented by (2), Pyr2, Pyr3, Pyr4, GSK2332255B, GSK2833503A, SAR7334, BI-749327, compounds disclosed in US2019 / 0169168 (e.g., compounds AA01 to AA95, etc.), compounds disclosed in WO2019 / 215268 (e.g., compounds BB01 to BB32, etc.), salts thereof, or prodrugs thereof are useful for the prevention and / or treatment of hearing loss, and the present invention has been completed. Representative aspects of the present invention are as follows.

[0010] Section 1. General formula (1) [ka]

[0011] [In the formula, A is an optionally substituted benzene ring. B is optionally substituted aryl or optionally substituted heteroaryl. X is an oxygen atom or a sulfur atom. Y is a nitrogen atom or a carbon atom. [ka] R 1 are each independently lower alkyl, or two R 1 may be bonded together to form a spiro ring or a bridged structure, or two R 1 may be bonded to each other to form a saturated condensed heterocyclic ring together with the carbon atom and nitrogen atom that constitute the ring containing Y. p is 0, 1, or 2. Or, (R 1 ) p is oxo.] A pharmaceutical composition for preventing and / or treating hearing loss, comprising a compound represented by the following formula (I):

[0012] Section 2. Item 2. The pharmaceutical composition according to Item 1, wherein, in formula (1), B is an optionally substituted monocyclic aryl or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaryl.

[0013] Section 3. In the general formula (1), A is any one of the following A-1) to A-16): A-1) halogen, A-2) hydroxyl group, A-3) Nitro, A-4) Cyano, A-5) carboxyl, A-6) optionally substituted amino, A-7) optionally substituted cyclic amino, A-8) optionally substituted lower alkyl, A-9) optionally substituted lower alkoxy, A-10) lower alkoxycarbonyl, A-11) lower alkylsulfonyl, A-12) carbamoyl optionally substituted by lower alkyl or lower alkylsulfonyl, A-13) optionally substituted cyclic aminocarbonyl, A-14) sulfamoyl optionally substituted by lower alkyl, A-15) optionally substituted cyclic aminosulfonyl, and A-16) Tetrazolyl Item 3. The pharmaceutical composition according to Item 1 or 2, wherein the benzene ring is optionally substituted with at least one group selected from the group consisting of:

[0014] Section 4. The pharmaceutical composition according to any one of items 1 to 3, wherein, in general formula (1), B is a monocyclic aryl or a monocyclic or bicyclic heteroaryl, the monocyclic aryl being optionally substituted with at least one group selected from the group consisting of B-1) to B-16) below, and the monocyclic or bicyclic heteroaryl being optionally substituted with at least one group selected from the group consisting of B-1) to B-17) below: B-1) halogen, B-2) hydroxyl group, B-3) Nitro, B-4) Cyano, B-5) Carboxyl B-6) optionally substituted amino, B-7) optionally substituted cyclic amino, B-8) optionally substituted lower alkyl, B-9) optionally substituted lower alkoxy, B-10) lower alkoxycarbonyl, B-11) lower alkylsulfonyl, B-12) carbamoyl optionally substituted with lower alkyl or lower alkylsulfonyl, B-13) optionally substituted cyclic aminocarbonyl, B-14) sulfamoyl optionally substituted with lower alkyl, B-15) optionally substituted cyclic aminosulfonyl, B-16) tetrazolyl, and B-17) Oxo.

[0015] Section 5. 5. The pharmaceutical composition according to any one of items 1 to 4, wherein in general formula (1), the 4-position of the benzisoxazole or benzisothiazole skeleton is substituted.

[0016] Section 6. In the general formula (1), B is a substituted pyridyl or substituted phenyl substituted at least on the carbon atom ortho to the carbon atom on the pyridine or benzene ring to which Y is bonded; Item 4. The pharmaceutical composition according to any one of Items 1 to 3.

[0017] Section 7. In the general formula (1), A is a benzene ring optionally substituted with at least one group selected from the group consisting of halogen, lower alkoxy, and lower alkyl optionally substituted with halogen; B is pyridyl or phenyl, and each of the following B-1), B-5), B-8), B-10), B-12), and B-13): B-1) halogen, B-5) carboxyl, B-8) optionally substituted lower alkyl, B-10) lower alkoxycarbonyl, B-12) carbamoyl optionally substituted with lower alkyl or lower alkylsulfonyl, and B-13) optionally substituted cyclic aminocarbonyl, may be substituted with at least one group selected from the group consisting of R 1 are each independently C1-C3 alkyl, or two R 1 are bonded to each other to form a methylene group, a dimethylene group, or a trimethylene group, Or, (R 1 ) p is oxo, Item 5. The pharmaceutical composition according to any one of Items 1 to 4.

[0018] Section 8. The compound represented by the general formula (1) is represented by the general formula (1A) [ka]

[0019] [In the formula, Z is a nitrogen atom or CH. Y is a nitrogen atom or a carbon atom. [ka] R 11 are, independently of each other, methyl or ethyl, or two R 11 may be bonded to each other to form a bridge structure via a methylene, dimethylene, or trimethylene. p is 0, 1, or 2. Or, (R 11 ) p is oxo. R 21 , R 22 , and R 23 are each independently a hydrogen atom, a halogen, a carbamoyl, or a trifluoromethyl. R 31 , R 32 , and R 33 are each independently a hydrogen atom, a halogen atom, a lower alkyl substituted with a halogen atom, a methyl atom, a carboxyl atom, a lower alkoxycarbonyl atom, a monomethylaminocarbonyl atom, or a dimethylaminocarbonyl atom. The compound represented by the formula: Item 8. The pharmaceutical composition according to any one of Items 1 to 4 and 7.

[0020] Section 9. In general formula (1A), R 21 is a chlorine atom or trifluoromethyl, R 22 and R 23 is a hydrogen atom, R 31 is a chlorine atom, R 32 is a hydrogen atom, R 33 is a hydrogen atom, carboxyl, or lower alkoxycarbonyl; Item 9. The pharmaceutical composition according to item 8.

[0021] Section 10. The pharmaceutical composition according to any one of items 1 to 4, wherein the compound is Compound 011, Compound 021, Compound 031, Compound 041, Compound 061, Compound 071, Compound 081, Compound 091, Compound 101, Compound 111, Compound 121, Compound 131, Compound 141, Compound 151, Compound 161, Compound 171, Compound 191, Compound 221, Compound 281, Compound 311, Compound 321, Compound 331, Compound 341, Compound 351, Compound 361, Compound 371, Compound 381, Compound 391, Compound 401, or Compound 431.

[0022] Section 11. General formula (2) [ka]

[0023] [In the formula, A is an optionally substituted benzene ring. B is optionally substituted aryl or optionally substituted heteroaryl. Y is a nitrogen atom or a carbon atom. [ka] R 1 are each independently lower alkyl, or two R 1 may be bonded together to form a spiro ring or a bridged structure, or two R 1 may be bonded to each other to form a saturated condensed heterocyclic ring together with the carbon atom and nitrogen atom that constitute the ring containing Y. p is 0, 1, or 2. Or, (R 1 ) p is oxo.] A pharmaceutical composition for preventing and / or treating hearing loss, comprising a compound represented by the following formula (I):

[0024] Section 12. A pharmaceutical composition for preventing and / or treating hearing loss, comprising a substance having inhibitory activity against at least one TRPC channel selected from the group consisting of TRPC3 channel and TRPC6 channel, a salt thereof, or a prodrug thereof.

[0025] Section 13. Item 13. The pharmaceutical composition according to item 12, wherein the substance having inhibitory activity against at least one TRPC channel selected from the group consisting of TRPC3 channel and TRPC6 channel is at least one compound selected from the group consisting of a compound represented by general formula (1), a compound represented by general formula (2), Pyr2, Pyr3, Pyr4, GSK2332255B, GSK2833503A, SAR7334, BI-749327, compounds AA01 to AA95 listed below, and compounds BB01 to BB32 listed below. Compound AA01: (4-(6-amino-4-methoxy-pyridin-3-yl)-piperazin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA02: (6-amino-4-methyl-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA03: (6-amino-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA04: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA05: (4-(6-amino-4-methoxy-pyridin-3-yl)-piperazin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA06: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-isopropoxy-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA07: ((R)-4-(6-amino-4-methyl-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA08: (7-(6-amino-4-methoxy-pyridin-3-yl)-4,7-diaza-spiro(2.5)oct-4-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA09: (7-(6-amino-4-methoxy-pyridin-3-yl)-4,7-diaza-spiro(2.5)oct-4-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA10: (6-amino-4-methyl-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA11: (4-(6-amino-5-methoxy-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA12: (4-(6-amino-pyridin-3-yl)-piperazin-1-yl)-(4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl)-methanone, Compound AA13: (4-(6-amino-pyridin-3-yl)-piperazin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA14: (6-amino-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA15: (4-(6-amino-pyridin-3-yl)-piperazin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA16: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA17: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA18: ((R)-4-(6-amino-4-methyl-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA19: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(2-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA20: ((R)-4-(6-amino-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA21: (4-(6-amino-5-methoxy-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA22: (6-amino-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl)-methanone, Compound AA23: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA24: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(4-methoxy-5-(4-trifluoromethyl-phenoxy)-pyridin-2-yl)-methanone, Compound AA25: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-cyclobutylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA26: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(4-methoxy-5-(1-methyl-cyclopropylmethoxy)-pyridin-2-yl)-methanone, Compound AA27: ((R)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-methoxymethyl-piperazin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA28: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl)-methanone, Compound AA29: (4-(6-amino-4-methyl-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA30: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-cyclohexyloxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA31: (4-(6-amino-4-methyl-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA32: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(4-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA33: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-(4-trifluoromethyl-phenoxy)-pyridin-2-yl)-methanone, Compound AA34: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-chloro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA35: (6-amino-4-methoxy-3,4,5,6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-cyclopentyloxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA36: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-isobutoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA37: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-cyclopropylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA38: (3-(6-amino-4-methoxy-pyridin-3-yl)-3,8-diaza-bicyclo(3.2.1)oct-8-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA39: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-isobutoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA40: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-cyclopropoxy-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA41: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA42: ((R)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA43: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-benzyloxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA44: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl)-methanone, Compound AA45: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(3,3-difluoro-cyclobutylmethoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA46: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(4-methoxy-5-propoxy-pyridin-2-yl)-methanone, Compound AA47: (4-(6-amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA48: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(2-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA49: (4-(6-amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA50: (1R)-1-((2R)-4-(6-amino-4-methoxypyridin-3-yl)-1-(5-phenoxypyridine-2-carbonyl)piperazin-2-yl)ethan-1-ol, Compound AA51: (3-(6-amino-4-methoxy-pyridin-3-yl)-3,8-diaza-bicyclo(3.2.1)oct-8-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA52: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(4-methoxy-5-phenethyloxy-pyridin-2-yl)-methanone, Compound AA53: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-cyclobutylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA54: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-difluoromethoxy-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA55: ((R)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-methoxymethyl-piperazin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA56: (4-(6-amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-(4-trifluoromethyl-phenoxy)-pyridin-2-yl)-methanone, Compound AA57: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(2-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA58: (1S)-1-((2R)-4-(6-amino-4-methoxypyridin-3-yl)-1-(5-phenoxypyridine-2-carbonyl)piperazin-2-yl)ethan-1-ol, Compound AA59: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(2,2-dimethyl-propoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA60: (4-(6-amino-5-methoxy-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl)-methanone, Compound AA61: (4-(6-amino-4-methoxy-pyridin-3-yl)-piperazin-1-yl)-(5-cyclopropylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA62: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-cyclohexyloxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA63: ((S)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl)-(5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA64: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(1-fluoromethyl-cyclopropylmethoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA65: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-ethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA66: (4-(6-amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl)-methanone, Compound AA67: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(2-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA68: (7-(6-amino-4-methoxy-pyridin-3-yl)-3-oxa-9-aza-bicyclo(3.3.1)non-9-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA69: ((R)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA70: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-((S)-1-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA71: ((S)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA72: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-isopropoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA73: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-phenethyloxy-pyridin-2-yl)-methanone, Compound AA74: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(2,2-dimethyl-propoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA75: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-(1-methyl-cyclopropylmethoxy)-pyridin-2-yl)-methanone, Compound AA76: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-propoxy-pyridin-2-yl)-methanone, Compound AA77: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-((R)-1-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA78: (4-(6-amino-4-methyl-pyridazin-3-yl)-piperidin-1-yl)-(5-cyclopropylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA79: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-((S)-1-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA80: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-(4-trifluoromethoxy-phenoxy)-pyridin-2-yl)-methanone, Compound AA81: ((R)-4-(6-amino-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA82: ((R)-4-(6-amino-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl)-(4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl)-methanone, Compound AA83: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(phenoxy)-4-ethoxy-pyridin-2-yl)-methanone, Compound AA84: (6-amino-4-cyclopropoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA85: (4-(6-amino-4-ethoxy-pyridazin-3-yl)-piperidin-1-yl)-(4-methoxy-5-(phenoxy)-pyridin-2-yl)-methanone, Compound AA86: (6-amino-4-propoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA87: (6-amino-4-ethoxy-3',4',5',6'-tetrahydro-2'H-(3,4')bipyridinyl-1'-yl)-(5-(4-trifluoromethyl-phenoxy)-4-methoxy-pyridin-2-yl)-methanone, Compound AA88: (4-(6-amino-pyridazin-3-yl)-piperidin-1-yl)-(5-(4-fluoro-phenoxy)-4-ethoxy-pyridin-2-yl)-methanone, Compound AA89: (3-(6-amino-pyridazin-3-yl)-8-aza-bicyclo(3.2.1)oct-8-yl)-(4-ethoxy-5-(4-fluoro-phenoxy)-pyridin-2-yl)-methanone, Compound AA90: 6-{1-{4-methoxy-5-(4-(trifluoromethyl)phenoxy)pyridine-2-carbonyl}piperidin-4-yl)-5-methylpyridazin-3-amine, Compound AA91: 5-Methoxy-6-(1-{5-(4-(trifluoromethyl)-phenoxy)-pyridine-2-carbonyl}piperidin-4-yl)-pyridazin-3-amine, Compound AA92: 4-Methoxy-5-(1-(4-methoxy-5-{(trans-3-(trifluoromethyl)cyclobutyl)-methoxy}pyridine-2-carbonyl)-piperidin-4-yl)pyridin-2-amine, Compound AA93: 4-Methoxy-5-(1-(4-methoxy-5-{((cis-3-(trifluoromethyl)-cyclobutyl)methoxy}-pyridine-2-carbonyl)piperidin-4-yl)pyridin-2-amine, Compound AA94: 4-Methoxy-5-(1-{4-methoxy-5-((2)-3,3,3-trifluoro-2-methylpropoxy)-pyridine-2-carbonyl}piperidin-4-yl)pyridin-2-amine, Compound AA95: 5-{1-{5-((2,2-difluorocyclobutyl)-methoxy)-4-methoxy-pyridine-2-carbonyl}-piperidin-4-yl)-4-methoxypyridin-2-amine, Compound BB01: 1-(4-(4-fluorophenyl)-2-(triazol-2-yl)cyclopentyl)piperidin-3-amine, Compound BB02: 1-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl)pyrazole-4-carbonitrile, Compound BB03: 1-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl)pyrazole-3-carbonitrile, Compound BB04: 1-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl)pyrrole-3-carbonitrile, Compound BB05: 1-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl)triazole-4-carbonitrile, Compound BB06: 1-(2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl)pyrazole-4-carbonitrile, Compound BB07: 1-(2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl)pyrazole-4-carbonitrile, Compound BB08: 1-(4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl)piperidin-3-amine, Compound BB09: 5-fluoro-1-(4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl)piperidin-3-amine, Compound BB10: 5-fluoro-1-(4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Compound BB11: 5-fluoro-1-(4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl)piperidin-3-amine, Compound BB12: 1-(4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl)piperidin-3-amine, Compound BB13: 1-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl)-1,2,4-triazole-3-carbonitrile, Compound BB14: 4-(2-(3-amino-1-piperidyl)-4-(4-fluoro-3-hydroxy-phenyl)cyclopentoxy)benzonitrile, Compound BB15: 4-(2-(3-amino-1-piperidyl)-4-(4-fluoro-3-methoxy-phenyl)cyclopentoxy)benzonitrile, Compound BB16: 4-(2-(3-amino-1-piperidyl)-4-(3-fluorophenyl)cyclopentoxy)-3-chloro-benzonitrile, Compound BB17: 4-(2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy)benzonitrile, Compound BB18: 4-(2-(5-amino-3,3-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy)benzonitrile, Compound BB19: 4-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy)-2-fluoro-benzonitrile, Compound BB20: 2-(2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxy)benzonitrile, Compound BB21: 4-(2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxy)-3-chloro-benzonitrile, Compound BB22: 6-(2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy)-5-methyl-pyridazine-3-carbonitrile, Compound BB23: 1-(2-(4-chloropyridazin-3-yl)oxy-4-(4-fluorophenyl)cyclopentyl)piperidin-3-amine, Compound BB24: 6-(2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy)pyridazine-3-carbonitrile, Compound BB25: 1-(4-(4-fluorophenyl)-2-(5-fluoropyridazin-3-yl)oxy-cyclopentyl)piperidin-3-amine, Compound BB26: 6-(2-((R)-3-aminopiperidin-1-yl)-4-(4-fluorophenyl)cyclopentyloxy)nicotinonitrile, Compound BB27: 6-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy)pyridine-3-carbonitrile, Compound BB28: 1-(4-(4-fluorophenyl)-2-pyridazin-3-yloxy-cyclopentyl)piperidin-3-amine, Compound BB29: 5-fluoro-1-(4-(4-fluorophenyl)-pyrimidin-4-yloxy-cyclopentyl)piperidin-3-amine, Compound BB30: 2-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy)pyrimidine-5-carbonitrile, Compound BB31: 5-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy)pyrazine-2-carbonitrile, Compound BB32: 5-(2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy)pyrimidine-2-carbonitrile.

[0026] Section 14. 14. The pharmaceutical composition according to any one of Items 1 to 13, which is for oral administration.

[0027] Section 15. 15. The pharmaceutical composition according to any one of Items 1 to 14, wherein the hearing loss is sensorineural hearing loss.

[0028] Section 16. 16. The pharmaceutical composition according to any one of Items 1 to 15, wherein the hearing loss is caused by a drug. Effect of the Invention

[0029] The pharmaceutical composition disclosed in the present invention has a preventive or therapeutic effect against hearing loss by containing a substance having inhibitory activity against at least one TRPC channel selected from the group consisting of TRPC3 channel and TRPC6 channel (e.g., a compound represented by general formula (1), a compound represented by general formula (2), Pyr2, Pyr3, Pyr4, GSK2332255B, GSK2833503A, SAR7334, BI-749327, a compound disclosed in US2019 / 0169168, a compound disclosed in WO2019 / 215268, etc.), a salt thereof, or a prodrug thereof. TRPC3 / 6 channel inhibitors, such as compounds represented by general formula (1) or (2), have activity of inhibiting the activity of TRPC channels, such as TRPC3 and / or TRPC6 channels, preferably the activity of the TRPC6 channel, and are therefore useful for the prevention and / or treatment of TRPC-related diseases, such as diseases caused by TRPC3 channel activity, diseases caused by TRPC6 channel activity, or diseases caused by both TRPC3 channel activity and TRPC6 channel activity (these may be collectively referred to as "TRPC3- and / or TRPC6-related diseases" in this specification), particularly hearing loss. [Brief description of the drawings]

[0030] [Figure 1] 1 is a graph showing the measurement results of changes in calcium ion concentration in TRPC6-expressing cells obtained in Test Example 1. The horizontal axis represents time (seconds), and the vertical axis represents intracellular calcium ion concentration ([Ca2+]i (nM)). [Diagram 2] 2 is a graph showing the measurement results of changes in calcium ion concentration in TRPC3-expressing cells obtained in Test Example 1. The horizontal axis represents time (seconds), and the vertical axis represents intracellular calcium ion concentration ([Ca2+]i (nM)). [Diagram 3] 3 is a graph showing the increase in calcium ions in TRPC6-expressing cells obtained in Test Example 2. The unit of the vertical axis is "%." [Figure 4] 4 is a graph showing the increase in calcium ions in TRPC6-expressing cells obtained in Test Example 3. The unit of the vertical axis is "%." [Diagram 5] 5 is a graph showing the electrophysiological evaluation of TRPC6-expressing cells obtained in Test Example 4. In this figure, the vertical axis of the graph on the left side is current (nA) and the horizontal axis is time (seconds). Also, a and b in the graph on the right side respectively show the current-voltage characteristic curves at the points a and b in the graph on the left side. [Figure 6] FIG. 6 is a photograph showing the results of Western blotting in Test Example 5. [Figure 7]7 is a graph showing α-SMA expression by immunofluorescence staining obtained using skin fibroblasts in Test Example 6. The vertical axis of the graph represents fluorescence intensity ( / pixel). [Figure 8] 8 is a graph showing α-SMA expression by immunofluorescence staining obtained using cardiac fibroblasts in Test Example 6. The vertical axis of the graph represents fluorescence intensity ( / pixel). [Figure 9] FIG. 9 is a graph showing the hearing thresholds measured in Test Example 7. [Figure 10] FIG. 10 is a graph showing the amount of change (dB) in the hearing threshold at each wavelength (Hz) measured in Test Example 7. [Figure 11] FIG. 11 is a graph showing the plasma platinum concentration (ng / ml) measured in Test Example 8. [Figure 12] FIG. 12 is a graph showing the number of neuromasts in zebrafish measured in Test Example 9. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] One embodiment of the present invention is a pharmaceutical composition for preventing and / or treating hearing loss, comprising a compound represented by the following general formula (1), a salt thereof, or a prodrug thereof.

[0032] General formula (1) [ka]

[0033] [In the formula, A is an optionally substituted benzene ring. B is optionally substituted aryl or optionally substituted heteroaryl. X is an oxygen atom or a sulfur atom. Y is a nitrogen atom or a carbon atom. [ka] R 1are each independently lower alkyl, or two R 1 may be bonded together to form a spiro ring or a bridged structure, or two R 1 may be bonded to each other to form a saturated condensed heterocyclic ring together with the carbon atom and nitrogen atom that constitute the ring containing Y. p is 0, 1, or 2. or, (R 1 ) p is oxo.]

[0034] In the present invention, examples of the substituent of the "optionally substituted benzene ring" include halogen, hydroxyl group, nitro, cyano, carboxyl, optionally substituted amino, optionally substituted cyclic amino, optionally substituted lower alkyl, optionally substituted lower alkoxy, lower alkoxycarbonyl, lower alkylsulfonyl, carbamoyl optionally substituted with lower alkyl or lower alkylsulfonyl, optionally substituted cyclic aminocarbonyl, sulfamoyl optionally substituted with lower alkyl, optionally substituted cyclic aminosulfonyl, tetrazolyl, etc. The substituent may be one type alone or two or more types.

[0035] In the present invention, "aryl" includes, for example, monocyclic or bicyclic aryl, specifically, phenyl, naphthyl, etc.

[0036] In the present invention, the aryl in "optionally substituted aryl" is as defined above. Examples of the substituent of the optionally substituted aryl include halogen, hydroxyl group, nitro, cyano, carboxyl, optionally substituted amino, optionally substituted cyclic amino, optionally substituted lower alkyl, optionally substituted lower alkoxy, lower alkoxycarbonyl, lower alkylsulfonyl, carbamoyl optionally substituted with lower alkyl or lower alkylsulfonyl, optionally substituted cyclic aminocarbonyl, sulfamoyl optionally substituted with lower alkyl, optionally substituted cyclic aminosulfonyl, tetrazolyl, oxo, etc. The substituent may be one type alone or two or more types.

[0037] In the present invention, "oxo" is a group represented by "=O".

[0038] In the present invention, examples of "heteroaryl" include monocyclic or bicyclic nitrogen-containing heteroaryl, and specific examples include monocyclic or bicyclic nitrogen-containing heteroaryl containing one or more (e.g., 1 to 3, 1 or 2, 1) nitrogen atoms on the ring and optionally containing one or more (e.g., 1 to 3, 1 or 2, 1) sulfur atoms or oxygen atoms as other heteroatoms. Specific examples of heteroaryl include pyrrolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furazanyl, oxadiazolyl, thiadiazolyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothienyl, isobenzothienyl, indazolyl, quinolyl, isoquinolyl, purinyl, phthalazinyl, pteridyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofurazanyl, benzothiadiazolyl, benzotriazolyl, isoxazolo[4,5-d]pyridazyl, benzisoxazolyl, and benzisothiazolyl. Preferred are monocyclic nitrogen-containing heteroaryl or benzimidazolyl.

[0039] In the present invention, the heteroaryl in "optionally substituted heteroaryl" is as defined above. Examples of the substituent of the optionally substituted heteroaryl include halogen, hydroxyl group, nitro, cyano, carboxyl, optionally substituted amino, optionally substituted cyclic amino, optionally substituted lower alkyl, optionally substituted lower alkoxy, lower alkoxycarbonyl, lower alkylsulfonyl, carbamoyl optionally substituted with lower alkyl or lower alkylsulfonyl, optionally substituted cyclic aminocarbonyl, sulfamoyl optionally substituted with lower alkyl, optionally substituted cyclic aminosulfonyl, tetrazolyl, oxo, etc. The substituent may be one type alone or two or more types.

[0040] In the present invention, examples of "lower alkyl" include C1-C8 alkyl having a linear, branched, or cyclic structure, preferably C1-C6 alkyl, more preferably C1-C4 alkyl, and particularly preferably C1-C3 alkyl. Specifically, examples of linear or branched lower alkyl include methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, isobutyl, t-butyl, n-pentyl, neopentyl, n-hexyl, isohexyl, 3-methylpentyl, and the like, and examples of lower alkyl having a cyclic structure include cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, and the like. Preferred examples include methyl, ethyl, 2-propyl, t-butyl, cyclopropyl, and the like.

[0041] In the present invention, "halogen" includes a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, etc., and is preferably a fluorine atom or a chlorine atom.

[0042] In the present invention, "optionally substituted amino" refers to an optionally substituted non-cyclic amino, and examples of the substituent include lower alkyl (e.g., methyl, ethyl, propyl, etc.), C1-C8 acyl (e.g., acetyl, propionyl, etc.), aryl (e.g., phenyl, etc.), or heteroaryl. The substituent may be one type alone or two or more types. Preferred optionally substituted amino includes, for example, amino, methylamino, dimethylamino, ethylamino, diethylamino, cyclohexylamino, acetylamino, benzoylamino, phenylamino, etc.

[0043] In the present invention, the "cyclic amino" refers to, for example, a 5- to 7-membered cyclic amino having a nitrogen atom as a ring-constituting atom and optionally further containing one or more oxygen atoms (for example, 1 to 3, 1 or 2, 1), and examples thereof include pyrrolidino, piperidino, piperazino, morpholino, etc., and preferably includes pyrrolidino, morpholino, etc.

[0044] In the present invention, the cyclic amino in the "cyclic amino which may be substituted" is as defined above. Examples of the substituent of the cyclic amino include lower alkyl, lower alkoxy, amino, hydroxyl, nitro, cyano, carboxyl, oxo, etc. The cyclic amino may be substituted with at least one group selected from the group consisting of the above-mentioned substituents. The number of the substituents may be, for example, 0, 1, 2, or 3, and preferably 0, 1, or 2. Specific examples of the cyclic amino which may be substituted include pyrrolidino, piperidino, piperazino, 4-methylpiperidino, morpholino, 2-pyrrolidonyl, etc., and preferably pyrrolidino, morpholino, etc.

[0045] In the present invention, the lower alkyl in the "optionally substituted lower alkyl" is as defined above. Examples of the substituent of the lower alkyl include a hydroxyl group; amino; C1-C8 alkylamino (e.g., methylamino, ethylamino, propylamino, t-butylamino, etc.); C1-C8 alkoxy (e.g., methoxy, ethoxy, 1-propyloxy, 2-propyloxy, t-butyloxy, etc.); halogen (e.g., fluorine atom, chlorine atom, bromine atom, etc.); halo C1-C8 alkoxy (e.g., trifluoromethoxy, etc.); aliphatic heterocyclic groups (e.g., morpholino, piperidinyl, pyrrolidinyl, 4-methyl-1-piperazino, etc.); aryl (e.g., phenyl, 1-naphthalene, etc.); butyl, etc.); heteroaryl (for example, pyridyl, thienyl, furanyl, etc.); carboxyl; C1-C8 alkoxycarbonyl (for example, methoxycarbonyl, ethoxycarbonyl, 1-propoxycarbonyl, 2-propoxycarbonyl, t-butoxycarbonyl, etc.); carbamoyl which may be substituted with lower alkyl (for example, carbamoyl, methylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, etc.); cyclic aminocarbonyl (for example, pyrrolidinocarbonyl, piperidinocarbonyl, morpholinocarbonyl, etc.), etc. Preferred substituents include methylamino, ethylamino, dimethylamino, diethylamino, methoxy, ethoxy, 2-propyloxy, t-butoxycarbonyl, hydroxyl group, fluorine atom, chlorine atom, trichloromethyl, trifluoromethyl, trifluoromethoxy, morpholino, piperidino, pyrrolidino, carboxyl, methoxycarbonyl, ethoxycarbonyl, morpholinocarbonyl, phenyl, pyridyl, etc. The optionally substituted lower alkyl may be substituted with at least one group selected from the group consisting of the above-mentioned substituents, and the number of substituents is, for example, 0, 1, 2 or 3, preferably 0, 1 or 2.

[0046] In the present invention, "lower alkyl substituted with halogen" refers to an alkyl in which all hydrogen atoms are substituted with halogen. The halogen and lower alkyl in the lower alkyl substituted with halogen are as defined above. It is preferable that the halogens substituting the alkyl are the same. The lower alkyl substituted with halogen is preferably trichloromethyl or trifluoromethyl, and more preferably trifluoromethyl.

[0047] In the present invention, examples of "lower alkoxy" include C1-C8 alkoxy having a linear, branched, or cyclic structure, preferably C1-C6 alkoxy, more preferably C1-C4 alkoxy, and particularly preferably C1-C3 alkoxy. Specifically, linear or branched alkoxy includes methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-butoxy, isobutoxy, t-butoxy, n-pentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 3-methylpentyloxy, and the like. Examples of alkoxy having a cyclic structure include cyclopropoxy, cyclopropylmethoxy, cyclobutyloxy, cyclobutylmethoxy, cyclopentyloxy, cyclopentylmethoxy, cyclohexyloxy, cyclohexylmethoxy, cyclohexylethoxy, and the like. Preferred examples include methoxy, ethoxy, 2-propoxy, t-butoxy, cyclopropoxy, and the like.

[0048] In the present invention, the lower alkoxy in the "optionally substituted lower alkoxy" is as defined above. Examples of the substituent of the lower alkoxy include a hydroxyl group; amino; C1-C8 alkylamino (e.g., methylamino, ethylamino, propylamino, t-butylamino, etc.); C1-C8 alkoxy (e.g., methoxy, ethoxy, 1-propyloxy, 2-propyloxy, t-butoxy, etc.); halogen (e.g., fluorine atom, chlorine atom, bromine atom, etc.); halo C1-C8 alkoxy (e.g., trifluoromethoxy, etc.); aliphatic heterocyclic groups (e.g., morpholino, piperidinyl, pyrrolidinyl, 4-methyl-1-piperazino, etc.); aryl (e.g., phenyl, 1-naphthyl, etc.); etc.); heteroaryl (e.g., pyridyl, thienyl, furanyl, etc.); carboxyl; C1-C8 alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, 1-propyloxycarbonyl, 2-propyloxycarbonyl, t-butoxycarbonyl, etc.); carbamoyl which may be substituted with lower alkyl (e.g., carbamoyl, methylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, etc.); cyclic aminocarbonyl (e.g., pyrrolidinocarbonyl, piperidinocarbonyl, morpholinocarbonyl, etc.), etc. Preferred substituents include methylamino, ethylamino, dimethylamino, diethylamino, methoxy, ethoxy, 2-propyloxy, t-butoxycarbonyl, hydroxyl group, fluorine atom, chlorine atom, trifluoro, morpholino, piperidino, pyrrolidino, carboxyl, methoxycarbonyl, morpholinocarbonyl, phenyl, pyridyl, etc. The optionally substituted lower alkoxy is optionally substituted with at least one group selected from the group consisting of the above-mentioned substituents, and the number of the substituents is, for example, 0, 1, 2 or 3, and preferably 0, 1 or 2.

[0049] In the present invention, the lower alkoxy in "lower alkoxycarbonyl" is as defined above. The lower alkoxycarbonyl is a group in which the above-mentioned lower alkoxy is bonded to a carbonyl. The lower alkoxycarbonyl includes, for example, a C1-C8 alkoxycarbonyl having a linear, branched, or cyclic structure. Specifically, the linear or branched alkoxycarbonyl includes methoxycarbonyl, ethoxycarbonyl, 1-propoxycarbonyl, 2-propoxycarbonyl, 1-butoxycarbonyl, 2-butoxycarbonyl, isobutoxycarbonyl, t-butoxycarbonyl, and the like. Examples of C1-C8 alkoxycarbonyl containing a cyclic structure include cyclopropoxycarbonyl, cyclopropylmethoxycarbonyl, cyclobutyloxycarbonyl, cyclobutylmethoxycarbonyl, cyclopentyloxycarbonyl, cyclopentylmethoxycarbonyl, cyclohexyloxycarbonyl, cyclohexylmethoxycarbonyl, cyclohexylethoxycarbonyl, etc. Examples of preferred lower alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, 2-propoxycarbonyl, cyclopropoxycarbonyl, etc.

[0050] In the present invention, the lower alkyl in "lower alkylsulfonyl" is as defined above. Lower alkylsulfonyl is a group in which the above-mentioned lower alkyl is bonded to sulfonyl. Examples of lower alkylsulfonyl include C1-C8 alkylsulfonyl having a linear, branched, or cyclic structure, and specifically, examples of linear or branched alkylsulfonyl include methanesulfonyl, ethanesulfonyl, 1-propylsulfonyl, 2-propylsulfonyl, 1-butylsulfonyl, 2-butylsulfonyl, isobutylsulfonyl, and t-butylsulfonyl. Examples of C1-C8 alkylsulfonyl having a cyclic structure include cyclopropylsulfonyl, cyclopropylmethylsulfonyl, cyclobutylsulfonyl, cyclobutylmethylsulfonyl, cyclopentylsulfonyl, cyclopentylmethylsulfonyl, cyclohexylsulfonyl, cyclohexylmethylsulfonyl, and cyclohexylethylsulfonyl. Preferred examples include methanesulfonyl, ethanesulfonyl, 2-propanesulfonyl, and cyclopropanesulfonyl.

[0051] In the present invention, in "carbamoyl optionally substituted with lower alkyl or lower alkylsulfonyl", lower alkyl and lower alkylsulfonyl are as defined above. Carbamoyl optionally substituted with lower alkyl or lower alkylsulfonyl includes "carbamoyl optionally substituted with lower alkyl" and "carbamoyl optionally substituted with lower alkylsulfonyl".

[0052] "Carbamoyl which may be substituted with lower alkyl" refers to a group in which one or two of the above-mentioned lower alkyls may be bonded to the carbamoyl. When two lower alkyls are bonded, the lower alkyls may be the same or different. Examples of carbamoyl which may be substituted with lower alkyl include carbamoyl, and aminocarbonyl substituted with C1-C8 alkyl, including linear, branched, or cyclic structures. Specific examples of carbamoyl which may be substituted with lower alkyl include carbamoyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, 2-propylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, ethylmethylaminocarbonyl, methylpropylaminocarbonyl, dicyclohexylaminocarbonyl, and the like.

[0053] "Carbamoyl which may be substituted with lower alkylsulfonyl" refers to a group in which one or two of the above-mentioned lower alkylsulfonyls may be bonded to the carbamoyl. When two lower alkylsulfonyls are bonded, the lower alkylsulfonyls may be the same or different. Examples of the carbamoyl which may be substituted with lower alkylsulfonyl include carbamoyl, or aminocarbonyl substituted with C1-C8 alkylsulfonyl, including linear, branched, or cyclic structures. Examples of the linear or branched C1-C8 alkylsulfonylaminocarbonyl include methanesulfonylaminocarbonyl, ethanesulfonylaminocarbonyl, 1-propylsulfonylaminocarbonyl, 2-propylsulfonylaminocarbonyl, 1-butylsulfonylaminocarbonyl, 2-butylsulfonylaminocarbonyl, isobutylsulfonylaminocarbonyl, t-butylsulfonylaminocarbonyl, and the like. Examples of C1-C8 alkylsulfonylaminocarbonyl containing a cyclic structure include cyclopropylsulfonylaminocarbonyl, cyclopropylmethylsulfonylaminocarbonyl, cyclobutylsulfonylaminocarbonyl, cyclobutylmethylsulfonylaminocarbonyl, cyclopentylsulfonylaminocarbonyl, cyclopentylmethylsulfonylaminocarbonyl, cyclohexylsulfonylaminocarbonyl, cyclohexylmethylsulfonylaminocarbonyl, cyclohexylethylsulfonylaminocarbonyl, etc. Preferred carbamoyl which may be substituted with lower alkylsulfonyl includes carbamoyl, methanesulfonylaminocarbonyl, ethanesulfonylaminocarbonyl, 2-propylsulfonylaminocarbonyl, cyclopropylsulfonylaminocarbonyl, etc.

[0054] In the present invention, the optionally substituted cyclic amino in "optionally substituted cyclic aminocarbonyl" is as defined above. The optionally substituted cyclic aminocarbonyl is a group in which the above-mentioned optionally substituted cyclic amino is bonded to carbonyl. Specific examples of the optionally substituted cyclic aminocarbonyl include pyrrolidinocarbonyl, piperidinocarbonyl, piperazinocarbonyl, 4-methylpiperidino, morpholinocarbonyl, 2-pyrrolidonylcarbonyl, etc., and preferably include pyrrolidinocarbonyl, morpholinocarbonyl, etc.

[0055] In the present invention, the lower alkyl in "sulfamoyl which may be substituted with lower alkyl" is as defined above. Sulfamoyl which may be substituted with lower alkyl is a group in which one or two of the above-mentioned lower alkyls may be bonded to sulfamoyl. When two lower alkyls are bonded, the lower alkyls may be the same or different. Examples of sulfamoyl which may be substituted with lower alkyl include sulfamoyl; aminosulfonyl substituted with C1-C8 alkyl having a linear, branched, or cyclic structure, and specifically include sulfamoyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, 2-propylaminosulfonyl, dimethylaminosulfonyl, diethylaminosulfonyl, ethylmethylaminosulfonyl, methylpropylaminosulfonyl, dicyclohexylaminosulfonyl, and the like.

[0056] In the present invention, the optionally substituted cyclic amino in "optionally substituted cyclic aminosulfonyl" is as defined above. The optionally substituted cyclic aminosulfonyl is a group in which the above-mentioned optionally substituted cyclic amino is bonded to sulfonyl. Specific examples of the optionally substituted cyclic aminosulfonyl include pyrrolidinosulfonyl, piperidinosulfonyl, piperazinosulfonyl, 4-methylpiperidinosulfonyl, morpholinosulfonyl, 4-piperidonylsulfonyl, etc., and preferably include pyrrolidinosulfonyl, morpholinosulfonyl, etc.

[0057] [ka]

[0058] In the compound represented by the general formula (1), A is an optionally substituted benzene ring. The substituent of A includes, for example, at least one selected from the group consisting of the following A-1) to A-16), and when there are multiple substituents, they may be the same or different from each other. A-1) halogen, A-2) hydroxyl group, A-3) Nitro, A-4) Cyano, A-5) carboxyl, A-6) optionally substituted amino, A-7) optionally substituted cyclic amino, A-8) optionally substituted lower alkyl, A-9) optionally substituted lower alkoxy, A-10) lower alkoxycarbonyl, A-11) lower alkylsulfonyl, A-12) carbamoyl optionally substituted by lower alkyl or lower alkylsulfonyl, A-13) optionally substituted cyclic aminocarbonyl, A-14) sulfamoyl optionally substituted by lower alkyl, A-15) optionally substituted cyclic aminosulfonyl, A-16) Tetrazolyl.

[0059] The number of substituents in A is, for example, 0 to 5, 0 to 4, or 0 to 3, preferably 0, 1 or 2, and more preferably 0 or 1. When a plurality of substituents are present, they may be the same or different.

[0060] Other examples of the substituent of A include at least one selected from the group consisting of A-1 and A-3 to A-16, and at least one selected from the group consisting of A-1 and A-3 to A-16 excluding methoxy.

[0061] A preferred substituent for A is at least one selected from the group consisting of halogen; lower alkoxy; carbamoyl which may be substituted with lower alkyl or lower alkylsulfonyl; and lower alkyl which may be substituted with halogen. A more preferred substituent for A is at least one selected from the group consisting of halogen; lower alkoxy; carbamoyl; and lower alkyl which may be substituted with halogen. An even more preferred substituent for A is at least one selected from the group consisting of halogen, methoxy, ethoxy, carbamoyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, and trifluoroethyl. A more preferred substituent for A is at least one selected from the group consisting of halogen, methoxy, ethoxy, carbamoyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, and trifluoroethyl. A particularly preferred substituent is at least one selected from the group consisting of a chlorine atom, a fluorine atom, and trifluoromethyl.

[0062] In the compound represented by general formula (1), the substituent A may be bonded to any of the carbon atoms at positions 4, 5, 6, and 7 of the benzisoxazole or benzisothiazole skeleton, but is preferably bonded to at least one of the carbon atoms at positions 4, 5, and 6, more preferably to the carbon atom at position 4 and / or 5, and particularly preferably to the carbon atom at position 4. In the present invention, the position numbers of the atoms constituting the benzisoxazole or benzisothiazole skeleton are as follows: [ka]

[0063] [In the formula, A and X are the same as above.]

[0064] In the compound represented by general formula (1), A is particularly preferably a benzene ring in which a halogen, a lower alkoxy, or a lower alkyl which may be substituted with a halogen is bonded to the carbon atom at position 4 of the benzisoxazole or benzisothiazole skeleton, and the carbon atoms at positions 5, 6, and 7 are unsubstituted.

[0065] In the compound represented by the general formula (1), B is an aryl which may be substituted or a heteroaryl which may be substituted. The aryl which may be substituted or the heteroaryl which may be substituted are as defined above. The aryl may be, for example, phenyl or naphthyl, and is preferably phenyl. The heteroaryl is preferably a monocyclic nitrogen-containing heteroaryl which does not contain other heteroatoms as ring-constituting atoms, or benzimidazolyl. The monocyclic nitrogen-containing heteroaryl which does not contain other heteroatoms as ring-constituting atoms is preferably a 5- or 6-membered heteroaryl which contains one nitrogen atom as a ring-constituting heteroatom, and examples thereof include pyrrolyl and pyridyl, and pyridyl is preferred, with 2-pyridyl being even more preferred. The benzimidazolyl is preferably benzimidazol-3-yl.

[0066] When B is a monocyclic aryl, B may be substituted with at least one group selected from the group consisting of B-1) to B-16) below.When B is a monocyclic or bicyclic heteroaryl, B may be substituted with at least one group selected from the group consisting of B-1) to B-17) below. B-1) halogen, B-2) hydroxyl group, B-3) Nitro, B-4) Cyano, B-5) Carboxyl B-6) optionally substituted amino, B-7) optionally substituted cyclic amino, B-8) optionally substituted lower alkyl, B-9) optionally substituted lower alkoxy, B-10) lower alkoxycarbonyl, B-11) lower alkylsulfonyl, B-12) carbamoyl optionally substituted with lower alkyl or lower alkylsulfonyl, B-13) optionally substituted cyclic aminocarbonyl, B-14) sulfamoyl optionally substituted with lower alkyl, B-15) optionally substituted cyclic aminosulfonyl, B-16) tetrazolyl, B-17) Oxo.

[0067] The number of substituents in B is, for example, 0 or at least 1, 0 to 5, 0 to 4, preferably 0 to 3, and more preferably 0, 1 or 2. When there are multiple substituents, they may be the same or different.

[0068] The substituent for B is preferably at least one selected from the group consisting of halogen, carboxyl, optionally substituted lower alkyl, lower alkoxycarbonyl, carbamoyl optionally substituted with lower alkyl or lower alkylsulfonyl, and optionally substituted cyclic aminocarbonyl, and specifically at least one selected from the group consisting of halogen, carboxyl, methyl, ethyl, 1-propyl, 2-propyl, hydroxymethyl, carboxymethyl, trichloromethyl, trifluoromethyl, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylmethylaminocarbonyl, methanesulfonylaminocarbonyl, pyrrolidinocarbonyl, and morpholinocarbonyl.

[0069] More preferably, the substituent for B is at least one selected from the group consisting of halogen; carboxyl; lower alkyl; lower alkyl substituted with halogen; lower alkoxycarbonyl; and carbamoyl which may be substituted with lower alkyl, and specifically, at least one selected from the group consisting of halogen, carboxyl, methyl, ethyl, trichloromethyl, trifluoromethyl, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, monomethylaminocarbonyl, and dimethylaminocarbonyl.

[0070] Particularly preferred examples of the substituent for B include at least one selected from the group consisting of a chlorine atom, a fluorine atom, methyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, and dimethylaminocarbonyl.

[0071] In the compound represented by general formula (1), when Y is a nitrogen atom, B is preferably an optionally substituted phenyl or an optionally substituted pyridyl, and when Y is a carbon atom, B is preferably an optionally substituted phenyl, an optionally substituted pyridyl, or 2-oxobenzimidazol-3-yl, and more preferably an optionally substituted phenyl or an optionally substituted pyridyl.

[0072] In the compound represented by general formula (1), when B is substituted pyridyl or substituted phenyl, it is preferred that one or two, preferably one, of the carbon atoms at the ortho position relative to the carbon atom on the pyridine or benzene ring bonded to Y are substituted. The substituent bonded to the carbon atom at the ortho position may be any of the substituents for B described above, but is preferably a halogen, more preferably a chlorine atom or a fluorine atom, and even more preferably a chlorine atom.

[0073] In addition, in the compound represented by general formula (1), when B is substituted pyridyl or substituted phenyl, it is preferable that the carbon atom at the para-position to the carbon atom on the pyridine or benzene ring bonded to Y is unsubstituted or substituted with carboxyl.

[0074] In addition, in the compound represented by general formula (1), when B is substituted pyridyl or substituted phenyl, it is preferable that all of the carbon atoms at the meta position relative to the carbon atom on the pyridine or benzene ring bonded to Y are not substituted.

[0075] In the compound represented by general formula (1), when B is a substituted pyridyl or a substituted phenyl, it is more preferred that one or two, preferably one, of the carbon atoms at the ortho position relative to the carbon atom on the pyridine or benzene ring bonded to Y are substituted with a chlorine atom or a fluorine atom, the carbon atom at the meta position is unsubstituted, and the carbon atom at the para position is unsubstituted or substituted with a carboxyl, methoxycarbonyl, or ethoxycarbonyl. When Y is a nitrogen atom and B is a substituted 2-pyridyl, it is particularly preferred that the carbon atom ortho to the carbon atom on the pyridine ring bonded to Y is substituted with a chlorine atom or a fluorine atom, all of the carbon atoms at the meta positions are unsubstituted, and the carbon atoms at the para positions are unsubstituted or substituted with carboxyl. When Y is a nitrogen atom and B is a substituted phenyl, it is particularly preferred that one of the two carbon atoms at the ortho position to the carbon atom on the benzene ring bonded to Y is substituted with a chlorine atom or a fluorine atom, and all other carbon atoms constituting the phenyl are unsubstituted. When Y is a carbon atom and B is a substituted 2-pyridyl, it is particularly preferred that the carbon atom ortho to the carbon atom on the pyridine ring bonded to Y is substituted with a chlorine atom or a fluorine atom, all of the carbon atoms at the meta position are unsubstituted, and the carbon atoms at the para position are unsubstituted or substituted with carboxyl, methoxycarbonyl or ethoxycarbonyl. When Y is a carbon atom and B is a substituted phenyl, it is particularly preferred that one of the two carbon atoms in the ortho position relative to the carbon atom on the benzene ring bonded to Y is substituted with a chlorine atom or a fluorine atom, the other ortho carbon atom is unsubstituted, all of the meta carbon atoms are unsubstituted, and the para carbon atom is unsubstituted or substituted with carboxyl, methoxycarbonyl or ethoxycarbonyl.

[0076] In the compound represented by general formula (1), X is an oxygen atom or a sulfur atom, and is preferably an oxygen atom.

[0077] In the compound represented by general formula (1), Y is a nitrogen atom or a carbon atom, and is preferably a nitrogen atom.

[0078] In the compound represented by general formula (1), Y is a nitrogen atom or a carbon atom, and is preferably a nitrogen atom.

[0079] [ka]

[0080] In the compound represented by the general formula (1), R 1 are each independently lower alkyl, or two R 1 may be bonded together to form a spiro ring or a bridged structure, or two R 1 may be bonded to each other to form a saturated condensed heterocyclic ring together with the carbon atom and nitrogen atom that constitute the ring containing Y.

[0081] R1 When R is lower alkyl, the preferred 1 Examples of the alkyl group include linear or branched C1 to C3 alkyl groups, more preferably methyl and ethyl, and even more preferably methyl.

[0082] 2 R's 1 are bonded to each other to form a spiro ring or a bridged structure, the formation of a spiro ring means that two R 1 is bonded, and the R 1 and bond to each other to form a ring together with the carbon atom.

[0083] 2 R's 1 are bonded to each other to form a spiro ring or a bridged structure, the formation of a bridged structure means that one R is bonded to each of two of the carbon atoms constituting the ring including Y in the general formula (1). 1 is bonded, and the R 1 This refers to the case where two molecules are bonded to each other.

[0084] 2 R's 1 are bonded to each other to form a spiro ring or a bridged structure, for example, two R 1 are bonded to each other to form a bridged structure by forming methylene, dimethylene, trimethylene, or tetramethylene, or to form a spiro ring by forming dimethylene or trimethylene. 1 are bonded to each other to form a crosslinked structure, such as methylene, dimethylene, or trimethylene. Particularly preferred is a crosslinked structure formed by dimethylene as shown in the following structural formula: [ka]

[0085] 2 R's 1are bonded to each other to form a saturated condensed heterocyclic ring together with the carbon atom and nitrogen atom constituting the ring containing Y, means that one R is bonded to each of two adjacent carbon atoms constituting the ring containing Y in the general formula (1). 1 is bonded, and the R 1 R and R are bonded to each other to form a saturated condensed heterocyclic ring together with the carbon atom and nitrogen atom that constitute the ring containing Y. The saturated condensed heterocyclic ring referred to here is a heterocyclic ring (pyrazine ring or piperidine ring) containing Y and R 1 It means two fused rings with a saturated carbocyclic ring containing:

[0086] Examples of the saturated condensed heterocycle include a condensed ring of a pyrazine ring or a piperidine ring with a cyclopentane ring or a cyclohexane ring. Specific examples of the saturated condensed heterocycle include octahydrocyclopentapyridine, octahydrocyclopentapyrazine, decahydroquinoline, and decahydroquinoxaline.

[0087] Preferred R 1 is a bridged structure formed by C1-C3 alkyl or dimethylene, and more preferred R 1 is a bridged structure formed by methyl, ethyl or dimethylene shown in the above structural formula.

[0088] In the compound represented by the general formula (1), p is 0, 1, or 2.

[0089] In the compound represented by the general formula (1), (R 1 ) p can be oxo.

[0090] Among the compounds represented by general formula (1), their salts, or their prodrugs, the compounds represented by the following general formula (1A), their salts, or their prodrugs are preferred. A pharmaceutical composition for preventing and / or treating hearing loss, which contains the compound represented by the following general formula (1A), its salt, or its prodrug, is also included in the present invention. [ka]

[0091] [In the formula, Z is a nitrogen atom or CH. Y is a nitrogen atom or a carbon atom. [ka] R 11 are, independently of each other, methyl or ethyl, or two R 11 may be bonded to each other to form a bridge structure via a methylene, dimethylene, or trimethylene. p is 0, 1, or 2. Or, (R 11 ) p is oxo. R 21 , R 22 , and R 23 are each independently a hydrogen atom, a halogen, a carbamoyl, or a trifluoromethyl. R 31 , R 32 , and R 33 are each independently a hydrogen atom, a halogen, a lower alkyl substituted with a halogen, a methyl, a carboxyl, a lower alkoxycarbonyl, a monomethylaminocarbonyl, or a dimethylaminocarbonyl.

[0092] In the compound represented by the general formula (1A), Z is a nitrogen atom or CH. When Y is a nitrogen atom, Z is preferably a nitrogen atom.

[0093] In the compound represented by general formula (1A), Y is a nitrogen atom or a carbon atom.

[0094] In the compound represented by the general formula (1A), R 11 are, independently of each other, methyl or ethyl, or two R 11 may be bonded to each other to form a bridge structure via a methylene, dimethylene, or trimethylene.

[0095] R 11is preferably a crosslinked structure consisting of methyl or ethyl, or dimethylene or trimethylene, and more preferably a crosslinked structure consisting of methyl or diethylene.

[0096] 2 R's 11 are bonded to each other to form a bridge structure with methylene, dimethylene, or trimethylene, one R is attached to each of two of the carbon atoms constituting the ring containing Y in general formula (1A). 11 is bonded, and the R 11 These groups bond with each other to form a methylene, dimethylene, or trimethylene group, forming a bridged structure in the piperazine ring.

[0097] The ring containing Y in the general formula (1A) is R 11 When substituted with (R 11 ) p is oxo or is as shown in the following structural formula: [ka]

[0098] [In the formula, * represents the side bonded to the carbon atom at the 3-position of isobenzoxazole, and R 111 represents C1-C3 alkyl. R 111 is preferably methyl or ethyl, more preferably methyl.

[0099] In the general formula (1A), (R 11 ) p may be oxo.

[0100] In the compound represented by the general formula (1A), R 21 , R 22 , and R 23 are each independently a hydrogen atom, a halogen atom, a carbamoyl, or a trifluoromethyl; R 21 , R 22 , and R 23It is preferred that at least one of R is halogen, carbamoyl, or trifluoromethyl. 21 R is preferably a chlorine atom, a fluorine atom, carbamoyl, or trifluoromethyl, and more preferably a chlorine atom or trifluoromethyl. 22 is preferably a hydrogen atom, a chlorine atom or trifluoromethyl, and more preferably a hydrogen atom. 23 is preferably a hydrogen atom, a chlorine atom, or trifluoromethyl, and more preferably a hydrogen atom. 21 is halogen (preferably a chlorine atom or a fluorine atom) or trifluoromethyl, and R 22 and R 23 It is particularly preferable that both of are hydrogen atoms.

[0101] In the compound represented by the general formula (1A), R 31 , R 32 , and R 33 are each independently a hydrogen atom, a halogen atom, a lower alkyl group substituted with a halogen atom, a methyl group, a carboxyl group, a lower alkoxycarbonyl group, a monomethylaminocarbonyl group, or a dimethylaminocarbonyl group. 31 is preferably a hydrogen atom, halogen, trichloromethyl, trifluoromethyl, or methyl, more preferably a halogen, trichloromethyl, trifluoromethyl, or methyl, and particularly preferably a chlorine atom. 32 is preferably a hydrogen atom, a halogen atom or a methyl, and more preferably a hydrogen atom. 33 is preferably a hydrogen atom, a halogen, a carboxyl, a methoxycarbonyl, an ethoxycarbonyl, a monomethylaminocarbonyl, or a dimethylaminocarbonyl, more preferably a hydrogen atom, a carboxyl, a methoxycarbonyl, or an ethoxycarbonyl, and particularly preferably a hydrogen atom or a carboxyl.

[0102] R 31 , R 32 , and R 33 A preferred example of31 is a halogen (preferably a chlorine atom or a fluorine atom), and R 32 is a hydrogen atom, and R 33 R is a hydrogen atom or a carboxyl group. 21 When is a halogen (preferably a chlorine atom), R 31 is a halogen (preferably a chlorine atom or a fluorine atom), and R 32 is a hydrogen atom, and R 33 is preferably a hydrogen atom. 21 When is trihalomethyl (preferably trifluoromethyl), R 31 is a halogen (preferably a chlorine atom or a fluorine atom), and R 32 is a hydrogen atom, and R 33 is preferably a hydrogen atom, carboxyl, methoxycarbonyl, or ethoxycarbonyl. 21 When is carbamoyl, R 31 is a halogen (preferably a chlorine atom or a fluorine atom, more preferably a chlorine atom), and R 32 is a hydrogen atom, and R 33 is preferably a hydrogen atom. 21 is a chlorine atom or trifluoromethyl, and R 22 and R 23 is a hydrogen atom, and R 31 is a chlorine atom, and R 32 is a hydrogen atom, and R 33 is preferably a hydrogen atom or a carboxyl group.

[0103] Specific examples of the compound represented by general formula (1), its salt, or its prodrug include, for example, Compound 011, Compound 021, Compound 031, Compound 041, Compound 051, Compound 061, Compound 071, Compound 081, Compound 091, Compound 101, Compound 111, Compound 121, Compound 131, Compound 141, Compound 151, Compound 161, Compound 171, Compound 181, Compound 191, Compound 201, Compound 211, Compound 221, Compound 231, Compound 241, Compound 251, Compound 261, Compound 271, Compound 281, Compound 291, Compound 301, Compound 311, Compound 321, Compound 331, Compound 341, Compound 351, Compound 361, Compound 371, Compound 381, Compound 391, Compound 401, Compound 411, Compound 421, Compound 431, Compound 441, Compound 451, Compound 461, Compound 471, Compound 481, Compound 491, Compound 501, Compound 511, Compound 521, Compound 531, Compound 541, Compound 551, Compound 561, Compound 571, Compound 581, Compound 591, Compound 601, Compound 611, Compound 621, Compound 631, Compound 641, Compound 651, Compound 661, Compound 671, Compound 681, Compound 691, Compound 701, Compound 711, Compound 721, Compound 731, Compound 741, Compound 751, Compound 761, Compound 771, Compound 781, Compound 791, Compound 801, Compound 811 Compounds include Compound 221, Compound 231, Compound 241, Compound 251, Compound 261, Compound 271, Compound 281, Compound 291, Compound 301, Compound 311, Compound 321, Compound 331, Compound 341, Compound 351, Compound 361, Compound 371, Compound 381, Compound 391, Compound 401, Compound 411, Compound 421, or Compound 431, and preferably include the following compounds, salts thereof, or prodrugs thereof:

[0104] [ka]

[0105] [ka]

[0106] More preferably, the compound represented by the general formula (1), a salt thereof, or a prodrug thereof is Compound 011, Compound 021, Compound 031, Compound 041, Compound 061, Compound 071, Compound 081, Compound 091, Compound 101, Compound 111, Compound 121, Compound 131, Compound 141, Compound 151, Compound 161, Compound 171, Compound 191, Compound 221, Compound 281, Compound 311, Compound 321, Compound 331, Compound 341, Compound 351, Compound 361, Compound 371, Compound 381, Compound 391, Compound 401, or Compound 431, a salt thereof, or a prodrug thereof, and more preferably, Compound 011, Compound 021, Compound 031, Compound 041, Compound 061, Compound 071, Compound 081, Compound 091, Compound 101, Compound 111, Compound 121, Compound 131, Compound 141, Compound 151, Compound 161, Compound 171, Compound 191, Compound 321, Compound 351, Compound 361, Compound 371, Compound 381, Compound 401, or Compound 431, a salt thereof, or a prodrug thereof, and even more preferably Compound 011, Compound 031, Compound 041, Compound 061, Compound 071, or Compound 191, Compound 361, Compound 371, Compound 381, Compound 401, or Compound 431, a salt thereof, or a prodrug thereof, and particularly preferably Compound 011, Compound 031, Compound 041, Compound 061, Compound 071, or Compound 191, Compound 361, Compound 371, Compound 381, or Compound 401, a salt thereof, or a prodrug thereof.

[0107] The present invention includes a pharmaceutical composition for preventing and / or treating hearing loss, which contains a compound represented by the following general formula (2), a salt thereof, or a prodrug thereof. The compound, its salt, or its prodrug may have an effect of preventing and / or treating hearing loss. In addition, the compound, its salt, or its prodrug may have an activity of regulating or inhibiting the activity of a TRPC channel, such as a TRPC3 and / or TRPC6 channel, preferably a TRPC6 channel. In addition, the compound or its salt may be an intermediate compound of the compound represented by general formula (1).

[0108] [ka]

[0109] [ka]

[0110] [ka]

[0111] In general formula (2), it is preferable that the carbon atom at the ortho position relative to the carbon atom of the A ring (benzene ring) bonded to the carbon atom constituting the oxime structure has a substituent. The substituent is the same as the substituent in the A ring (benzene ring) in general formula (1) unless otherwise specified. Therefore, the substituent may be, for example, at least one group selected from the group consisting of the above A-1) to A-16). In addition, in general formula (2), the bond between the nitrogen atom and the hydroxyl group is represented by a wavy line, i.e., the line represented below, which indicates that the compound represented by general formula (2) may be any of the geometric isomers E and Z, or a mixture thereof, which exist due to the partial structure ">C=N-OH". This also applies to compounds represented by wavy lines other than general formula (2). [ka]

[0112] Among the compounds represented by the general formula (2), salts thereof, or prodrugs thereof, the compounds represented by the following general formula (2A), salts thereof, or prodrugs thereof are preferred. [ka]

[0113] [ka]

[0114] Among the compounds represented by general formula (2), their salts, or their prodrugs, the compounds represented by the following general formula (2B), their salts, or their prodrugs are preferred. The compounds represented by the following general formula (2B) or their salts are also preferred as intermediate compounds in the production of the compounds represented by general formula (1). [ka]

[0115] [ka] G 1 is halogen, lower alkylsulfonyl which may be substituted with halogen, or benzenesulfonyl which may be substituted with lower alkyl or nitro.

[0116] [ka] is as described above. In addition, the compound represented by general formula (2B) or a salt thereof has geometric isomers, E and Z isomers, which exist due to the partial structure ">C=N-OH", and when the compound represented by general formula (2B) or a salt thereof is used as an intermediate compound in the production of the compound represented by general formula (1), the E isomer is preferred.

[0117] G 1 Examples of the halogen represented by the formula (I) include a chlorine atom, a fluorine atom, a bromine atom, and an iodine atom.

[0118] G 1The lower alkylsulfonyl in the lower alkylsulfonyl which may be substituted with halogen represented by the formula: is as defined above. The lower alkylsulfonyl is a group in which a lower alkyl is bonded to a sulfonyl, and the lower alkyl may be substituted with a halogen. The lower alkylsulfonyl which may be substituted with a halogen may, for example, be a linear or branched C1-C6 alkyl (preferably C1-C4 alkyl, more preferably C1-C3 alkyl)sulfonyl which may be substituted with 1 to 3 halogens, and specific examples thereof include methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, etc.

[0119] G 1 Examples of benzenesulfonyl which may be substituted with lower alkyl represented by the following formula (I) include benzenesulfonyl which may be substituted with 1 to 3 (preferably 1 or 2, more preferably 1) linear or branched C1 to C6 alkyl (preferably C1 to C4 alkyl, more preferably C1 to C3 alkyl), and specific examples include p-toluenesulfonyl.

[0120] G 1 Examples of the benzenesulfonyl optionally substituted with nitro represented by the formula (I) include benzenesulfonyl optionally substituted with 1 to 3 (preferably 1) nitro, and specific examples thereof include o-nitrobenzenesulfonyl, p-nitrobenzenesulfonyl, and the like.

[0121] Preferred G 1 is a chlorine atom, a fluorine atom, a bromine atom, methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, p-toluenesulfonyl, or p-nitrobenzenesulfonyl. 1 is a chlorine atom or a bromine atom.

[0122] The compound represented by formula (2), a salt thereof, or a prodrug thereof includes, for example, the following compounds, a salt thereof, or a prodrug thereof. [ka]

[0123] The compound represented by formula (2), a salt thereof, or a prodrug thereof is preferably compound 062, compound 202, compound 362, compound 372, a salt thereof, or a prodrug thereof, and more preferably the (E)-isomer of compound 202, the (E)-isomer of compound 362, the (Z)-isomer of compound 362, or the (Z)-isomer of compound 372, a salt thereof, or a prodrug thereof.

[0124] The above compounds can be produced by, for example, appropriately modifying or combining the production methods 1 to 3 described below, methods similar thereto, known methods, etc. The compounds used as raw materials may be used as salts. The methods shown below are merely illustrative, and the compounds can be produced by other methods as appropriate based on the knowledge of those skilled in organic synthesis. In addition, when using non-commercially available 1,2-benzisothiazole or its derivatives or 1,2-benzisoxazole or its derivatives as raw materials, they can be produced and procured by referring to the methods described in the following publications. Advances in heterocyclic chemistry, Heterocyclic Chemistry in the 21st Century: A Tribute to Alan Katritzky, Elsevier, Cambridge (2017). RA Shastri, Review on Synthesis of 3-Substituted 1,2-Benzisoxazole Derivatives, Chem. Sci. Trans., 2016: 5; 8-20.

[0125] In each reaction in the production, functional groups can be protected as necessary. Protective groups and techniques for protecting and deprotecting them can be appropriately applied using known methods, such as those described in TW Greene and PG M Huts, "Protective Groups in Organic Synthesis", 3rd Ed., John Wiley and Sons, Inc., New York (1999).

[0126] [Manufacturing method 1] In one embodiment, the compound represented by general formula (1) can be produced by the synthesis scheme shown in the following reaction scheme-1. That is, the compound represented by general formula (1) can be produced from the compound represented by general formula (3) and the compound represented by general formula (4).

[0127] [ka]

[0128] [ka] G 2 is halogen, lower alkylsulfonyl which may be substituted with halogen, or benzenesulfonyl which may be substituted with lower alkyl or nitro.

[0129] [ka]

[0130] G 2 Examples of the halogen represented by the formula (I) include a chlorine atom, a fluorine atom, a bromine atom, and an iodine atom.

[0131] G 2The lower alkyl in the lower alkylsulfonyl which may be substituted with halogen represented by the formula: is as defined above. The lower alkylsulfonyl is a group in which a lower alkyl is bonded to a sulfonyl, and the lower alkyl may be substituted with a halogen. The lower alkylsulfonyl which may be substituted with a halogen may be, for example, a linear or branched C1-C6 alkyl (preferably C1-C4 alkyl, more preferably C1-C3 alkyl)sulfonyl which may be substituted with 1 to 3 halogens, and specific examples thereof include methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, etc.

[0132] G 2 Examples of benzenesulfonyl which may be substituted with lower alkyl represented by the following formula (I) include benzenesulfonyl which may be substituted with 1 to 3 linear or branched C1 to C6 alkyl (preferably C1 to C4 alkyl, more preferably C1 to C3 alkyl), and specific examples include p-toluenesulfonyl.

[0133] G 2 Examples of the benzenesulfonyl optionally substituted with nitro represented by the formula (I) include benzenesulfonyl optionally substituted with 1 to 3 (preferably 1) nitro, and specific examples thereof include o-nitrobenzenesulfonyl, p-nitrobenzenesulfonyl, and the like.

[0134] Preferred G 2 is a chlorine atom, a fluorine atom, a bromine atom, methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, p-toluenesulfonyl, or p-nitrobenzenesulfonyl.

[0135] The reaction between the compound represented by the general formula (3) and the compound represented by the general formula (4) can be carried out, for example, in an inert solvent in the presence or absence of a base. If necessary, an activator may be added to the reaction system. The compound represented by the general formula (3) and the compound represented by the general formula (4) are known compounds and can be produced by known methods.

[0136] Examples of the inert solvent include ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, dimethoxymethane, etc., aromatic hydrocarbon solvents such as toluene, benzene, xylene, etc., halogenated hydrocarbon solvents such as dichloromethane, chloroform, dichloroethane, carbon tetrachloride, etc., ketone solvents such as acetone, etc., aprotic solvents such as dimethyl sulfoxide, N,N-dimethylformamide (DMF), acetonitrile, etc., pyridine, etc. Two or more of these solvents may be mixed in an appropriate ratio for use.

[0137] Examples of the base include metal hydrides such as sodium hydride and potassium hydride, metal hydroxides such as potassium hydroxide and sodium hydroxide, metal carbonates such as potassium carbonate, potassium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, and cesium carbonate, alkylamines such as triethylamine and ethyldiisopropylamine, and metal alkoxides such as sodium methoxide and potassium t-butoxide.

[0138] The amount of the base used is usually 1 mol or more, preferably 1 to 5 mol, and more preferably 1 to 2 mol, relative to 1 mol of the compound represented by formula (4).

[0139] The amount of the compound represented by formula (3) used is usually 0.2 mol or more, preferably 0.2 to 2 mol, and more preferably 0.2 to 1.5 mol, per mol of the compound represented by formula (4).

[0140] The reaction temperature is usually -50° C. to 180° C., preferably -30° C. to 180° C., more preferably -10° C. to 180° C. Microwaves may be used to promote the reaction, and in that case, the reaction temperature is, for example, 80° C. to 180° C., preferably 100° C. to 180° C. The reaction time is usually 10 minutes to 48 hours, preferably 10 minutes to 24 hours.

[0141] [Manufacturing method 2] In one embodiment, the compound represented by general formula (1B) can be produced by the synthesis scheme shown in the following reaction scheme-2. That is, the compound represented by general formula (1B) can be produced from the compound represented by general formula (5) and the compound represented by general formula (6).

[0142] [ka]

[0143] [In the formula, A, B, X, R 1 , and p are the same as above. G 3 is halogen, lower alkylsulfonyl which may be substituted with halogen, or benzenesulfonyl which may be substituted with lower alkyl or nitro.

[0144] In reaction scheme 2, A, B, X, and R 1 , and p is as above.

[0145] G 3 Examples of the halogen represented by the formula (I) include a chlorine atom, a fluorine atom, a bromine atom, and an iodine atom.

[0146] G 3 The lower alkyl in the lower alkylsulfonyl which may be substituted with halogen represented by the formula: is as defined above. The lower alkylsulfonyl is a group in which a lower alkyl is bonded to a sulfonyl, and the lower alkyl may be substituted with a halogen. The lower alkylsulfonyl which may be substituted with a halogen may be, for example, a linear or branched C1-C6 alkyl (preferably C1-C4 alkyl, more preferably C1-C3 alkyl)sulfonyl which may be substituted with 1 to 3 halogens, and specific examples thereof include methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, etc.

[0147] G 3Examples of benzenesulfonyl which may be substituted with lower alkyl represented by the following formula (I) include benzenesulfonyl which may be substituted with 1 to 3 linear or branched C1 to C6 alkyl (preferably C1 to C4 alkyl, more preferably C1 to C3 alkyl), and specific examples include p-toluenesulfonyl.

[0148] G 3 Examples of the benzenesulfonyl optionally substituted with nitro represented by the formula (I) include benzenesulfonyl optionally substituted with 1 to 3 (preferably 1) nitro, and specific examples thereof include o-nitrobenzenesulfonyl, p-nitrobenzenesulfonyl, and the like.

[0149] Preferred G 3 is a chlorine atom, a fluorine atom, a bromine atom, methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, p-toluenesulfonyl, or p-nitrobenzenesulfonyl.

[0150] A compound represented by general formula (1B) can be obtained by coupling a compound represented by general formula (5) with a compound represented by general formula (6). The compound represented by general formula (5) and the compound represented by general formula (6) are known compounds and can be produced by known methods.

[0151] This reaction can be carried out, for example, in an inert solvent in the presence of a base.

[0152] Examples of the inert solvent include ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, dimethoxymethane, etc., aromatic hydrocarbon solvents such as toluene, benzene, xylene, etc., halogenated hydrocarbon solvents such as dichloromethane, chloroform, dichloroethane, carbon tetrachloride, etc., ketone solvents such as acetone, etc., aprotic solvents such as dimethyl sulfoxide, N,N-dimethylformamide (DMF), acetonitrile, etc., pyridine, etc. Two or more of these solvents may be mixed in an appropriate ratio for use.

[0153] Examples of the base include metal hydrides such as sodium hydride and potassium hydride, metal hydroxides such as potassium hydroxide and sodium hydroxide, metal carbonates such as potassium carbonate, potassium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, and cesium carbonate, alkylamines such as triethylamine and ethyldiisopropylamine, and metal alkoxides such as sodium methoxide and potassium t-butoxide.

[0154] The amount of the compound represented by general formula (6) used is usually 0.5 mol or more, further 1 mol or more, preferably 0.9 to 2 mol, and more preferably 0.9 to 1.5 mol, relative to 1 mol of the compound represented by general formula (5).

[0155] The amount of the base used is usually 1 mol or more, preferably 1 to 5 mol, and more preferably 1 to 2 mol, relative to 1 mol of the compound represented by formula (5).

[0156] The reaction temperature is usually 30° C. to a temperature 10° C. higher than the boiling point of the solvent, and preferably 80° C. to a temperature 10° C. higher than the boiling point of the solvent. Microwaves may be used to promote the reaction, and in that case, the reaction temperature is, for example, 80° C. to 180° C., and preferably 100° C. to 180° C. The reaction time is usually 10 minutes to 48 hours, and preferably 10 minutes to 24 hours.

[0157] Furthermore, the reaction between the compound represented by general formula (5) and the compound represented by general formula (6) can also be carried out by utilizing the Buchward reaction. For example, the compound represented by general formula (5) and the compound represented by general formula (6) are reacted in a solvent in the presence of a palladium catalyst, a phosphine ligand, and a base.

[0158] Examples of the palladium catalyst include divalent palladium catalysts such as Pd(OAc)2, PdCl2, allylpalladium(II) chloride (dimer), bis(acetonitrile)palladium(II) dichloride, and bis(benzonitrile)palladium(II) dichloride; and zero-valent palladium catalysts such as Pd2(dba)3 (tris(dibenzylideneacetone)dipalladium(0)), bis(dibenzylideneacetone)palladium(0), and palladium on carbon (Pd / C).

[0159] Examples of the phosphine ligand include bidentate phosphine ligands such as BINAP ((2,2'-bis(diphenylphosphanyl)-1,1'-bisnaphthalene) and Xphos (2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl).

[0160] The base may be a strong base such as t-BuONa (sodium tert-butoxide).

[0161] In this reaction, the amount of the compound represented by general formula (6) used is usually 0.5 mol or more, and even 1 mol or more, preferably 0.9 to 2 mol, and more preferably 1 to 1.5 mol, relative to 1 mol of the compound represented by general formula (5).

[0162] The amount of the palladium catalyst used is usually 0.005 to 1 mol, and preferably 0.01 to 0.2 mol, per 1 mol of the compound represented by the general formula (5).

[0163] The amount of the phosphine ligand used is usually 0.5 to 5 mol, preferably 1 to 2 mol, per 1 mol of the palladium catalyst.

[0164] The amount of the base used is usually 0.5 mol or more, further 1 mol or more, and preferably 1 to 2 mol, relative to 1 mol of the compound represented by the general formula (5).

[0165] The reaction temperature is usually 40° C. to 150° C., preferably 80° C. to 110° C., and the reaction time is usually 1 to 24 hours, preferably 3 to 12 hours.

[0166] [Manufacturing method 3] In one embodiment, the compound represented by general formula (1) or (2) can be produced by the synthesis scheme shown in the following reaction scheme-3. That is, the compound represented by general formula (1C) can be produced by converting the compound represented by general formula (7) to the compound represented by general formula (8), reacting it with the compound represented by general formula (4) to produce the oxime compound represented by general formula (2B), and ring-closing it. Note that a person skilled in the art can understand that the compound represented by general formula (2) can be produced by using a suitable corresponding compound having an optionally substituted benzene ring A instead of the compound represented by general formula (7) or (8) in the reaction shown in reaction scheme-3. In addition, the compound represented by general formula (7) is a known compound and can be produced by a known method.

[0167] [ka]

[0168] [ka]

[0169] [ka]

[0170] G 4 Examples of the halogen represented by the formula (I) include a chlorine atom, a fluorine atom, a bromine atom, and an iodine atom.

[0171] Step 1, i.e., a step of converting a compound represented by general formula (7) to a compound represented by general formula (8), can be performed, for example, by reacting a compound represented by general formula (7) with a halogenating agent in an inert solvent.

[0172] Examples of the inert solvent in this reaction include ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, dimethoxymethane, etc., aromatic hydrocarbon solvents such as toluene, benzene, xylene, etc., halogenated hydrocarbon solvents such as dichloromethane, chloroform, dichloroethane, carbon tetrachloride, etc., ketone solvents such as acetone, etc., aprotic solvents such as dimethyl sulfoxide, N,N-dimethylformamide (DMF), acetonitrile, etc., pyridine, etc. Two or more of these solvents may be mixed in an appropriate ratio for use.

[0173] Examples of the halogenating agent include general halogenating agents such as N-bromosuccinimide and N-chlorosuccinimide.

[0174] The amount of the halogenating agent used is usually equimolar to excess molar amount, preferably 1 to 5 times molar, more preferably 1 to 2 times molar, relative to the compound represented by formula (7).

[0175] The reaction temperature is usually −30 to 150° C., preferably −10 to 100° C., and more preferably −10 to 40° C. The reaction time is usually 10 minutes to 48 hours, preferably 10 minutes to 24 hours, and more preferably 30 minutes to 18 hours.

[0176] Step 2, i.e., a step of reacting a compound represented by general formula (8) with a compound represented by general formula (4) to synthesize a compound represented by general formula (2B), can be carried out, for example, in an inert solvent in the presence of a base.

[0177] Examples of the inert solvent in this reaction include ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, dimethoxymethane, etc., aromatic hydrocarbon solvents such as toluene, benzene, xylene, etc., halogenated hydrocarbon solvents such as dichloromethane, chloroform, dichloroethane, carbon tetrachloride, etc., ketone solvents such as acetone, etc., aprotic solvents such as dimethyl sulfoxide, N,N-dimethylformamide (DMF), acetonitrile, etc., pyridine, etc. Two or more of these solvents may be mixed in an appropriate ratio for use.

[0178] Examples of the base include metal hydrides such as sodium hydride and potassium hydride, metal hydroxides such as potassium hydroxide and sodium hydroxide, metal carbonates such as potassium carbonate, potassium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, and cesium carbonate, alkylamines such as triethylamine and ethyldiisopropylamine, and metal alkoxides such as sodium methoxide and potassium t-butoxide.

[0179] The amount of the compound represented by general formula (8) used is usually 0.5 mol or more, 0.8 mol or more, preferably 0.9 to 2 mol, and more preferably 0.9 to 1.5 mol, per mol of the compound represented by general formula (4).

[0180] The amount of the base used is usually 1 mole or more, preferably 1 to 5 moles, and more preferably 1 to 2 moles, per mole of the compound represented by formula (4).

[0181] The reaction temperature is usually from −20° C. to a temperature 10° C. higher than the boiling point of the solvent, preferably from 0° C. to 40° C. The reaction time is usually from 10 minutes to 48 hours, preferably from 10 minutes to 24 hours, more preferably from 30 minutes to 18 hours.

[0182] Step 3, i.e., a step of converting a compound represented by general formula (2B) into a compound represented by general formula (1) by ring closure, can be carried out, for example, in an inert solvent in the presence of a base.

[0183] The compound represented by the general formula (2B) exists as geometric isomers, that is, (E) form and (Z) form, and the (E) form is preferred since less heating is required during the ring-closing reaction.

[0184] Examples of the inert solvent in this reaction include ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, dimethoxymethane, etc., aromatic hydrocarbon solvents such as toluene, benzene, xylene, etc., halogenated hydrocarbon solvents such as dichloromethane, chloroform, dichloroethane, carbon tetrachloride, etc., ketone solvents such as acetone, etc., aprotic solvents such as dimethyl sulfoxide, N,N-dimethylformamide (DMF), acetonitrile, etc., pyridine, etc. Two or more of these solvents may be mixed in an appropriate ratio for use.

[0185] Examples of the base include metal hydrides such as sodium hydride and potassium hydride, metal hydroxides such as potassium hydroxide and sodium hydroxide, metal carbonates such as potassium carbonate, potassium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, and cesium carbonate, alkylamines such as triethylamine and ethyldiisopropylamine, and metal alkoxides such as sodium methoxide and potassium t-butoxide.

[0186] The amount of the base used is usually 1 mole or more, preferably 1 to 5 moles, and more preferably 1 to 2 moles, per mole of the compound represented by formula (2B).

[0187] The reaction temperature is usually 50° C. to a temperature 10° C. higher than the boiling point of the solvent, and preferably 80° C. to a temperature 10° C. higher than the boiling point of the solvent. Microwaves may be used to promote the reaction, and in that case, the reaction temperature is, for example, 80° C. to 180° C., and preferably 100° C. to 180° C. The reaction time is usually 10 minutes to 8 hours, and preferably 10 minutes to 2 hours.

[0188] The compounds represented by general formula (1) or (2) according to the present invention, their intermediate compounds and starting compounds can be produced by the above-mentioned synthesis methods. They can also be produced based on the synthesis methods described in the Examples of this specification, taking into consideration techniques that are known or publicly known at the time of filing of this application (e.g., BR Kiran et al., SYNTHESIS, EVALUATION OF ANALGESIC AND ANTI-INFLAMMATORY ACTIVITIES OF SUBSTITUTED 1,2-BENZOXAZOLONE AND 3-CHLORO-1,2-BENZOXAZOLE DERIVATIVES, International Journal of Pharmaceutical Sciences and Research, 2015; 6: 2918-2925.).

[0189] Regarding the starting material compounds and intermediate compounds shown in each of the above reaction schemes, before being subjected to the reaction, functional groups can be protected with appropriate protecting groups by a known method, if necessary, and after completion of the reaction, the protecting groups can be deprotected by a known method.

[0190] Each of the target compounds obtained according to the above reaction scheme can be isolated and purified. For example, after cooling the reaction mixture, an isolation procedure such as filtration, concentration, extraction, etc. is carried out to separate the crude reaction product, and then the crude reaction product can be isolated and purified from the reaction mixture by subjecting it to a general purification procedure such as column chromatography, recrystallization, etc.

[0191] The starting compounds shown in each of the above reaction schemes and the compounds represented by general formula (1) or (2) include compounds in the form of solvates (e.g., hydrates, ethanol solvates, etc.) to which a solvent is added.

[0192] The present invention encompasses pharmaceutical compositions for preventing and / or treating hearing loss, which contain a substance (TRPC3 / 6 channel inhibitor) having activity to inhibit at least one TRPC channel selected from the group consisting of TRPC3 channel and TRPC6 channel (sometimes referred to herein as "TRPC3 / 6 channel inhibitory activity"), a salt thereof, or a prodrug thereof.

[0193] As a TRPC3 / 6 channel inhibitor, a substance (sometimes referred to as a "TRPC6 channel inhibitor" herein) having activity to inhibit the TRPC6 channel (sometimes referred to as a "TRPC6 channel inhibitor activity" herein) is suitable.

[0194] Examples of TRPC3 / 6 channel inhibitors include compounds represented by general formula (1), compounds represented by general formula (2), Pyr2 (also referred to as "BTP2"), Pyr3, Pyr4, GSK2332255B, GSK2833503A, SAR7334, BI-749327, compounds disclosed in US2019 / 0169168, compounds disclosed in WO2019 / 215268, and the like. Preferred are compounds represented by general formula (1), compounds represented by general formula (2), Pyr2, Pyr3, Pyr Compounds represented by general formula (1), Pyr2, Pyr3, Pyr4, GSK2332255B, GSK2833503A, SAR7334, BI-749327, compounds AA01 to AA95, compounds BB01 to BB32, etc., more preferably compounds represented by general formula (1), compounds represented by general formula (2), Pyr2, Pyr3, Pyr4, GSK2332255B, GSK2833503A, SAR7334, BI-749327, etc., even more preferably compounds represented by general formula (1), compounds represented by general formula (2), Pyr4, etc.

[0195] Examples of substances having an activity of inhibiting a TRPC3 channel (sometimes referred to as a "TRPC3 channel inhibitor" herein) include a compound represented by general formula (1), a compound represented by general formula (2), Pyr2, Pyr3, Pyr4, GSK2332255B, GSK2833503A, and compounds disclosed in WO2019 / 215268. Preferably, the compound represented by general formula (1) is Preferred are compounds represented by general formula (1), compounds represented by general formula (2), Pyr2, Pyr3, Pyr4, GSK2332255B, GSK2833503A, compounds BB01 to BB32, etc., more preferred are compounds represented by general formula (1), compounds represented by general formula (2), Pyr2, Pyr3, Pyr4, GSK2332255B, GSK2833503A, etc., even more preferred are compounds represented by general formula (1), compounds represented by general formula (2), Pyr4, etc.

[0196] Examples of TRPC6 channel inhibitors include compounds represented by general formula (1), compounds represented by general formula (2), Pyr2, Pyr4, GSK2332255B, GSK2833503A, SAR7334, BI-749327, compounds disclosed in US2019 / 0169168, compounds disclosed in WO2019 / 215268, and the like. Preferred are compounds represented by general formula (1), compounds represented by general formula (2), Pyr2, Pyr4, GSK2332255B, GSK2833503A, SAR7334, BI-749327, compounds disclosed in US2019 / 0169168, compounds disclosed in WO2019 / 215268, and the like. 55B, GSK2833503A, SAR7334, BI-749327, compounds AA01 to AA95, compounds BB01 to BB32, etc., more preferably compounds represented by general formula (1), compounds represented by general formula (2), Pyr2, Pyr4, GSK2332255B, GSK2833503A, SAR7334, BI-749327, etc., even more preferably compounds represented by general formula (1), compounds represented by general formula (2), Pyr4, etc.

[0197] Pyr2 is also called BTP2 and has the CAS number 223499-30-7. Pyr3 has been assigned the CAS No. 1160541-60-2. Pyr4 has been assigned the CAS No. 223499-35-2. GSK2332255B has been assigned CAS No. 1366233-41-1. GSK2833503A has been assigned CAS No. 1333207-63-8. SAR7334 has been assigned CAS No. 1333210-07-3. BI-749327 has been assigned the CAS No. 2361241-23-6. [ka]

[0198] Examples of the compound described in claim 1 of US2019 / 0169168 include: Compound AA01: [4-(6-amino-4-methoxy-pyridin-3-yl)-piperazin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA02: (6-amino-4-methyl-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA03: (6-amino-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA04: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA05: [4-(6-amino-4-methoxy-pyridin-3-yl)-piperazin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA06: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-isopropoxy-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA07: [(R)-4-(6-amino-4-methyl-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA08: [7-(6-amino-4-methoxy-pyridin-3-yl)-4,7-diaza-spiro[2.5]oct-4-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA09: [7-(6-amino-4-methoxy-pyridin-3-yl)-4,7-diaza-spiro[2.5]oct-4-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA10: (6-amino-4-methyl-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA11: [4-(6-amino-5-methoxy-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA12: [4-(6-amino-pyridin-3-yl)-piperazin-1-yl]-[4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl]-methanone, Compound AA13: [4-(6-amino-pyridin-3-yl)-piperazin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA14: (6-amino-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA15: [4-(6-amino-pyridin-3-yl)-piperazin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA16: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA17: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA18: [(R)-4-(6-amino-4-methyl-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA19: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(2-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA20: [(R)-4-(6-amino-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA21: [4-(6-amino-5-methoxy-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA22: (6-amino-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl]-methanone, Compound AA23: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA24: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[4-methoxy-5-(4-trifluoromethyl-phenoxy)-pyridin-2-yl]-methanone, Compound AA25: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-(5-cyclobutylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA26: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[4-methoxy-5-(1-methyl-cyclopropylmethoxy)-pyridin-2-yl]-methanone, Compound AA27: [(R)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-methoxymethyl-piperazin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA28: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl]-methanone, Compound AA29: [4-(6-amino-4-methyl-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA30: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(5-cyclohexyloxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA31: [4-(6-amino-4-methyl-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA32: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(4-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA33: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-trifluoromethyl-phenoxy)-pyridin-2-yl]-methanone, Compound AA34: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-chloro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA35: (6-amino-4-methoxy-3,4,5,6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(5-cyclopentyloxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA36: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-(5-isobutoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA37: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(5-cyclopropylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA38: [3-(6-amino-4-methoxy-pyridin-3-yl)-3,8-diaza-bicyclo[3.2.1]oct-8-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA39: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(5-isobutoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA40: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-cyclopropoxy-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA41: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA42: [(R)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA43: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(5-benzyloxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA44: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl]-methanone, Compound AA45: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(3,3-difluoro-cyclobutylmethoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA46: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(4-methoxy-5-propoxy-pyridin-2-yl)-methanone, Compound AA47: [4-(6-amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA48: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(2-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA49: [4-(6-amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA50: (1R)-1-[(2R)-4-(6-amino-4-methoxypyridin-3-yl)-1-(5-phenoxypyridine-2-carbonyl)piperazin-2-yl]ethan-1-ol, Compound AA51: [3-(6-amino-4-methoxy-pyridin-3-yl)-3,8-diaza-bicyclo[3.2.1]oct-8-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA52: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(4-methoxy-5-phenethyloxy-pyridin-2-yl)-methanone, Compound AA53: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(5-cyclobutylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA54: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-difluoromethoxy-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA55: [(R)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-methoxymethyl-piperazin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA56: [4-(6-amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-trifluoromethyl-phenoxy)-pyridin-2-yl]-methanone, Compound AA57: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(2-fluoro-benzyloxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA58: (1S)-1-[(2R)-4-(6-amino-4-methoxypyridin-3-yl)-1-(5-phenoxypyridine-2-carbonyl)piperazin-2-yl]ethan-1-ol, Compound AA59: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(2,2-dimethyl-propoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA60: [4-(6-amino-5-methoxy-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl]-methanone, Compound AA61: [4-(6-amino-4-methoxy-pyridin-3-yl)-piperazin-1-yl]-(5-cyclopropylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA62: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-(5-cyclohexyloxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA63: [(S)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA64: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(1-fluoromethyl-cyclopropylmethoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA65: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(5-ethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA66: [4-(6-amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl]-methanone, Compound AA67: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(2-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA68: [7-(6-amino-4-methoxy-pyridin-3-yl)-3-oxa-9-aza-bicyclo[3.3.1]non-9-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA69: [(R)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA70: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-((S)-1-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA71: [(S)-4-(6-amino-4-methoxy-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA72: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-(5-isopropoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA73: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-phenethyloxy-pyridin-2-yl)-methanone, Compound AA74: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(2,2-dimethyl-propoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA75: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(1-methyl-cyclopropylmethoxy)-pyridin-2-yl]-methanone, Compound AA76: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-propoxy-pyridin-2-yl)-methanone, Compound AA77: (6-amino-4-methoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-((R)-1-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA78: [4-(6-amino-4-methyl-pyridazin-3-yl)-piperidin-1-yl]-(5-cyclopropylmethoxy-4-methoxy-pyridin-2-yl)-methanone, Compound AA79: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-((S)-1-cyclopropyl-ethoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA80: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-trifluoromethoxy-phenoxy)-pyridin-2-yl]-methanone, Compound AA81: [(R)-4-(6-amino-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone, Compound AA82: [(R)-4-(6-amino-pyridin-3-yl)-2-hydroxymethyl-piperazin-1-yl]-[4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl]-methanone, Compound AA83: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(phenoxy)-4-ethoxy-pyridin-2-yl]-methanone, Compound AA84: (6-amino-4-cyclopropoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA85: [4-(6-amino-4-ethoxy-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(phenoxy)-pyridin-2-yl]-methanone, Compound AA86: (6-amino-4-propoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA87: (6-amino-4-ethoxy-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-yl)-[5-(4-trifluoromethyl-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, Compound AA88: [4-(6-amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-ethoxy-pyridin-2-yl]-methanone, Compound AA89: [3-(6-amino-pyridazin-3-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-[4-ethoxy-5-(4-fluoro-phenoxy)-pyridin-2-yl]-methanone, Compound AA90: 6-{1-{4-methoxy-5-[4-(trifluoromethyl)phenoxy]pyridine-2-carbonyl}piperidin-4-yl)-5-methylpyridazin-3-amine, Compound AA91: 5-Methoxy-6-(1-{5-[4-(trifluoromethyl)-phenoxy]-pyridine-2-carbonyl}piperidin-4-yl)-pyridazin-3-amine, Compound AA92: 4-Methoxy-5-[1-(4-methoxy-5-{[trans-3-(trifluoromethyl)cyclobutyl]-methoxy}pyridine-2-carbonyl)-piperidin-4-yl]pyridin-2-amine, Compound AA93: 4-Methoxy-5-[1-(4-methoxy-5-{[(cis-3-(trifluoromethyl)-cyclobutyl]methoxy}-pyridine-2-carbonyl)piperidin-4-yl]pyridin-2-amine, Compound AA94: 4-Methoxy-5-(1-{4-methoxy-5-[(2)-3,3,3-trifluoro-2-methylpropoxy]-pyridine-2-carbonyl}piperidin-4-yl)pyridin-2-amine, Compound AA95: 5-{1-{5-[(2,2-difluorocyclobutyl)-methoxy]-4-methoxy-pyridine-2-carbonyl}-piperidin-4-yl)-4-methoxypyridin-2-amine The following are some of the reasons: Preferred examples include compound AA29, compound AA31, compound AA49, compound AA56, compound AA66, compound AA85, compound AA87, and compound AA90.

[0199] Examples of the compounds described in WO2019 / 215268 include: Compound BB01: 1-[4-(4-fluorophenyl)-2-(triazol-2-yl)cyclopentyl]piperidin-3-amine, Compound BB02: 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile, Compound BB03: 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-3-carbonitrile, Compound BB04: 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrrole-3-carbonitrile, Compound BB05: 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]triazole-4-carbonitrile, Compound BB06: 1-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile, Compound BB07: 1-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile, Compound BB08: 1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl]piperidin-3-amine, Compound BB09: 5-fluoro-1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl]piperidin-3-amine, Compound BB10: 5-fluoro-1-[4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine, Compound BB11: 5-fluoro-1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl]piperidin-3-amine, Compound BB12: 1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl]piperidin-3-amine, Compound BB13: 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]-1,2,4-triazole-3-carbonitrile, Compound BB14: 4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-hydroxy-phenyl)cyclopentoxy]benzonitrile, Compound BB15: 4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-methoxy-phenyl)cyclopentoxy]benzonitrile, Compound BB16: 4-[2-(3-amino-1-piperidyl)-4-(3-fluorophenyl)cyclopentoxy]-3-chloro-benzonitrile, Compound BB17: 4-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]benzonitrile, Compound BB18: 4-[2-(5-amino-3,3-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]benzonitrile, Compound BB19: 4-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]-2-fluoro-benzonitrile, Compound BB20: 2-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxy]benzonitrile, Compound BB21: 4-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxy]-3-chloro-benzonitrile, Compound BB22: 6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]-5-methyl-pyridazine-3-carbonitrile, Compound BB23: 1-[2-(4-chloropyridazin-3-yl)oxy-4-(4-fluorophenyl)cyclopentyl]piperidin-3-amine, Compound BB24: 6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyridazine-3-carbonitrile, Compound BB25: 1-[4-(4-fluorophenyl)-2-(5-fluoropyridazin-3-yl)oxy-cyclopentyl]piperidin-3-amine, Compound BB26: 6-(2-((R)-3-aminopiperidin-1-yl)-4-(4-fluorophenyl)cyclopentyloxy)nicotinonitrile, Compound BB27: 6-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyridine-3-carbonitrile, Compound BB28: 1-[4-(4-fluorophenyl)-2-pyridazin-3-yloxy-cyclopentyl]piperidin-3-amine, Compound BB29: 5-fluoro-1-[4-(4-fluorophenyl)-pyrimidin-4-yloxy-cyclopentyl]piperidin-3-amine, Compound BB30: 2-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyrimidine-5-carbonitrile, Compound BB31: 5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyrazine-2-carbonitrile, Compound BB32: 5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyrimidine-2-carbonitrile etc.

[0200] In the TRPC3 / 6 channel inhibitor, the compound represented by the general formula (1) or (2), the intermediate compound obtained in each of the above reaction formulas, and the starting compound, isomers (E, Z, cis, trans) in double bonds, rings, and condensed rings, isomers due to the presence of asymmetric carbons, etc. (R, S, α, β, enantiomers, diastereomers), optically active isomers having optical rotation (D, L, d, l), polar isomers (high polarity, low polarity) by chromatographic separation, equilibrium compounds, rotational isomers, mixtures of these in any ratio, and racemic mixtures include all isomers such as geometric isomers, stereoisomers, and optical isomers. For example, optical isomers can be separated using various known resolution methods (e.g., optical resolution by crystallization, direct optical resolution by chromatography, etc.).

[0201] Salts of TRPC3 / 6 channel inhibitors (e.g., compounds represented by general formula (1) or (2)) include all pharma- ceutically acceptable salts. Pharmaceutically acceptable salts are not particularly limited, and include, for example, alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; inorganic metal salts such as zinc salts; organic base salts such as triethylamine, triethanolamine, trihydroxymethylaminomethane, and amino acids; inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate, and nitrate; organic acid salts such as acetate, carbonate, propionate, succinate, lactate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, p-toluenesulfonate, benzenesulfonate, and ascorbate. These salts can be prepared according to conventional methods.

[0202] Various isomers can be isolated by known separation methods. For example, racemic compounds can be converted into stereochemically pure isomers by general optical resolution methods (e.g., optical resolution by crystallization, direct optical resolution by chromatography, etc.). Optically active compounds can also be produced by using appropriate optically active raw materials.

[0203] The starting compounds, intermediate compounds, and target compounds shown in each of the above reaction schemes can be used in the form of a suitable salt.

[0204] In the present invention, in the TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2)), its salt, or its prodrug, one or more atoms can be replaced with one or more isotope atoms. Examples of isotope atoms include deuterium (2H), tritium (3H), 13C, 14N, 18O, etc.

[0205] The present invention includes a pharmaceutical composition for preventing and / or treating hearing loss, which contains a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2)), a salt thereof, or a prodrug thereof. The pharmaceutical composition of the present invention may be a formulation of a TRPC3 / 6 channel inhibitor, a salt thereof, or a prodrug thereof in the form of a conventional pharmaceutical composition, and may be prepared using the compound, a salt thereof, or a prodrug thereof and a pharma- ceutically acceptable carrier. Examples of such carriers include commonly used diluents or excipients, such as fillers, bulking agents, binders, wetting agents, disintegrants, surfactants, and lubricants.

[0206] In the present invention, a prodrug refers to a compound that is converted into a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2)) by a reaction in vivo (e.g., an enzyme reaction, a reaction by gastric acid). For example, when a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2)) has a carboxyl, the prodrug is a compound in which the carboxyl is converted into an ester. Examples of the ester include methyl ester, ethyl ester, 1-propyl ester, 2-propyl ester, pivaloyloxymethyl ester, acetyloxymethyl ester, cyclohexylacetyloxymethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester, ethyloxycarbonyloxy-1-ethyl ester, and cyclohexyloxycarbonyloxy-1-ethyl ester.

[0207] The pharmaceutical composition of the present invention can be selected from various forms depending on the purpose of treatment, and representative forms include tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, injections (liquids, suspensions, etc.), ointments, inhalants, ear drops, etc. Among these, oral administration preparations, topical (preferably intraaural) administration preparations, and injections are preferred, with oral administration preparations being more preferred.

[0208] A wide variety of known carriers can be used for tablet formation, including excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, and crystalline cellulose; binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, methylcellulose, potassium phosphate, polyvinylpyrrolidone, carboxymethylcellulose, and shellac; sodium alginate, dry starch, agar powder, laminaran powder, calcium carbonate, and carbonated water. Examples of suitable disintegrants include disintegrants such as sodium phosphate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearate monoglyceride, starch, and lactose; absorption promoters such as quaternary ammonium bases and sodium lauryl sulfate; disintegration inhibitors such as stearin, cocoa butter, and hydrogenated oils; moisturizers such as glycerin and starch; adsorbents such as starch, lactose, kaolin, bentonite, and colloidal silicic acid; and lubricants such as purified talc, stearates, powdered boric acid, and polyethylene glycol.

[0209] Furthermore, the tablets may be, if necessary, coated with a conventional tablet coating, for example, sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, or double-layered or multi-layered tablets.

[0210] A wide variety of known carriers can be used for forming pills, including, for example, excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oil, kaolin, and talc; binders such as powdered gum arabic, powdered tragacanth, gelatin, and ethanol; and disintegrants such as laminaran and agar.

[0211] As the carrier used for forming suppositories, a wide variety of known carriers can be used, including, for example, polyethylene glycol, cacao butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, and the like.

[0212] When prepared as an injection, the liquid, emulsion and suspension are preferably sterilized and isotonic with blood.The diluent used in preparing these liquids, emulsions and suspensions can be widely known, for example, water, ethanol, propylene glycol, polyoxylated isostearyl alcohol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, etc.In addition, in the case of injections, sufficient amount of salt, glycerin, glucose, etc. to prepare an isotonic solution can be contained in the pharmaceutical preparation, and ordinary dissolving agents, buffers, soothing agents, etc. can be contained, and further coloring agents, preservatives, fragrances, flavors, sweeteners, etc. and other pharmaceuticals can be contained as necessary.

[0213] Ointments are available in the form of pastes, creams, gels, etc., and when preparing these forms, diluents such as white petrolatum, paraffin, glycerin, cellulose derivatives, polyethylene glycol, silicone, bentonite, etc. can be used.

[0214] Inhalants are preparations intended to be applied to the bronchi or lungs by inhaling the active ingredient as an aerosol, and include powder inhalants, inhalation liquids, inhalation aerosols, etc. Powder inhalants refer to preparations inhaled as an aerosol of powdered solid particles, and can usually be produced by making the active ingredient fine particles and mixing them with additives such as lactose as necessary to make them homogeneous. Inhalation liquids refer to liquid inhalants applied by a nebulizer, etc., and can usually be produced by adding a solvent and a suitable isotonicity agent, pH regulator, etc. to the active ingredient and mixing them. Inhalation aerosols are metered-dose inhalants that spray a fixed amount of the active ingredient together with a propellant filled in a container. Inhalation aerosols can usually be produced by adding a solvent and a suitable dispersant, stabilizer, etc. to the active ingredient to make a solution or suspension, filling it into a pressure-resistant container together with a liquid propellant, and attaching a metered-dose valve.

[0215] The pharmaceutical composition of the present invention may contain, as necessary, colorants, preservatives, fragrances, flavorings, sweeteners and other pharmaceutical agents.

[0216] The amount of a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2)), a salt thereof, or a prodrug thereof contained in the pharmaceutical composition of the present invention is not particularly limited and can be appropriately selected from a wide range, but is usually 0.5 to 90% by weight, 1 to 85% by weight, and preferably 1 to 80% by weight in the pharmaceutical composition.

[0217] The method of administration of the pharmaceutical composition of the present invention is not particularly limited, and it is administered according to various formulations, age, sex, disease state, and other conditions of the patient. For example, in the case of tablets, pills, liquids, suspensions, emulsions, granules, and capsules, it is administered orally. In the case of injections, it can be administered intravenously alone or mixed with normal fluids such as glucose and amino acids, or it can be administered alone intramuscularly, intradermally, subcutaneously, intraperitoneally, etc., as necessary. In the case of suppositories, it is administered rectally. In the case of inhalants, it is administered nasally. In the case of ear drops, it is administered through the ear. Preferred administration methods are oral administration, injection administration (including subcutaneous administration, intramuscular administration, intravenous administration, and intrathecal administration), and through the ear, and more preferably oral administration.

[0218] The dosage of the pharmaceutical composition of the present invention may be selected in consideration of the method of use, the age and sex of the patient, the severity of the disease, and other conditions. The active ingredient, a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2)), a salt thereof, or a prodrug thereof, is usually administered in an amount of 0.01 to 100 mg, preferably 0.1 to 50 mg per kg of body weight per day, once or several times per day, or at intervals of once every 2, 3, 4, 5, or 6 days, 1 week, 2 weeks, or 4 weeks. The dosage varies depending on various conditions, so a dosage less than the above range may be sufficient in some cases, and a dosage exceeding the above range may be necessary in other cases.

[0219] Furthermore, the pharmaceutical composition of the present invention can be used as a concomitant drug in combination with other drugs.

[0220] The present invention may include a method for preventing and / or treating hearing loss, comprising administering to a patient in need of such prevention and / or treatment an effective amount of a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2)), a pharma- ceutically acceptable salt thereof, or a prodrug thereof.

[0221] A TRPC3 / 6 channel inhibitor (eg, a compound represented by general formula (1) or (2)), a salt thereof, or a prodrug thereof has an effect of preventing and / or treating hearing loss. The hearing loss includes sensorineural hearing loss, conductive hearing loss, mixed hearing loss, non-organic hearing loss, and the like, and is preferably sensorineural hearing loss or mixed hearing loss, and more preferably sensorineural hearing loss. The hearing loss includes mild, moderate, severe, and profound hearing loss, preferably mild, moderate, and severe hearing loss, and more preferably mild and moderate hearing loss. Furthermore, the hearing loss is preferably drug-induced hearing loss, that is, hearing loss caused by a drug (e.g., hearing loss caused by a drug). Examples of drugs include platinum preparations, antibacterial agents, salicylic acid agents, diuretics, etc. Examples of platinum preparations include cisplatin, carboplatin, nedaplatin, oxaliplatin, etc. Examples of antibacterial agents include aminoglycoside antibacterial agents, such as streptomycin, kanamycin, amikacin, gentamicin, bekanamycin, ribostamycin, dibekacin, tobramycin, isepamicin, arbekacin, habekacin, etc. Examples of salicylic acid agents include aspirin, sodium salicylate, etc. Examples of diuretics include furosemide, torasemide, bumetanide, azosemide, piretanide, etc. As drug-induced hearing loss, hearing loss caused by platinum preparations, hearing loss caused by antibacterial agents, and hearing loss caused by salicylates are preferred, hearing loss caused by platinum preparations and hearing loss caused by antibacterial agents are more preferred, and hearing loss caused by platinum preparations is particularly preferred.

[0222] A TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2), a salt thereof, or a prodrug thereof may have an effect of regulating the activity of a TRPC3 channel, an effect of regulating the activity of a TRPC6 channel, or an effect of regulating the activity of both a TRPC3 channel and a TRPC6 channel. In addition, the compound of the present invention, a salt thereof, or a prodrug thereof has a TRPC3 / 6 channel inhibitory activity. Therefore, a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2), a salt thereof, or a prodrug thereof is effective as a TRPC3 and / or TRPC6 regulator or a TRPC3 and / or TRPC6 inhibitor, or for preventing or treating a TRPC3 and / or TRPC6-related disease. The TRPC3 and / or TRPC6 channel is a channel that exists in the cell membrane and controls the influx of cationic ions into cells. Inhibition of the TRPC3 and / or TRPC6 channel increases Ca2+ in myofibroblasts. + It acts to suppress the phosphorylation signal downstream of TGF-β through the influx, and to suppress the production of collagen I, smooth muscle actin (α-SMA), etc. (e.g., Inflammatory Bowel Diseases, 2015, Mar, 21(3), 496-506). TRPC3 and / or TRPC6-related diseases are diseases in which excessive activation of TRPC3 and / or TRPC6 channels (channels are opened and excessive influx of cationic ions into cells) is observed.

[0223] The pharmaceutical composition of the present invention is also useful as a preventive or therapeutic agent for TRPC3 and / or TRPC6-related diseases. The TRPC3 and / or TRPC6-related diseases are not particularly limited as long as they are caused by excessive activation or excessive inactivation of the TRPC3 channel and / or TRPC6 channel, but are preferably caused by excessive activation or excessive inactivation of the TRPC6 channel. Examples of the TRPC3 and / or TRPC6-related diseases include fibrosis (e.g., pulmonary fibrosis, renal fibrosis, liver cirrhosis caused by fibrosis), neurodegenerative diseases (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, etc.), myodegenerative diseases (e.g., muscular dystrophy, etc.), inflammatory diseases (e.g., Crohn's disease, ulcerative colitis, nonalcoholic steatohepatitis (NASH), etc.), Williams syndrome, chronic nephropathy, cardiac hypertrophy, pulmonary hypertension, etc. A preferred disease is, for example, fibrosis.

[0224] In addition, the compounds represented by general formula (1) or (2) are not easily metabolized in the liver. Furthermore, they have high PBS solubility, which is advantageous for formulation, and high membrane permeability, which is advantageous in terms of bioavailability. For these reasons, the compounds represented by general formula (1) or (2) are excellent in terms of pharmacokinetics. Therefore, compared with conventional TRPC3 and / or TRPC6 inhibitors, or compared with conventional preventive and / or therapeutic agents for hearing loss, they can exert inhibitory activity or preventive and / or therapeutic activity for hearing loss for a long period of time with a small amount.

[0225] In addition, the compounds represented by general formula (1) or (2) can be used to inhibit other TRP channels (e.g., TRPC1, TRPC2, TRPC5, TRPC7, TRPM2, TRPV1, TRPV6) other than TRPC3 and TRPC6 channels, or other Ca 2+ Channel, N + Channel, K + It is expected to have a small effect on the channels and therefore be highly selective for TRPC6 and TRPC3 channels and have few side effects.

[0226] The present invention may include a method for inhibiting TRPC3 and / or TRPC6, comprising administering to a patient in need of TRPC3 and / or TRPC6 inhibitory treatment an effective amount of a compound represented by general formula (1) or (2), a pharma- ceutically acceptable salt thereof, or a prodrug thereof.

[0227] The present invention may include a method for preventing or treating a TRPC3- and / or TRPC6-related disease, comprising administering an effective amount of a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2)), a pharma- ceutically acceptable salt thereof, or a prodrug thereof to a patient in need of such prevention or treatment.

[0228] The present invention may include a method for preventing or treating fibrosis, comprising administering to a patient in need of such prevention or treatment an effective amount of a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2)), a pharma- ceutically acceptable salt thereof, or a prodrug thereof.

[0229] The present invention may include the use of a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2), a pharma- ceutically acceptable salt thereof, or a prodrug thereof for the manufacture of an agent for the prophylaxis or treatment of a TRPC3- and / or TRPC6-related disease.

[0230] The present invention may include the use of a TRPC3 / 6 channel inhibitor (e.g., a compound represented by general formula (1) or (2), a pharma- ceutically acceptable salt thereof, or a prodrug thereof for the manufacture of an agent for the prophylaxis or treatment of fibrosis. EXAMPLES

[0231] The present invention will be specifically described below with reference to Reference Examples and Examples, but the present invention is not limited thereto. The following conditions were used for LC / MS analysis of the compounds. [LC / MS analysis conditions] LC / MS System: Waters ACQUITY UPLC H-Class / QDa Sample Manager - FTN Quaternary Solvent Manager Column Heater A PDAeλ Detector QDa Detector Column: ACQUITY UPLC BEH C18 1.7 μm (2.1 × 50 mm) Flow rate: 0.5 mL / min Elution conditions: Mobile phase A: acetonitrile, Mobile phase B: 0.1% formic acid aqueous solution

[0232] [Table 1]

[0233] [Example 1] Synthesis of 5-chloro-6-(4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (compound 011) [ka]

[0234] Step 1-1 A 1N aqueous sodium hydroxide solution (12.5mL, 12.5mmol) was added to a solution of 2-fluoro-6-(trifluoromethyl)benzaldehyde (2g, 10.41mmol) and hydroxylamine hydrochloride (0.868g, 12.49mmol) in ethanol (10mL), and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure and extracted with ethyl acetate. The organic layer was washed with water and saturated saline, then dried over magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 2-fluoro-6-(trifluoromethyl)benzaldehyde oxime (2.126g).

[0235] Step 1-2 To a solution of 2-fluoro-6-(trifluoromethyl)benzaldehyde oxime (2.12 g, 10.24 mmol) in DMF (10 mL), NCS (N-chlorosuccinimide) (1.435 g, 10.75 mmol) was added at 0° C. and stirred at room temperature overnight. LC / MS showed 100% conversion of the oxime to the chloride. The solution of 2-fluoro-N-hydroxy-6-(trifluoromethyl)benzimidoyl chloride was used in the next reaction without purification.

[0236] Step 1-3 A solution of 5-chloro-6-(piperazin-1-yl)nicotinic acid hydrochloride (1836 mg, 6.6 mmol) and triethylamine (2.93 mL, 21 mmol) in dichloromethane (10 mL) was added to a DMF solution of 2-fluoro-N-hydroxy-6-(trifluoromethyl)benzimidoyl chloride (6 mL, approximately 6 mmol) from step 1-2 at room temperature and stirred overnight. A 10% aqueous solution of KHSO4 was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / methanol) to give (E)-5-chloro-6-(4-((2-fluoro-6-(trifluoromethyl)phenyl)(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid (compound 012(E); 1258 mg; LC-MS: rt 2.45 min., m / z 447 (M+1)) and its Z isomer (compound 012(Z); 93 mg; LC-MS: rt 2.26 min., m / z 447 (M+1)).

[0237] Step 1-4 A mixed solution of (E)-5-chloro-6-(4-((2-fluoro-6-(trifluoromethyl)phenyl)(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid (1026 mg) in 2N aqueous potassium hydroxide solution (6 mL) and dioxane (18 mL) was stirred and heated at 105° C. for 3 hours. LC / MS analysis showed a conversion rate of 100%. The solution was concentrated under reduced pressure and neutralized with 2N aqueous hydrochloric acid solution, and the resulting solid was filtered off. It was dried to give 876 mg of the title compound. (Rf = 0.5, ethyl acetate) 1 H NMR (DMSO, 400 MHz)δ8.68 (d, 1 H, J = 1.6 Hz), 8.06 - 8.11 (m, 2 H), 7.83 - 7.88 (m, 2 H), 3.59 - 3.64 (m, 4 H), 3.33 - 3.38 (m, 4H), LC-MS: rt 3.23 min., m / z 427 (M+1).

[0238] [Example 2] Synthesis of 5-chloro-N-methyl-6-(4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinamide (Compound 021) [ka]

[0239] A solution of 5-chloro-6-(4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (compound of Example 1, 22.5 mg, 0.053 mmol), triethylamine (29.4 μL, 0.211 mmol), 1-[dimethylamino(dimethyliminio)methyl]-1H-1,2,3-triazolo[4,5-b]pyridine 3-oxide hexafluorophosphate (hereinafter sometimes referred to as HATU) (40.1 mg, 0.105 mmol) and methylamine (0.2 mmol) in THF (0.5 mL) was stirred at room temperature overnight. The solution was concentrated, and the residue was purified by preparative liquid silica gel chromatography (hexane / ethyl acetate) to obtain 20.8 mg of the title compound. (Rf = 0.5, 1 : 2 hexane / ethyl acetate) 1H NMR (CDCl3, 400 MHz)δ8.52 (d, 1 H, J = 2.0 Hz), 8.04 (d, 1 H, J = 2.0 Hz), 7.73 (d, 1 H, J = 7.2 Hz), 7.63 (dd, 1 H, J = 7.6, 8.8 Hz), 7.64 (bs, 1H), 6.10 (br, 1H), 3.67 - 3.72 (m, 4H), 3.44 - 3.48 (m, 4H), 3.02 (d, 3H, J = 6.8 Hz), LC-MS: rt 2.84 min., m / z 440 (M+1).

[0240] [Example 3] Synthesis of (S)-5-chloro-6-(3-methyl-4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (Compound 031) [ka]

[0241] A solution of (S)-2-methylpiperazine (1.002 g, 10 mmol), 5,6-dichloronicotinic acid (1.92 g, 10 mmol) and N-ethyl-N-isopropylpropan-2-amine (3.48 mL, 20 mmol) in DMF (20 mL) was heated and stirred at 90° C. for 10 hours. After dilution with purified water, the mixture was neutralized with 10% KHSO4 to a pH of about 6, and the resulting solid was collected by filtration and dried under reduced pressure to obtain 429 mg of crude (S)-5-chloro-6-(3-methylpiperazin-1-yl)nicotinic acid. This was used in the next step without purification.

[0242] The title compound was obtained according to the methods of Steps 1-3 and 1-4 of Example 1, except that the crude (S)-5-chloro-6-(piperazin-1-yl)nicotinic acid was used instead of 5-chloro-6-(piperazin-1-yl)nicotinic acid hydrochloride. (Rf = 0.25, 2:1 ethyl acetate / hexane). 1H NMR (DMSO, 400 MHz)δ8.70 (d, 1 H, J = 2.4 Hz), 8.11 (d, 1 H, J = 2.4 Hz), 8.10 (d, 1 H, J = 7.6 Hz), 7.85 (d, 1 H, J = 7.6 Hz), 7.83 (d, 1 H, J = 7.6 Hz), 3.64 - 3.90 (m, 3 H), 3.04 - 3.52 (m, 4H), 1.08 (d, 3 H, J = 6.0 Hz), LC-MS: rt 3.03 min., m / z 441 (M+1).

[0243] [Example 4] Synthesis of (R)-5-chloro-6-(3-methyl-4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (Compound 041) [ka]

[0244] Following the procedure of Example 3, except substituting (R)-2-methylpiperazine for (S)-2-methylpiperazine, the title compound was obtained. 1 H NMR (DMSO, 400 MHz)δ8.70 (d, 1 H, J = 2.4 Hz), 8.11 (d, 1 H, J = 2.4 Hz), 8.10 (d, 1 H, J = 7.6 Hz), 7.85 (d, 1 H, J = 7.6 Hz), 7.83 (d, 1 H, J = 7.6 Hz), 3.64 - 3.90 (m, 3 H), 3.04 - 3.52 (m, 4H), 1.08 (d, 3 H, J = 6.0 Hz), LC-MS: rt 3.03 min., m / z 441 (M+1).

[0245] [Example 5] Synthesis of 5-chloro-6-(4-(4-(methoxy)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (compound 051) [ka]

[0246] Following the procedure of Example 1, except substituting 2-fluoro-6-(methoxy)benzaldehyde for 2-fluoro-6-(trifluoromethyl)benzaldehyde, the title compound was obtained. Rf = 0.2, 10%methanol / ethyl acetate 1 H NMR (DMSO, 400 MHz)δ8.69 (d, 1 H, J = 1.6 Hz), 8.11 (d, 1 H, J = 1.6 Hz), 7.54 (t, 1 H, J = 8.4 Hz), 7.16 (d, 1 H, J = 8.4 Hz), 6.84 (d, 1 H, J = LC-MS: rt 2.60 min., m / z 389 (M+1). During the synthesis, 5-chloro-6-(4-((2-fluoro-6-methoxyphenyl(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid (compound 052) was obtained (LC-MS: rt 2.11 min., m / z 409 (M+1)).

[0247] [Example 6] Synthesis of 4-chloro-3-(4-(2-chlorophenyl)piperazin-1-yl)benzo[d]isoxazole (Compound 061) [ka]

[0248] Step 6-1 A DMF solution of 2,6-dichloro-N-hydroxy-6-benzimidoyl chloride was obtained according to the methods of Steps 1-1 and 1-2 of Example 1, except that 2,6-dichlorobenzaldehyde was used instead of 2-fluoro-6-(trifluoromethyl)benzaldehyde.

[0249] Step 6-2 A solution of 1-(2-chlorophenyl)piperazine (118 mg, 0.6 mmol) and triethylamine (83 μL, 0.6 mmol) in dichloromethane (2 mL) was added with a DMF solution of 2,6-dichloro-N-hydroxy-6-benzimidoyl chloride (0.5 mL, approximately 0.5 mmol) from step 6-1 at room temperature and stirred for 3 hours. A saturated aqueous solution of ammonium chloride was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / methanol) to obtain (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime (58.7 mg) and Z isomer (50 mg).

[0250] (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime (Compound 062(E)): Rf: 0.5, 3 : 1 hexane / ethyl acetate, 1H NMR (CDCl3, 400 MHz)δ7.41 (d, 1 H, J = 1.6 Hz), 7.39 (s, 1 H), 7.36 (dd, 1 H, J =1.6, 8.0 Hz), 7.30 (dd, 1 H, J =7.2, 8.8 Hz), 7.21 (dd, 1H, J =1.2, 7.2 Hz), 7.03 (dd, 1H, J = 2.0, 8.0 Hz), 6.98 (dt, 1 H, J =1.2, 8.0 Hz), 5.72 (br, 1 H), 3.35 - 3.40 (m, 4 H), 3.04 - 3.09 (m, 4H), LC-MS: rt 3.03 min., m / z 384 (M+1). (Z)-(4-(2-chlorophenyl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime (Compound 062(Z)): Rf: 0.3, 3:1 hexane / ethyl acetate 1 H NMR (CDCl3, 400 MHz)δ7.36 (dd, 1 H, J = 1.2, 7.2 Hz), 7.35 (d, 1 H, J = 1.2, 8.0 Hz), 7.26 (dd, 1 H, J = 1.2, 8.0 Hz), 7.28 (dd, 1 H, J = 2.0, 8.0 Hz), 7.22 (dt, 1H, J = 1.2, 7.2 Hz), 7.04 (dd, 1H, J = 8.0 Hz), 6.97 (dt, 1 H, J = 1.2, 8.0 Hz), 6.46 (br, 1 H), 3.53 - 3.57 (m, 4 H), 3.09 - 3.13 (m, 4H), LC-MS : rt 3.03 min., m / z 384 (M+1).

[0251] Step 6-3 A mixed solution of (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime (58.7 mg, 0.152 mmol) in 2N aqueous potassium hydroxide solution (1 mL) and dioxane (3 mL) was stirred and heated at 120° C. for 25 hours. The solution was concentrated under reduced pressure, neutralized with 2N aqueous hydrochloric acid solution, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / methanol) to obtain 6.9 mg of the title compound. 1 H NMR (CDCl3, 400 MHz)δ7.42 (t, J = 8.0 Hz), 7.37 - 7.41 (m, 2 H), 7.44-7.52 (m, 2H), 7.21 - 7.27 (m, 2H), 7.11 (dd, 1 H, J = 1.6, 8.0 Hz), 7.00 (dt, 1 H, J = 1.6, 8.0 Hz), 3.60 - 3.67 (m, 4 H), 3.26 - 3.30 (m, 4H), LC-MS: rt 3.01 min., m / z 384 (M+1).

[0252] [Example 7] Synthesis of 4-chloro-3-(4-(3-chloropyridin-2-yl)piperazin-1-yl)benzo[d]isoxazole (Compound 071) [ka]

[0253] Step 7-1 (E)-(4-(3-chloropyridin-2-yl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime and Z isomer were obtained according to the method of Step 6-2 of Example 6, except that 1-(3-chloropyridin-2-yl)piperazine hydrochloride was used instead of 1-(2-chlorophenyl)piperazine. (E)-(4-(3-chloropyridin-2-yl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime (Compound 072(E)): 1 H NMR (CDCl3, 400 MHz)δ8.17 (dd, 1 H, J = 1.6, 4.8 Hz), 7.58 (dd, 1 H, J = 1.2, 7.6 Hz), 7.39 (dd, 1 H, J =1.2, 7.6 Hz), 7.33 (s, 1 H), 7.28 (dd, 1H, J = 7.6, 9.2 Hz), 7.06 (br, 1H), 6.85 (dd, 1 H, J =4.8, 8.0 Hz), 5.72 (br, 1 H), 3.25 - 3.34 (m, 8 H), LC-MS: rt 3.03 min., m / z 384 (M+1). (Z)-(4-(3-chloropyridin-2-yl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime (Compound 072(Z)): 1 H NMR (CDCl3, 400 MHz)δ8.18 (d, 1 H, J = 3.6 Hz), 7.57 (d, 1 H, J = 7.6 Hz), 7.38 (t, 1 H, J =8.0 Hz), 7.34 (d, 1 H, J = 7.6 Hz), 7.26 (t, 1H, J = 8.0 Hz), 7.08 (br, 1H), 6.84 (dd, 1 H, J =4.8, 8.0 Hz), 5.72 (br, 1 H), 3.52 - 3.58 (m, 3 H), 3.40 - 3.44 (m, 3 H), 3.35 - 3.38 (m, 2 H), LC-MS: rt 2.70 min., m / z 385 (M+1).

[0254] Step 7-2 A mixture of (E)-(4-(3-chloropyridin-2-yl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime (192 mg, 0.498 mmol) in 2N aqueous potassium hydroxide solution (2 mL) and dioxane (6 mL) was stirred and heated in a microwave at 120° C. for 1 hour. LC / MS analysis showed a conversion rate of about 50%. The solution was neutralized with 1N aqueous hydrochloric acid and saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / methanol) to obtain 70.6 mg of the title compound and 79 mg of the starting material. 1 H NMR (CDCl3, 400 MHz)δ7.42 (t, 1 H, J = 8.0 Hz), 7.37 - 7.41 (m, 2 H), 7.44-7.52 (m, 2H), 7.21 - 7.27 (m, 2H), 7.11 (dd, 1 H, J = 1.6, 8.0 Hz), 7.00 (dt, 1 H, J = 1.6, 8.0 Hz), 3.60 - 3.67 (m, 4 H), 3.26 - 3.30 (m, 4H), LC-MS: rt 3.01 min., m / z 384 (M+1).

[0255] [Example 8] Synthesis of 5-chloro-6-(4-(4-chlorobenzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (compound 081) [ka]

[0256] Step 8-1 According to the method of step 6-2 of example 6, except that 5-chloro-6-(piperazin-1-yl)nicotinic acid trifluoroacetate was used instead of 1-(2-chlorophenyl)piperazine, 5-chloro-6-(4-((2,6-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid (Compound 082) was obtained.

[0257] Step 8-2 A mixture of 5-chloro-6-(4-((2,6-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid (215 mg, 0.5 mmol) in 2N aqueous potassium hydroxide solution (2 mL) and dioxane (6 mL) was stirred and heated in a microwave at 140° C. for 1 hour. LC / MS analysis showed a conversion rate of about 90%. The solution was neutralized with 1N aqueous hydrochloric acid solution and 10% aqueous KHSO4 solution, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / methanol) to obtain 75 mg of the title compound. 1 H NMR (DMSO, 400 MHz)δ8.66 (d, 1 H, J = 2.0 Hz), 8.08 (d, 1 H, J = 2.0 Hz), 7.63 (d, 1 H, J = 8.0 Hz), 7.60 (t, 1 H, J = 8.0 Hz), 7.42 (d, 1 H, J = 8.0 Hz), 3.63 - 3.67 (m, 4H), 3.43 - 3.47 (m, 4H), LC-MS: rt 2.87 min., m / z 393 (M+1).

[0258] [Example 9] Synthesis of 5-chloro-6-(4-(4-chlorobenzo[d]isoxazol-3-yl)piperazin-1-yl)N,N-dimethylnicotinamide (Compound 091) [ka]

[0259] Step 9-1 A solution of 6-(4-(tert-butoxycarbonyl)piperazin-1-yl)-5-chloroniconic acid (171 mg, 0.5 mmol), dimethylamine (0.75 mmol), triethylamine (209 μL, 1.5 mmol) and HATU (285 mg, 0.75 mmol) in DMF (3 mL) was stirred at room temperature for 3 hours, saturated saline was added and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography to obtain 153.2 mg of tert-butyl 4-(3-chloro-5-(dimethylcarbamoyl)pyridin-2-yl)piperazine-1-carboxylate (Rf = 0.45, 1:3 hexane / ethyl acetate). This compound was treated with an excess of trifluoroacetic acid to give 5-chloro-N,N-dimethyl-6-(piperazin-1-yl)nicotinamide trifluoroacetate.

[0260] Step 9-2 A solution of 5-chloro-N,N-dimethyl-6-(piperazin-1-yl)nicotinamide (159 mg, 0.415 mmol) and triethylamine (289 μL, 2.075 mmol) in DMF (2 mL) was added to a solution of 2,6-dichloro-N-hydroxy-6-benzimidoyl chloride (0.5 mL, about 0.5 mmol) from step 6-1 of Example 6 at room temperature and stirred for 3 hours. A saturated aqueous solution of ammonium chloride was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / methanol) to obtain (E)-5-chloro-6-(4-((2,6-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)-N,N-dimethylnicotinamide (compound 092(E); 77.2 mg; LC-MS: rt 2.27 min., m / z 456 (M+1)) and the Z isomer (30 mg). (Z)-5-chloro-6-(4-((2,6-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)-N,N-dimethylnicotinamide (compound 092(Z)): 1H NMR (CDCl3, 400 MHz)δ8.24 (d, 1 H, J = 2.0 Hz), 7.72 (d, 1 H, J = 2.4 Hz), 7.39 (dd, 1 H, J = 0.8, 8.0 Hz), 7.38 (s, 1 H), 7.30 (dd, 1H, J = LC-MS: rt 2.08 min., m / z 456 (M+1).

[0261] Step 9-3 A mixture of (E)-5-chloro-6-(4-((2,6-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)-N,N-dimethylnicotinamide (77.2 mg, 0.048 mg) in 2N aqueous potassium hydroxide solution (2 mL) and dioxane (6 mL) was stirred and heated in a microwave at 140°C for 1 hour. LC / MS analysis showed a conversion rate of about 70%. A 10% aqueous KHSO4 solution was added to the solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting solid was recrystallized from isopropanol to obtain 20.2 mg of the title compound. 1 H NMR (CDCl3, 400 MHz)δ8.28 (d, 1 H, J = 2.4 Hz), 7.74 (d, 1 H, J = 2.4 Hz), 7.42 (dd, 1 H, J = 6.8, 8.8 Hz), 7.39 (dd, 1 H, J = 1.2, 8.8 Hz), 7.26 (dd, 1 H, J = 1.2, 6.8 Hz), 3.64 - 3.68 (m, 4 H), 3.58 - 3.61 (m, 4H), LC-MS: rt 2.89 min., m / z 420 (M+1).

[0262] [Example 10] Synthesis of 3-chloro-4-(4-(4-chlorobenzo[d]isoxazol-3-yl)piperazin-1-yl)benzoic acid (compound 101) [ka]

[0263] Step 10-1 Following the procedure of step 6-2 of Example 6, except that 3-chloro-4-(piperazin-1-yl)benzoic acid methyl ester was used instead of 1-(2-chlorophenyl)piperazine, 3-chloro-4-(4-((2,6-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)benzoic acid methyl ester (compound 102) was obtained (LC-MS: rt 2.97 min., m / z 442 (M+1)).

[0264] Step 10-2 The title compound was obtained according to the method of Step 8-2 of Example 8, except that 3-chloro-4-(4-((2,6-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)benzoic acid methyl ester was used instead of 5-chloro-6-(4-((2,6-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid. 1 H NMR (DMSO, 400 MHz)δ7.85 (d, 1 H, J = 1.6 Hz), 7.79 (dd, 1 H, J = 1.6, 8.4 Hz), 7.67 (dd, 1 H, J = 1.6, 8.4 Hz), 7.63 (dd, 1 H, J = 7.2, 8.8 Hz), 7.45 (dd, 1 H, J = 1.2, 8.0 Hz), 7.22 (bd, 1 H, J = 8.0 Hz), 3.48 - 3.53 (m, 4 H), 3.24 - 3.28 (m, 4H), LC-MS: rt 2.94 min., m / z 392 (M-1).

[0265] [Example 11] Synthesis of 5-chloro-3-(4-(3-chloropyridin-2-yl)piperazin-1-yl)benzo[d]isoxazole (Compound 111) [ka]

[0266] Step 11-1 A DMF solution of 2,5-dichloro-N-hydroxy-6-benzimidoyl chloride was obtained according to the methods of steps 1-1 and 1-2 of Example 1, except that 2,5-dichlorobenzaldehyde was used instead of 2-fluoro-6-(trifluoromethyl)benzaldehyde.

[0267] Step 11-2 (E)-4-(3-chloropyridin-2-yl)piperazin-1-yl)(2,5-dichlorophenyl)methanone oxime, its Z isomer and E,Z mixture were obtained according to the method of Step 6-2 of Example 6, except that 1-(3-chloropyridin-2-yl)piperazine hydrochloride was used instead of 1-(2-chlorophenyl)piperazine, and a DMF solution of 2,5-dichloro-N-hydroxy-6-benzimidoyl chloride was used instead of a DMF solution of 2,6-dichloro-N-hydroxy-6-benzimidoyl chloride. (E)-4-(3-chloropyridin-2-yl)piperazin-1-yl)(2,5-dichlorophenyl)methanone oxime (compound 112(E)): 1 H NMR (CDCl3, 400 MHz)δ8.18 (dd, 1 H, J = 1.2, 4.8 Hz), 7.59 (dd, 1 H, J = 2.0. 8.0 Hz), 7.40 (d, 1 H, J = 8.0 Hz), 7.33 (dd, 1H, J = 4.8, 8.0 Hz), 5.83 (br, 1 H), 3.29 - 3.37 (m, 6 H), 3.18 - 3.25 (m, 2 H), LC-MS: rt 2.83 min., m / z 385 (M+1). (Z)-4-(3-chloropyridin-2-yl)piperazin-1-yl)(2,5-dichlorophenyl)methanone oxime (compound 112(Z)): 1H NMR (CDCl3, 400 MHz)δ8.40 (br, 1 H), 8.17 (dd, 1 H, J = 1.6, 4.8 Hz), 7.57 (dd, 1 H, J = 2.0. 7.6 Hz), 7.41 (d, 1 H, J =2.0 Hz), 7.32 (s, 1 H), 7.31 (d, 1H, J = 2.4 Hz), 6.83 (dd, 1 H, J = 4.8, 8.0 Hz), 3.47 - 3.52 (m, 4 H), 3.36 - 3.41 (m, 4 H), LC-MS: rt 2.83 min., m / z 385 (M+1).

[0268] Step 11-3 A mixed solution of (E)-(4-(3-chloropyridin-2-yl)piperazin-1-yl)(2,5-dichlorophenyl)methanone oxime (26.8 mg, 0.069 mmol) in 2N potassium hydroxide aqueous solution (1 mL) and dioxane (3 mL) was stirred and heated in a microwave at 120° C. for 0.5 hours and then at 140° C. for 1 hour. The solution was neutralized with 1N hydrochloric acid aqueous solution and saturated ammonium chloride aqueous solution, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate) to obtain 17.6 mg of the title compound. 1 H NMR (CDCl3, 400 MHz)δ8.2 (dd, 1 H, J = 1.6, 4.8 Hz), 7.71 (d, 1 H, J = 1.6 Hz), 7.63 (dd, 1 H, J = 1.2, 8.0 Hz), 7.46 (dd, 1 H, J = 2.0, 8.4 Hz), 7.40 (d, 1 H, 8.4 Hz), 6.90 (dd, 1 H, J = 4.8, 8.0 Hz), 3.68 - 3.72 (m, 4 H), 3.55 - 3.59 (m, 4H), LC-MS: rt 3.18 min., m / z 349 (M+1).

[0269] [Example 12] Synthesis of 5-chloro-6-(4-(5-chlorobenzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (compound 121) [ka]

[0270] Step 12-1 Following the procedure of step 6-2 of Example 6, except that 5-chloro-6-(piperazin-1-yl)nicotinic acid hydrochloride was used instead of 1-(2-chlorophenyl)piperazine, and a DMF solution of 2,5-dichloro-N-hydroxy-6-benzimidoyl chloride was used instead of a DMF solution of 2,6-dichloro-N-hydroxy-6-benzimidoyl chloride, 5-chloro-6-(4-((2,5-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid (compound 122) was obtained (LC-MS: rt 2.46 min., m / z 429 (M+1)).

[0271] Step 12-2 A mixture of 5-chloro-6-(4-((2,5-dichlorophenyl)(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid (115.1 mg, 0.5 mmol) in 2N aqueous potassium hydroxide solution (2 mL) and dioxane (6 mL) was stirred and heated at 140° C. for 2 hours in a microwave oven. LC / MS analysis showed a conversion rate of about 100%. The solution was neutralized with 1N aqueous hydrochloric acid solution and 10% aqueous KHSO4 solution, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was recrystallized from isopropanol to obtain 26.8 mg of the title compound. 1H NMR (DMSO, 400 MHz)δ8.65 (d, 1 H, J = 2.0 Hz), 8.17 (bs, 1 H), 8.08 (d, 1 H, J = 1.6 Hz), 7.60 - 7.61 (m, 2 H), 3.59 - 3.61 (m, 4 H), 3.25 - 3.35 (m, 4H), LC-MS: rt 2.83 min., m / z 393 (M+1).

[0272] [Example 13] Synthesis of 5-chloro-6-(4-(5-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (compound 131) [ka]

[0273] Step 13-1 A 1N aqueous solution of sodium hydroxide (28.8mL, 28.8mmol) was added to a solution of 2-chloro-5-(trifluoromethyl)benzaldehyde (5g, 23.97mmol) and hydroxylamine hydrochloride (2g, 28.8mmol) in ethanol (20mL), and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure and extracted with ethyl acetate. The organic layer was washed with water and saturated saline, then dried over magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 2-chloro-5-(trifluoromethyl)benzaldehyde oxime (4.77g) as a mixture of Z and E isomers.

[0274] Step 13-2 To a solution of 2-chloro-5-(trifluoromethyl)benzaldehyde oxime (4.77 g, 21.33 mmol) in DMF (10 mL) was added NCS (N-chlorosuccinimide) (2.99 g, 22.4 mmol) at 0° C. and stirred at room temperature overnight. LC / MS showed 100% conversion of the oxime to the chloride. The solution of 2-chloro-N-hydroxy-6-(trifluoromethyl)benzimidoyl chloride was used in the next reaction without purification.

[0275] Step 13-3 A solution of 5-chloro-6-(piperazin-1-yl)nicotinic acid hydrochloride (70 mg, 0.252 mmol) and triethylamine (140 μL, 1.0 mmol) in dichloromethane (1 mL) was added to a DMF solution of 2-chloro-N-hydroxy-5-(trifluoromethyl)benzimidoyl chloride (0.252 mL, approximately 0.252 mmol) from step 13-2 at room temperature and stirred for 3 hours. A 10% KHSO4 aqueous solution was added to the reaction solution, and the insoluble matter was filtered off, and the filtrate was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure to obtain crude 5-chloro-6-(4-((2-chloro-5-(trifluoromethyl)phenyl)(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid (compound 132) (LC-MS: rt 2.59 min., m / z 463 (M+1)). This compound was used in the next step without purification.

[0276] Step 13-4 A mixture of 5-chloro-6-(4-((2-chloro-6-(trifluoromethyl)phenyl)(hydroxyimino)methyl)piperazin-1-yl)nicotinic acid (117 mg, 0.253 mmol) in 2N aqueous potassium hydroxide solution (1 mL, 2 mmol) and dioxane (5 mL) was stirred and heated in a microwave at 160° C. for 1 h. LC / MS analysis showed a conversion rate of 100%. The solution was neutralized with 10% aqueous KHSO4 and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate) to obtain 42 mg of the crude title compound. This was further washed with warmed acetonitrile to obtain 29.9 mg of the title compound. 1H NMR (DMSO, 400 MHz)δ8.70 (d, 1 H, J = 2.4 Hz), 8.50 (bs, 1 H), 8.13 (d, 1 H, J = 1.6 Hz), 7.95 (dd, 1 H, 1.6, 8.4 Hz), 7.84 (d, 1 H, J = 8.4 Hz), 3.68 - 3.71 (m, 4H), 3.31 - 3.34 (m, 4H), LC-MS: rt 2.92 min., m / z 427 (M+1).

[0277] [Example 14] Synthesis of 3-(4-(pyridin-2-yl)piperazin-1-yl)benzo[d]isoxazole (compound 141) [ka]

[0278] A solution of 3-chlorobenzo[d]isoxazole (100 mg, 0.651 mmol) and 1-(pyridin-2-yl)piperazine (319 mg, 1.954 mmol) in pyridine (1 mL) was stirred and heated in a microwave at 150° C. for 1 hour. The solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate) to obtain 61.1 mg of the title compound. 1 H NMR (CDCl3, 400 MHz)δ8.31 (dd, 1H, J = 4.0, 1.6 Hz), 7.72 (d, 1H, J = 8.4 Hz), 7.45-7.56 (m, 3H), 7.25 (dt, 1H, J = 1.2, 6.4 Hz), 6.72 (d, 1H, J = 8.8 Hz), 6.68 (dd, 1H, J = 4.8, 7.2 Hz), 3.74 - 3.78 (m, 4 H), 3.67 - 3.71 (m, 4H), LC-MS: rt 1.52 min., m / z 281 (M+1).

[0279] [Example 15] Synthesis of 3-(4-(2-chlorophenyl)piperazin-1-yl)benzo[d]isoxazole (Compound 151) [ka]

[0280] A solution of 3-chlorobenzo[d]isoxazole (77.5 mg, 0.505 mmol) and 1-(2-chlorophenyl)piperazine (84 μL, 0.505 mmol) in pyridine (1 mL) was stirred and heated in a microwave at 180° C. for 40 minutes. The solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 8.7 mg of the title compound. Rf: 0.5 (10 : 1 hexane / ethyl acetate) 1 H NMR (CDCl3, 400 MHz)δ7.74 (d, 1H, J = 8.4 Hz), 7.45-7.52 (m, 2H), 7.39 (dd, 1H, J = 1.6, 8.4 Hz), 7.20 - 7.28 (m, 3H), 7.10 (d, 1 H, J = 7.2 Hz), 7.02 (dd, 1H, J = 1.6, 7.2 Hz), 3.74 - 3.78 (m, 4 H), 3.24 - 3.28 (m, 4H), LC-MS: rt 3.15 min., m / z 314 (M+1).

[0281] [Example 16] Synthesis of 3-(4-(2,3-dimethylphenyl)piperazin-1-yl)benzo[d]isoxazole (compound 161) [ka]

[0282] A solution of 3-chlorobenzo[d]isoxazole (50 mg, 0.326 mmol) and 1-(2,3-dimethylphenyl)piperazine (62 mg, 0.326 mmol) in pyridine (1 mL) was stirred and heated in a microwave at 180° C. for 30 minutes. The solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 2.4 mg of the title compound. Rf: 0.8 (5 : 1 hexane / ethyl acetate), 1 H NMR (CDCl3, 400 MHz)δ7.73 (d, 1H, J = 8.0 Hz), 7.44-7.52 (m, 2H), 7.22 (dd, 1H, J = 1.6, 8.0 Hz), 7.10 (d, 1 H, J = 8.0 Hz), 6.92 - 6.97 (m, 2H), 3.64 - 3.81 (m, 4H), 3.05 - 3.12 (m, 4H), 2.28 (s, 3H), 2.27 (S, 3H), LC-MS: rt 3.34 min., m / z 308 (M+1).

[0283] [Example 17] Synthesis of 3-(4-(2,4-dichlorophenyl)piperazin-1-yl)benzo[d]isoxazole (compound 171) [ka]

[0284] A solution of 3-chlorobenzo[d]isoxazole (55 mg, 0.358 mmol) and 1-(2,4-dichlorophenyl)piperazine (190 mg, 0.822 mmol) in dimethoxyethane (0.5 mL) was stirred and heated in a microwave oven at 160° C. for 120 minutes. The solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 13.3 mg of the title compound. 1H NMR (CDCl3, 400 MHz)δ7.71 (d, 1 H, J = 8.4 Hz), 7.49 (t, 1 H, J = 8.0 Hz), 7.46 (d, 1 H, J = 8.0 Hz), 7.39 (d, 2H, J = 2.4 Hz), 7.19 - 7.24 (m, 2H), 7.00 (d, 1H, J = 8.4 Hz), 3.72 - 3.77 (m, 4H), 3.19 - 3.23 (m, 4H), LC-MS: rt 3.40 min., m / z 348 (M+1).

[0285] [Example 18] Synthesis of 3-(4-(3-chloropyridin-2-yl)piperazin-1-yl)benzo[d]isothiazole (compound 181) [ka]

[0286] A solution of 2-bromo-3-chloropyridine (96 mg, 0.5 mmol), 3-(piperazin-1-yl)benzo[d]isothiazole (110 mg, 0.5 mmol), Pd2(dba)3 (tris(dibenzylideneacetone)dipalladium(0), 46.8 mg, 0.05 mmol), sodium tert-butoxide (57.7 mg, 0.6 mmol) and (2,2'-bis(diphenylphosphanyl)-1,1'-bisnaphthalene (62.3 mg, 0.1 mmol) in dioxane (10 mL) was stirred and heated at 90 ° C for 9 hours. The mixture was extracted with ethyl acetate, the organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 42 mg of the crude title compound. This was further washed with warm acetonitrile to obtain 44.6 mg of the title compound. Rf = 0.75,(2 : 1 hexane / ethyl acetate) 1H NMR (CDCl3, 400 MHz)δ8.22 (d, 1 H, J = 4.8 Hz), 7.96 (d, 1 H, J = 8.0 Hz), 7.83 (d, 1 H, J = 8.0 Hz), 7.62 (d, 1 H, J = 8.0 Hz), 7.48 (t, 1H, J = 8.0 Hz), 7.38 (t, 1 H, J = 8.0 Hz), 6.88 (dd, 1 H, J = 4.8, 8.0 Hz), 3.69 - 3.73 (m, 4 H), 3.58 - 3.62 (m, 4H), LC-MS: rt 2.86 min., m / z 331 (M+1).

[0287] [Example 19] Synthesis of 5-chloro-6-(8-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)-3,8-diazabicyclo[3,2,1]octan-3-yl)nicotinic acid (compound 191) [ka]

[0288] Step 19-1 A solution of tert-butyl (1R,5S)-3,8-diazabicyclo[3,2,1]octane-8-carboxylate (0.5 g, 2.355 mmol), 5,6-dichloronicotinic acid (0.452 g, 2.355 mmol) in pyridine (5 mL) was heated and stirred at 90° C. for 10 hours. After dilution with purified water, the mixture was neutralized with 10% KHSO4 to a pH of about 6, and the resulting solid was collected by filtration, washed with purified water, and dried under reduced pressure to obtain 248 mg of crude 6-(8-(Tert-butoxycarbonyl)-3,8-diazabicyclo[3,2,1]octan-3-yl)-5-chloronicotinic acid. This was used in the next step without purification.

[0289] Step 19-2 To a solution of the above crude 6-(8-(Tert-butoxycarbonyl)-3,8-diazabicyclo[3,2,1]octan-3-yl)-5-chloronicotinic acid (227 mg, 0.617 mmol) in methanol (5 mL) was added excess thionyl chloride at room temperature and allowed to stand overnight. The reaction mixture was concentrated to dryness to give 208.2 mg of crude 6-(3,8-diazabicyclo[3,2,1]octan-3-yl)-5-chloronicotinic acid hydrochloride, which was used in the next step without purification.

[0290] Step 19-3 To a solution of the above crude 6-(3,8-diazabicyclo[3,2,1]octan-3-yl)-5-chloronicotinic acid hydrochloride (152 mg, 0.5 mmol) and triethylamine (279 μL, 2.0 mmol) in DMF (1.5 mL), a solution of approximately 1 N 2-fluoro-N-hydroxy-6-(trifluoromethyl)benzimidoyl chloride in DMF (0.5 mL) was added at room temperature and stirred overnight. After dilution with purified water, the mixture was neutralized with 10% KHSO4 to a pH of about 6, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 136.4 mg of 5-chloro-6-(8-((2-fluoro-6-(trifluoromethyl)phenyl(hydroxyimino)methyl)-3,8-diazabicyclo[3,2,1]octan-3-yl)nicotinic acid (compound 192) (LC-MS: rt 2.54 min., m / z 473 (M+1)). (Rf = 0.1, 2:1 ethyl acetate / hexane).

[0291] Step 19-4 A mixture of 5-chloro-6-(8-((2-fluoro-6-(trifluoromethyl)phenyl(hydroxyimino)methyl)-3,8-diazabicyclo[3,2,1]octan-3-yl)nicotinic acid (90 mg) in 2N potassium hydroxide aqueous solution (0.6 mL) and dioxane (1.8 mL) was stirred and heated at 100 ° C for 10 hours. LC / MS analysis showed a conversion rate of about 95%. The reaction solution was diluted with purified water, neutralized with 1N hydrochloric acid and 10% KHSO4 to a pH of about 6, extracted with ethyl acetate, the organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane), and the obtained solid was filtered and washed with warm isopropanol. This was dried to obtain 16.3 mg of the title compound. Rf = 0.25(2 : 1 ethyl acetate / hexane) 1 H NMR (DMSO, 400 MHz)δ8.63 (dd, 1 H, J =0.8, 1.6 Hz), 8.07 - 8.11 (m, 2 H), 7.83 - 7.87 (m, 2 H), 4.85 - 4.88 (br, 2 H), 3.33 - 3.38 (m, 6H), 2.13 (dd, 2 H. J = 12.8, 6.0 Hz), 1.91 - 1.99 (m, 2 H), LC-MS: rt 3.21 min., m / z 453 (M+1).

[0292] [Example 20] Synthesis of 7-chloro-3-(4-(2-chlorophenyl)piperazin-1-yl)benzo[d]isoxazole (Compound 201) [ka]

[0293] According to the method of Steps 6-1 and 6-2 of Example 6, except that 2,3-dichlorobenzaldehyde was used instead of 2,6-dichlorobenzaldehyde, (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,3-dichlorophenyl)methanone oxime and its Z isomer were obtained. (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,3-dichlorophenyl)methanone oxime (Compound 202(E)): Rf: 0.5, 3 : 1 hexane / ethyl acetate, 1 H NMR (CDCl3, 400 MHz)δ7.52 (dd, 1 H, J = 1.2, 8.0 Hz), 7.36 (dd, 1 H, J = 1.2, 8.0 Hz), 7.32 (dd, 1 H, J =2.0, 8.0 Hz), 7.25 (dd, 1 H, J =2.0, 8.0 Hz), 7.21 (dd, 1H, J =2.0, 8.0 Hz), 7.04 (dd, 1H, J = 2.0, 8.0 Hz), 6.98 (dt, 1 H, J =1.2, 8.0 Hz), 3.50 - 3.54 (m, 4 H), 3.07 - 3.11 (m, 4H), LC-MS: rt 3.08 min., m / z 384 (M+1) (Z)-(4-(2-chlorophenyl)piperazin-1-yl)(2,3-dichlorophenyl)methanone oxime (compound 202(Z)): Rf: 0.3, 3:1 hexane / ethyl acetate 1H NMR (CDCl3, 400 MHz)δ7.52 (dd, 1 H, J = 1.2, 8.0 Hz), 7.36 (d, 1 H, J = 8.0 Hz), 7.31 (t, 1 H, J = 8.0 Hz), 7.25 (d, 1 H, J = 8.0 Hz), 7.21 (d, 1H, J = 8.0 Hz), 7.02 (d, 1H, J = 8.0 Hz), 6.99 (t, 1 H, J = 8.0 Hz), 5.77 - 5.89 (br, 1 H), 3.21 - 3.40 (m, 4 H), 3.03 - 3.07 (m, 4H), LC-MS: rt 3.08 min., m / z 384 (M+1).

[0294] The title compound was obtained by following the procedure of Step 6-3 of Example 6, except that (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime was used instead of (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,3-dichlorophenyl)methanone oxime. 1 H NMR (CDCl3, 400 MHz)δ7.63 (d, 1 H, J = 8.8 Hz), 7.50 (d, 1 H, J = 7.6 Hz), 7.42 (dd, 1 H, J =1.2, 7.6 Hz), 7.26 (dt, 1 H, J = 1.2, 7.6 Hz), 7.20 (t, 1 H, J = 7.6 Hz), 7.08 (dd, 1 H, J = 1.2, 7.6 Hz),7.02 (dt, 1 H, J = 1.2, 7.6 Hz), 3.74 - 3.78 (m, 4 H), 3.23 - 3.28 (m, 4H), LC-MS: rt 3.38 min., m / z 384 (M+1).

[0295] [Example 21] Synthesis of 6-chloro-3-(4-(2-chlorophenyl)piperazin-1-yl)benzo[d]isoxazole (Compound 211) [ka]

[0296] According to the method of Steps 6-1 and 6-2 of Example 6, except that 2,4-dichlorobenzaldehyde was used instead of 2,6-dichlorobenzaldehyde, (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,4-dichlorophenyl)methanone oxime and its Z isomer were obtained. (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,4-dichlorophenyl)methanone oxime (Compound 212(E)): Rf: 0.5 (3 : 1 hexane / ethyl acetate) 1H NMR (CDCl3, 400 MHz)δ7.41 (d, 1 H, J = 1.6 Hz), 7.39 (s, 1 H), 7.36 (dd, 1 H, J =1.6, 8.0 Hz), 7.30 (dd, 1 H, J =7.2, 8.8 Hz), 7.21 (dd, 1H, J =1.2, 7.2 Hz), 7.03 (dd, 1H, J = 2.0, 8.0 Hz), 6.98 (dt, 1 H, J =1.2, 8.0 Hz), 5.72 (br, 1 H), 3.35 - 3.40 (m, 4 H), 3.04 - 3.09 (m, 4H), LC-MS: rt 3.03 min., m / z 384 (M+1). (Z)-(4-(2-chlorophenyl)piperazin-1-yl)(2,4-dichlorophenyl)methanone oxime (compound 212(Z)): Rf: 0.3 (3 : 1 hexane / ethyl acetate) 1 H NMR (CDCl3, 400 MHz)δ7.36 (dd, 1 H, J = 1.2, 7.2 Hz), 7.35 (d, 1 H, J = 1.2, 8.0 Hz), 7.26 (dd, 1 H, J = 1.2, 8.0 Hz), 7.28 (dd, 1 H, J = 2.0, 8.0 Hz), 7.22 (dt, 1H, J = 1.2, 7.2 Hz), 7.04 (dd, 1H, J = 8.0 Hz), 6.97 (dt, 1 H, J = 1.2, 8.0 Hz), 6.46 (br, 1 H), 3.53 - 3.57 (m, 4 H), 3.09 - 3.13 (m, 4H), LC-MS: rt 3.03 min., m / z 384 (M+1).

[0297] The title compound was obtained by following the procedure of Step 6-3 of Example 6, except that (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,6-dichlorophenyl)methanone oxime was used instead of (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2,4-dichlorophenyl)methanone oxime. 1 H NMR (CDCl3, 400 MHz)δ7.64 (d, 1 H, J = 8.8 Hz), 7.49 (d, 1 H, J = 2.0 Hz), 7.40 (dd, 1 H, J =1.6, 8.0 Hz), 7.26 (dt, 1 H, J = 1.2, 7.6 Hz), 7.22 (dd, 1 H, J = 2.0, 8.8 Hz), 7.08 (dd, 1 H, J = 1.6, 8.0 Hz),7.02 (dt, 1 H, J = 1.2, 7.6 Hz), 3.72 - 3.76 (m, 4 H), 3.23 - 3.27 (m, 4H), LC-MS: rt 3.42 min., m / z 384 (M+1).

[0298] [Example 22] Synthesis of 5-chloro-6-(4-(4-chlorobenzo[d]isoxazol-3-yl)piperazin-1-yl)pyridin-3-yl)(morpholino)methanone (compound 221) [ka]

[0299] Following the procedure of Example 2, except substituting 5-chloro-6-(4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid with 5-chloro-6-(4-(4-chlorobenzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (Compound 081) and substituting morpholine for methylamine, gave the title compound. 1H NMR (CDCl3, 400 MHz)δ8.34 (d, 1 H, J = 2.0 Hz), 8.25 (d, 1 H, J = 1.6 Hz), 7.73 (d, 1 H, J = 1.6 Hz), 7.43 (dd, 1 H, J = 7.2, 8.4 Hz), 7.40 (dd, 1 H, J = 1.6, 8.4 Hz), 7.26 (dd, 1 H, J = 1.2, 6.8 Hz), 3.57 - 3.85 (m, 12 H), LC-MS: rt 2.80 min., m / z 413 (M+1).

[0300] [Example 23] Synthesis of 5-chloro-6-(4-(4-chlorobenzo[d]isoxazol-3-yl)piperazin-1-yl)-N-(methylsulfonyl)nicotinamide (Compound 231) [ka]

[0301] A solution of 5-chloro-6-(4-(4-chlorobenzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (compound 081, 79 mg, 0.2 mmol), methanesulfonamide (28.5 mg, 0.3 mmol), DMAP (4-dimethylaminopyridine, 36.7 mg, 0.3 mmol) and EDC (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, 57.5 mg, 0.3 mmol) in dichloromethane (1 mL) was stirred at room temperature overnight. The reaction mixture was adjusted to pH 3 with 10% KHSO4 and saturated aqueous sodium bicarbonate, then extracted with ethyl acetate, the organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 40.1 mg of the title compound. Rf = 0.3, 5% methanol / ethyl acetate 1H NMR (DMSO, 400 MHz)δ8.67 (s, 1 H), 8.12 (s, 1 H), 7.67 (d, 1 H, J = 8 Hz), 7.63 (t, 1 H, J = 8 Hz), 7.45 (d, 1 H, J = 7.2 Hz), 3.53 - 3.58 (m, 4 H), 3.47 - 3.52 (m, 4 H), LC-MS: rt 2.78 min., m / z 470 (M+1).

[0302] [Example 24] Synthesis of methyl 5-chloro-6-(4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinate (Compound 241) [ka]

[0303] 5-Chloro-6-(4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (compound 011, 110 mg) in 1N hydrogen chloride methanol solution (12 mL) was heated and stirred at 68° C. for 24 hours. Analysis by LC / MS showed a conversion rate of about 90%. The reaction mixture was concentrated, diluted with purified water, neutralized with saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 84.9 mg of the title compound. (Rf = 0.5, 2 : 1 hexane / ethyl acetate). 1H NMR (CDCl3, 400 MHz)δ8.77 (d, 1 H, J = 2.0 Hz), 8.16 (d, 1 H, J = 2.0 Hz), 7.74 (dd, 1 H, J = 1.2, 7.2 Hz), 7.66 (dd, 1 H, J = 1.2, 8.0 Hz), 7.63 (t, 1 H, J = 6.8 Hz), 3.92 (s, 3 H), 3.75 - 3.78 (m, 4 H), 3.44 - 3.48 (m, 4H), LC-MS: rt 2.21 min., m / z 423 (M+1).

[0304] [Example 25] Synthesis of (5-chloro-6-(4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)pyridin-3-yl)methanol (Compound 251) [ka]

[0305] Isopropanol (0.08mL) was added to a THF solution of 5-chloro-6-(4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)methyl nicotinate (compound 241, 24mg) and sodium borohydride (4mg), and the mixture was heated and stirred at 65°C for 4 hours. Methanol was added to the reaction mixture and the mixture was concentrated. The residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 4.7mg of the title compound. Rf = 0.27, 1:1 hexane / ethyl acetate 1H NMR (CDCl3, 400 MHz)δ8.18 (d, 1 H, J = 2.0 Hz), 7,73 (dd, 1 H, J = 1.2, 8 Hz), 7.69 (d, 1 H, J = 2.0 Hz), 7.65 (d, 1 H, J = 8 Hz), 7.62 (t, 1 H, J = 8 Hz), 4.66 (d, 2 H, J = 4.8 Hz), 3.55 - 3.59 (m, 4 H), 3.45 - 3.49 (m, 4H), LC-MS: rt 3.23 min., m / z 413 (M+1).

[0306] [Example 26] Synthesis of 3-(4-(3-methylpyridin-2-yl)piperazin-1-yl)-4-(trifluoromethyl)benzo[d]isoxazole (compound 261) [ka]

[0307] The title compound was obtained according to the methods of Steps 1-3 and 1-4 of Example 1, except for using 1-(3-methylpyridin-2-yl)piperazine instead of 5-chloro-6-(piperazin-1-yl)nicotinic acid hydrochloride. 1 H NMR (CDCl3, 400 MHz)δ8.20 (dd, 1 H, J = 2.0, 5.2 Hz), 7,73 (dd, 1 H, J = 1.2, 8 Hz), 7.65 (d, 1 H, J = 8 Hz), 7.61 (t, 1 H, J = 8 Hz), 7.44 (d, 1 LC-MS: rt 2.42 min., m / z 363 (M+1).

[0308] [Example 27] Synthesis of 4-methoxy-3-(4-(2-chlorophenyl)piperazin-1-yl)benzo[d]isoxazole (Compound 271) [ka]

[0309] The title compound was obtained by following the procedure of Example 1, except substituting 2-fluoro-6-(methoxy)benzaldehyde for 2-fluoro-6-(trifluoromethyl)benzaldehyde. Rf: 0.6 (2 : 1 hexane / ethyl acetate), 1 H NMR (CDCl3, 400 MHz)δ7.43 (t, 1H, J = 8.0 Hz), 7.39 (dd, 1H, J = 1.2, 8.0 Hz), 7.25 (dt, 1 H, J = 1.2, 8.4 Hz), 7.11 (dd, 1H, J = 1.2, 8.4 Hz), 7.00 (dt, 1H, J = 1.6, 8.0 Hz), 6.62 (d, 1H, J = 8.4 Hz), 3.97 (s, 3 H), 3.68 - 3.73 (m, 4 H), 3.24 - 3.28 (m, 4H), LC-MS: rt 3.21 min., m / z 344 (M+1).

[0310] [Example 28] Synthesis of 1-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (Compound 281) [ka]

[0311] The title compound was obtained by following the procedures of steps 1-3 and 1-4 of Example 1, except that 1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one was used instead of 5-chloro-6-(piperazin-1-yl)nicotinic acid hydrochloride. 1 H NMR (CDCl3, 400 MHz)δ7.88 (br, 1 H), 7.74 (d, 1 H, J = 8 Hz), 7.67 (d, 1 H, J = 6.4 Hz), 7.63 (t, 1H, J = 8 Hz), 7.30 (d, 1H, J = 7.6 Hz), 7.05 - 7.16 (m, 3 H), 4.65 (tt, 1 H, J = 12, 4.8 Hz), 3.79 (d, 2 H, J = 10.4 Hz), 3.16 (t, 2 H, J = 11.6 Hz), 2.69 (dq, 2 H, J = 4, 12 Hz), 1.96 (d, 2H, J = 12 Hz), LC-MS: rt 2.68 min., m / z 403 (M+1). In addition, in step 1-3 of the synthetic process, 1-(1-((2-fluoro-6-(trifluoromethyl)phenyl(hydroxyimino)methyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one was obtained (compound 282; LC-MS: rt 2.20 min., m / z 423 (M+1)).

[0312] [Example 29] Synthesis of 2-(2-oxo-3-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetic acid tert-butyl ester (compound 291) [ka]

[0313] A solution of 1-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (compound 281, 67 mg, 0.171 mmol), bromoacetic acid tert-butyl ester (50 mg, 0.256 mmol) and 60% sodium hydride (10.4 mg, 0.256 mmol) in DMF (1 mL) was stirred at room temperature for 2 hours, saturated saline was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and concentrated, and the residue was purified by preparative liquid silica gel column chromatography (hexane / ethyl acetate) to obtain the title compound (86.6 mg). 1 H NMR (CDCl3, 400 MHz)δ7.55 (d, 1 H, J = 8 Hz), 7.67 (d, 1 H, J = 6.4 Hz), 7.43 (t, 1H, J = 8 Hz), 7.31 (d, 1H, J = 7.6 Hz), 7.13 (t, 1 H, J = 7.2 Hz), 7.10 (t, 1 H, J = 7.2 Hz), 6.90 (d, 1 H, J = 7.2 Hz), 4.65 (tt, 1 H, J = 12, 4.8 Hz), 4.55 (s, 2 H), 3.77 (d, 2 H, J = 10.4 Hz), 3.15 (t, 2 H, J = 11.6 Hz), 2.70 (dq, 2 H, J = 4, 12 Hz), 1.96 (d, 2 H, J = 12 Hz), 1.46 (s, 9 H), LC-MS: rt 3.25 min., m / z 517 (M+1).

[0314] [Example 30] Synthesis of 2-(2-oxo-3-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetic acid (Compound 301) [ka]

[0315] 2-(2-oxo-3-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetic acid tert-butyl ester (compound 291, 78.3 mg) was dissolved in DME (dimethyl ether, 5 mL), 1N aqueous sodium hydroxide solution (2 mL) was added, and the mixture was stirred at room temperature for 2 hours. The mixture was neutralized with 1N hydrochloric acid, and the precipitated crystals were collected by filtration, washed with purified water, and dried to obtain the title compound (50.8 mg). 1 H NMR (DMSO, 400 MHz)δ8.06 - 8.11 (m, 1 H), 7.87 (d, 1 H, J = 7.6 Hz), 7.84 (t, 1H, J = 3.6 Hz), 7.31 (d, 1H, J = 7.2 Hz), 7.17 (t, 1 H, J = 7.2 Hz), 7.10 (dt, 1 H, J = 1.2, 7.2 Hz), 7.06 (dt, 1 H, J = 1.2, 7.2 Hz), 4.60 (s, 2 H), 4.50 (tt, 1 H, J = 12, 4 Hz), 3.12 (t, 2 H, J = 12 Hz), 2.55 - 2.68 (m, 2 H), 1.84 (d, 2H, J = 12 Hz), LC-MS: rt 2.65 min., m / z 461 (M+1).

[0316] [Example 31] Synthesis of 3-(4-(2-chloropyridin-3-yl)piperazin-1-yl)benzo[d]isoxazole (compound 311) [ka]

[0317] The title compound was obtained by following the procedure of Example 14, except substituting 1-(2-chloropyridin-3-yl)piperazine for 1-(pyridin-2-yl)piperazine. LC-MS: rt 2.60 min., m / z 315 (M+1).

[0318] [Example 32] Synthesis of 3-(4-(3-chloropyridin-2-yl)piperazin-1-yl)benzo[d]isoxazole (compound 321) [ka]

[0319] The title compound was obtained by following the procedure of Example 14, except substituting 1-(3-chloropyridin-2-yl)piperazine for 1-(pyridin-2-yl)piperazine. LC-MS: rt 2.89 min., m / z 315 (M+1).

[0320] [Example 33] Synthesis of 3-(4-(3,5-dichlorophenyl)piperazin-1-yl)benzo[d]isoxazole (compound 331) [ka]

[0321] Following the procedure of Example 17, except substituting 1-(3,5-dichlorophenyl)piperazine for 1-(2,4-dichlorophenyl)piperazine, the title compound was obtained. LC-MS: rt 3.40 min., m / z 348 (M+1)

[0322] [Example 34] Synthesis of methyl 5-chloro-6-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperidin-4-yl)nicotinate (compound 341) [ka]

[0323] Step 34-1 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate tert-butyl (618mg, 2mmol), 5,6-dichloronicotinic acid (384mg, 2mmol), potassium carbonate (691mg, 5mmol), and bistriphenylphosphine palladium dichloride (140mg, 0.2mmol) were added to a mixture (12mL) of dimethoxyethane:ethanol:water (volume ratio 1:1:1) and heated at 90°C for 2 hours under a nitrogen atmosphere. A 10% aqueous solution of potassium hydrogen sulfate was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative diol silica gel column chromatography (5% methanol / ethyl acetate) to obtain 696 mg of 1'-(tert-butoxycarbonyl)-3-chloro-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-carboxylic acid (yield 103%). 1 H NMR (DMSO, 400 MHz)δ8.95 (d, 1 H, J = 1.6 Hz), 8.27 (d, 1 H, J = 1.6 Hz), 6.25 - 6.33 (m, 1 H), 4.02 - 4.08 (m, 2 H), 3.51 - 3.57 (m, 2 H), 3.3 (m, 2H), 1.44 (s, 9H) LC-MS: rt 2.78 min., m / z 284 (M+1-C4H8).

[0324] Step 34-2 1'-(tert-Butoxycarbonyl)-3-chloro-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-carboxylic acid (696 mg, 2 mmol) was added to methanol (5 mL), followed by excess thionyl chloride and heating for 3 h at 45° C. The solvent was concentrated to give methyl 3-chloro-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-carboxylate hydrochloride, which was used in the next step without purification. LC-MS: rt 1.55 min., m / z 253 (M+1).

[0325] Step 34-3 3-Chloro-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-carboxylate methyl ester hydrochloride (322 mg, 1.114 mmol) was dissolved in methanol (5 mL), Pd / C (53 mg) was added, and the mixture was stirred at room temperature under a hydrogen atmosphere for 1 hour. LC / MS confirmed the formation of 5-chloro-6-(piperidin-4-yl)nicotinate methyl ester hydrochloride (1.114 mmol) in the reaction mixture. The reaction mixture was filtered through Celite to remove Pd / C, and the filtrate was concentrated and used in the next reaction. LC-MS: rt 1.57 min., m / z 255 (M+1).

[0326] Step 34-4 The concentrate containing methyl 5-chloro-6-(piperidin-4-yl)nicotinate hydrochloride (1.114 mmol) and triethylamine (0.621 mL, 4.46 mmol) were added to DMF (3 mL) to prepare the first solution. 1.114 mmol of 2-fluoro-N-hydroxy-6-(trifluoromethyl)benzimidoyl chloride was added to DMF to prepare the second solution (0.88235 mmol / mL in DMF). The entire amount of the second solution was added to the entire amount of the first solution at room temperature and stirred overnight. A saturated aqueous solution of ammonium chloride was added to the reaction solution, and it was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 12 mg of methyl 5-chloro-6-(1-((2-fluoro-6-(trifluoromethyl)phenyl)(hydroxyimino)methyl)piperidin-4-yl)nicotinate (compound 342) as an E / Z mixture. 1H NMR (DMSO, 400 MHz)δ9.48 (s, 1 H), 8.99 (d, 1 H, J = 1.6 Hz), 8.27 (d, 1 H, J = 1.6 Hz), 7.59 - 7.73 (m, 3 H), 3.89 (s, 3 H), 3.54 (bd, 1 H, J LC-MS: rt 3.49 min., m / z 460 (M+1).

[0327] Step 34-5 5-Chloro-6-(1-((2-fluoro-6-(trifluoromethyl)phenyl)(hydroxyimino)methyl)piperidin-4-yl)methyl nicotinate (12 mg) and p-toluenesulfonic acid (1 mg) were added to DMSO (1 mL) and heated at 80° C. for 1 hour. DBU (diazabicycloundecene; 100 μL) was added thereto and heated at 100° C. for 90 minutes. A saturated aqueous ammonium chloride solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 7.7 mg of the title compound. 1 H NMR (DMSO, 400 MHz)δ9.04 (d, 1 H, J = 1.6 Hz), 8.31 (d, 1 H, J = 1.6 Hz), 8.06 (dd, 1 H, J = 2.8, 6.4 Hz), 7.80 - 7.86 (m, 2 H), 3.89 (s, 3 H), 3.64 (bd, 2 H, J = 12.4 Hz), 3.44 - 3.52 (m, 1 H), 3.06 (bt, 2 H, J = 11.2 Hz), 2.04 (dq, 2 H, J = 3.2, 11.6 Hz), 1.91 (bd, 2 H, J = 10.4 Hz).LC-MS: rt 4.08 min., m / z 440 (M+1).

[0328] [Example 35] Synthesis of 5-chloro-6-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperidin-4-yl)nicotinic acid (compound 351) [ka]

[0329] 5-Chloro-6-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperidin-4-yl)methyl nicotinate (compound 341; 7.7 mg) was added to DME (dimethyl ether; 1 mL), followed by addition of 1 N aqueous sodium hydroxide solution (0.2 mL) and stirring at room temperature overnight. The resulting solution was concentrated under reduced pressure and neutralized by adding 1 N hydrochloric acid (0.2 mL). The resulting powder was collected by filtration and dried under reduced pressure to obtain 3.1 mg of the title compound. 1 H NMR (DMSO, 400 MHz)δ8.94 (d, 1 H, J = 1.6 Hz), 8.18 (d, 1 H, J = 1.6 Hz), 8.03 (dd, 1 H, J = 2.8, 6.4 Hz), 7.77 - 7.83 (m, 2 H), 3.60 (bd, 2 H, J = 12.4 Hz), 3.37 - 3.48 (m, 1 H), 3.02 (bt, 2 H, J = 11.6 Hz), 2.02 (dq, 2 H, J = 3.2, 12.4 Hz), 1.86 (bd, 2 H, J = 11.2 Hz). LC-MS: rt 3.66 min., m / z 426 (M+1).

[0330] [Example 36] Synthesis of 3-(4-(2-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)-4-(trifluoromethyl)benzo[d]isoxazole (Compound 361) [ka]

[0331] Step 36-1 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate tert-butyl (309 mg, 1 mmol), 1-chloro-2-iodobenzene (238 mg, 1 mmol), potassium carbonate (207 mg, 1.5 mmol), and bistriphenylphosphine palladium chloride (70.2 mg, 0.1 mmol) were added to a mixture (12 mL) of dimethoxyethane:water (volume ratio 2:1) and heated at 90°C for 1 hour under a nitrogen atmosphere. A 10% aqueous solution of potassium hydrogen sulfate was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (hexane / ethyl acetate) to obtain 287.2 mg of tert-butyl 4-(2-chlorophenyl)-3,6-dihydropyridine-1(2H)-carboxylate (yield 98%). 1 H NMR (CDCl3, 400 MHz)δ7.34 - 7.37 (m, 1 H), 7.19 - 7.23 (m, 2 H), 7.15 - 7.18 (m, 1 H), 5.62 - 5.72 (br, 1 H), 4.02 - 4.08 (br, 2 H), 3.60 - 3.66 (bt, 2 H, J = 5.4 Hz), 2.41 - 2.48 (br, 2 H), 1.50 (s, 9 H).LC-MS: rt 3.77 min., m / z 238 (M+1-C4H8).

[0332] Step 36-2 4-(2-chlorophenyl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate (280.5 mg) was added to 4N hydrochloric acid / ethyl acetate (5 mL) and left at room temperature overnight. The solvent was concentrated to give 4-(2-chlorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride, which was used in the next step without purification. LC-MS: rt 1.75 min., m / z 194 (M+1).

[0333] Step 36-3 4-(2-chlorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride (115 mg, 0.5 mmol) and triethylamine (0.209 mL, 1.5 mmol) were added to DMF (3 mL) to prepare the first liquid. 0.5 mmol of 2-fluoro-N-hydroxy-6-(trifluoromethyl)benzimidoyl chloride was added to DMF to prepare the second liquid (0.88235 mmol / mL in DMF). The entire amount of the second liquid was added to the entire amount of the first liquid at room temperature and stirred for 1 hour. A saturated aqueous solution of ammonium chloride was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 158.5 mg of E-(4-(2-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)(2-fluoro-6-(trifluoromethyl)phenyl)methanone oxime (compound 362) as an E / Z mixture. Of this, 80 mg was separated for use in the next reaction, and the remainder was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain E-(4-(2-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)(2-fluoro-6-(trifluoromethyl)phenyl)methanone oxime (Compound 362(E)) and its Z isomer (Compound 362(Z)). (E)-(4-(2-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)(2-fluoro-6-(trifluoromethyl)phenyl)methanone oxime (27.6 mg, Rf = 0.56) 1 H NMR (CDCl3, 400 MHz)δ 7.52 - 7.61 (m, 2 H), 7.32 - 7.41 (m, 2 H), 7.16 - 7.25 (m, 3 H), 6.25 (brs, 1 H), 5.69 (brm, 1 H), 3.84 - 3.99 (m, 2 H), 3.17 - 3.31 (m, 2 H), 2.33 - 2.49 (m, 2 H). LC-MS: rt 3.41 min., m / z 399 (M+1). (Z)-(4-(2-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)(2-fluoro-6-(trifluoromethyl)phenyl)methanone oxime (17.1 mg, Rf = 0.34) 1 H NMR (CDCl3, 400 MHz)δ 7.51 - 7.59 (m, 2 H), 7.31 - 7.39 (m, 2 H), 7.15 - 7.23 (m, 3 H), 6.25 (brs, 1 H), 5.62 (brm, 1 H), 3.91 - 4.15 (m, 2 H), 3.50 - 3.58 (m, 2 H), 2.45 - 2.51 (m, 2 H). LC-MS: rt 3.49 min., m / z 399 (M+1).

[0334] Step 36-4 (4-(2-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)(2-fluoro-6-(trifluoromethyl)phenyl)methanone oxime (compound 362, mixture of E and Z isomers; 80 mg, 0.2 mmol) and p-toluenesulfonic acid (2 mg) were added to DMSO (1 mL) and heated at 80° C. for 30 minutes. DBU (100 μL) was added to this and heated at 100° C. for 90 minutes. A saturated aqueous solution of ammonium chloride was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain 67.6 mg of the title compound (yield 89%). 1H NMR (CDCl3, 400 MHz)δ 7.73 (d, 1 H, J = 8.0 Hz), 7.59 - 7.67 (m, 2 H), 7.38 (dd, 1 H, J = 7.2, 2.0 Hz), 7.19 - 7.28 (m, 3 H), 5.79 - 5.83 (m, 1 H), 4.05 (dd, 2 H, J = 6, 2.8 Hz), 3.53 (t, 2 H, J = 7.6 Hz), 2.67 - 2.72 (m, 2 H).LC-MS: rt 4.22 min., m / z 379 (M+1).

[0335] [Example 37] Synthesis of ethyl 5-chloro-6-(2-oxo-4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinate (compound 371) [ka]

[0336] Step 37-1 tert-Butyl 3-oxopiperazine-1-carboxylate (2.0 g, 9.99 mmol), ethyl 5,6-dichloronicotinate (2.3 g, 10.45 mmol), cesium carbonate (6.51 g, 19.98 mmol), xantphos (578 mg, 0.999 mmol) and Pd2(dba)3 (457 mg, 0.499 mmol) were added to toluene (20 mL) and heated at 120°C under nitrogen atmosphere for 3 hours. The reaction solution was passed through a silica gel pad and the filtrate was concentrated. The residue was purified by preparative silica gel column chromatography (hexane / ethyl acetate) to obtain 2.67 g of tert-butyl 4-(3-chloro-5-(ethoxycarbonyl)pyridin-2-yl)-3-oxopiperazine-1-carboxylate (70% yield). 1H NMR (CDCl3, 400 MHz)δ 9.05 (d, 1 H, J = 1.6 Hz), 8.40 (d, 1 H, J = 1.6 Hz), 4.43 (q, 2 H, J = 7.2 Hz), 4.20 - 4.35 (m, 2 H), 4.05 (brm, 1 H), 3.84 (brm, 2 H), 3.61 (brm, 1 H), 1.50 (s, 9 H), 1.41 (t, 3 H, J = 7.2 Hz).LC-MS: rt 2.82 min., m / z 328 (M+1).

[0337] Step 37-2 4-(3-chloro-5-(ethoxycarbonyl)pyridin-2-yl)-3-oxopiperazine-1-carboxylate tert-butyl (369 mg, 0.961 mmol) was added to a 4 N hydrochloric acid / ethyl acetate mixture (5 mL) and stirred at room temperature overnight. The solvent was concentrated to dryness to give 5-chloro-6-(2-oxopiperazin-1-yl)nicotinic acid ethyl hydrochloride. The residue was used in the next step without purification. 1 H NMR (DMSO, 400 MHz)δ 8.21 (br, 1 H), 7.08 (br, 1 H), 4.06 (br, 2 H), 3.63 (q, 2 H, J = 7.2 Hz), 2.89 - 3.42 (brm, 4 H), 0.61 (t, 3 H, J = 7.2 Hz).LC-MS: rt 1.37 min., m / z 284 (M+1).

[0338] Step 37-3 5-Chloro-6-(2-oxopiperazin-1-yl)ethyl nicotinate hydrochloride (296 mg, 0.925 mmol) and triethylamine (0.515 mL, 3.7 mmol) were added to DMF (6 mL) to prepare solution 1. 0.925 mmol of 2-fluoro-N-hydroxy-6-(trifluoromethyl)benzimidoyl chloride was added to DMF to prepare solution 2 (0.88235 mmol / mL in DMF). Solution 2 was added to solution 1 at room temperature and stirred overnight. 10% KHSO4 aqueous solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed with an aqueous solution of NaHCO3, dried over magnesium sulfate, the solvent was removed under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain (Z)-5-chloro-6-(4-((2-fluoro-6-(trifluoromethyl)phenyl)(hydroxyimino)methyl)-2-oxopiperazin-1-yl)ethyl nicotinate (compound 372(Z)) (262.3 mg, Rf = 0.4, 1:1 hexane / ethyl acetate). Yield 58%. 1 H NMR (CDCl3, 400 MHz)δ 9.00 (d, 1 H, J = 1.6 Hz), 8.38 (d, 1 H, J = 1.6 Hz), 8.17 (br, 0.5 H), 7.54 - 7.58 (m, 2 H), 7.32 - 7.40 (m, 1 H), 4.42 (q, 2 H, J = 7.2 Hz), 3.58 - 4.30 (br, 4.5 H), 1.40 (t, 3 H, J = 7.2 Hz).LC-MS: rt 2.61 min., m / z 489 (M+1).

[0339] Step 37-4 (Z)-5-chloro-6-(4-((2-fluoro-6-(trifluoromethyl)phenyl)(hydroxyimino)methyl)-2-oxopiperazin-1-yl)ethyl nicotinate (compound 372(Z); 128.8 mg) and p-toluenesulfonic acid (10 mg) were added to DMSO (2 mL) and heated at 80° C. for 1 hour. DBU (910 μL) was added to this and heated at 120° C. for 30 minutes. A saturated aqueous ammonium chloride solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by preparative silica gel column chromatography (ethyl acetate / hexane) to obtain the title compound (50 mg, Rf = 0.4, 1:1 hexane / ethyl acetate). 1 H NMR (CDCl3, 400 MHz)δ 9.04 (d, 1 H, J = 1.6 Hz), 8.43 (d, 1 H, J = 1.6 Hz), 7.79 (dd, 1 H, J = 1.6, 7.2 Hz), 7.65 - 7.71 (m, 2 H), 4.44 (q, 2 LC-MS: rt 2.66 min., m / z 441 (M+1).

[0340] [Example 38] Synthesis of 5-chloro-6-(2-oxo-4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid (compound 381) [ka]

[0341] Ethyl 5-chloro-6-(2-oxo-4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinate (Compound 371; 45 mg) was added to DME (2 mL), and 2 N aqueous sodium hydroxide solution (1 mL) was added and stirred at room temperature overnight. The solution was concentrated under reduced pressure and neutralized by adding 1 N hydrochloric acid (2 mL). The resulting powder was collected by filtration and dried under reduced pressure to obtain 18.3 mg of the title compound. 1 H NMR (DMSO, 400 MHz)δ 8.96 (d, 1 H, J = 1.6 Hz), 8.42 (d, 1 H, J = 1.6 Hz), 8.10 - 8.16 (m, 1 H), 7.86 - 7.89 (m, 2 H), 4.02 - 4.15 (m, 3 H), 3.62 - 3.75 (m, 3 H). LC-MS: rt 2.66 min., m / z 441 (M+1).

[0342] [Example 39] Synthesis of methyl 3-chloro-4-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)benzoate (Compound 391) [ka]

[0343] Following the procedure of Example 36, except substituting methyl 4-bromo-3-chlorobenzoate for 1-chloro-2-iodobenzene, the title compound was obtained. 1H NMR (CDCl3, 400 MHz)δ8.05 (d, 1 H, J = 1.2 Hz), 7.92 (dd, 1 H, J = 1.2, 8.4 Hz), 7.76 (d, 1 H, J = 7.2 Hz), 7.62 - 7.68 (m, 2 H), 7.57 (d, 1 H, J = 8.4 Hz), 5.83 (m, 1 H, J = 7.6 Hz), 4.87 (dd, 1 H, J = 3.6, 8.0 Hz), 4.10 - 4.16 (m, 1 H), 3.92 (s, 3 H), 3.64 - 3.71 (m, 1 H), 3.51 - 3.58 (m, 1H), 2.36 - 2.46 (m, 1 H), 1.86 - 1.95 (m, 1 H). LC-MS: rt 3.72 min., m / z 437 (M+1).

[0344] [Example 40] Synthesis of methyl 3-chloro-4-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)benzoate (Compound 401) [ka]

[0345] The title compound was obtained by following the procedure of Example 38, except that methyl 3-chloro-4-(1-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)benzoate (Compound 391) was used instead of Compound 371. 1H NMR (CDCl3, 400 MHz)δ8.13 (d, 1 H, J = 2 Hz), 7.97 (dd, 1 H, J = 2, 7.6 Hz), 7.74 (d, 1 H, J = 7.6 Hz), 7.62 - 7.68 (m, 2 H), 7.39 (d, 1 H, J = 8 Hz), 5.87 - 5.91 (m, 1 H), 4.05 - 4.09 (m, 2 H), 3.54 (t, 2 H, J = 6.8 Hz), 2.68 - 2.73 (m, 2 H). LC-MS: rt 3.40 min., m / z 423 (M+1).

[0346] [Example 41] Synthesis of 3-(4-(2-chlorophenyl)piperazin-1-yl)-4-iodobenzo[d]isoxazole (Compound 411) [ka]

[0347] Step 41-1 A solution of 2-fluoro-6-iodobenzaldehyde (2.5 g, 10 mmol) in ethanol (15 mL) was added with hydroxylamine hydrochloride (0.790 g, 11 mmol) in 2N aqueous sodium hydroxide solution (5.5 mL, 11 mmol) and stirred at room temperature overnight. Water was added to the reaction solution, and the precipitated crystals were collected by filtration, washed with water, and dried under reduced pressure to obtain 2-fluoro-6-iodobenzaldehyde oxime (2.505 g).

[0348] Step 41-2 To a solution of 2-fluoro-6-iodobenzaldehyde oxime (0.530 g, 2 mmol) in DMF (10 mL) was added NCS (N-chlorosuccinimide) (0.276 g, 2 mmol) and stirred at room temperature overnight. LC / MS showed 100% conversion of the oxime to the chloride. The solution of 2-fluoro-N-hydroxy-6-iodobenzimidoyl chloride was used in the next reaction without purification.

[0349] Step 41-3 A solution of 1-(2-chlorophenyl)piperazine (176 μL, 1 mmol) and triethylamine (168 μL, 1.2 mmol) in DMF (1 mL) was added to a DMF solution of 2-fluoro-N-hydroxy-6-iodobenzimidoyl chloride (5 mL, approximately 1 mmol) from step 41-2 at room temperature and stirred overnight. A saturated aqueous ammonium chloride solution and water were added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was removed under reduced pressure to obtain (E)-(4-(2-chlorophenyl)piperazin-1-yl)(2-fluoro-6-iodophenyl)methanone oxime (compound 412(E)) and its Z isomer (compound 412(Z)) as an E / Z mixture (657.8 mg).

[0350] Step 41-4 (4-(2-chlorophenyl)piperazin-1-yl)(2-fluoro-6-iodophenyl)methanone oxime (657 mg, 1 mmol) and p-toluenesulfonic acid (approximately 10 mg) were added to DMSO (5 mL) and heated at 80°C for 2 hours. DBU (diazabicycloundecene; 238 μL) was added to this and heated at 120°C for 60 minutes. A saturated aqueous ammonium chloride solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate / hexane = 10:1 to 3:1) to obtain 295.8 mg of the title compound. 1H NMR (CDCl3, 400 MHz)δ7.47 (t, 0.5 H, J = 7.6 Hz), 7.46 (t, 0.5 H, J = 7.6 Hz), 7.39 (dd, 1 H, J = 1.2, 8.0 Hz), 7.28 (d, 1 H, 8.0 Hz), 7.25 (dt, 1 H, J = 1.2, 7.6 Hz), 7.10 (dd, 1 H, J = 1.2, 6.8 Hz), 7.01 (dt, 1 H, J = 1.2, 7.6 Hz), 6.93 (d, 0.5 H, J = 8.0 Hz), 6.91 (d, 0.5 H, J = 8.0 Hz), 3.67 - 3.72 (m, 4 H), 3.23 - 3.28 (m, 4 H), LC-MS: rt 4.18 min., m / z 440 (M+1).

[0351] [Example 42] Synthesis of 3-(4-(2-chlorophenyl)piperazin-1-yl)-4-cyanobenzo[d]isoxazole (Compound 421) [ka]

[0352] 3-(4-(2-chlorophenyl)piperazin-1-yl)-4-iodobenzo[d]isoxazole (compound of Example 41, 183 mg, 0.42 mmol), zinc cyanide (73 mg, 0.62 mmol), and tetrakistriphenylphosphine palladium (48 mg, 0.042 mmol) were added to DMF (5 mL) and stirred under nitrogen at 80° C. for 7 hours. An aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate / hexane=10:1 to 3:1) to obtain 119 mg of the title compound. 1H NMR (CDCl3, 400 MHz)δ7.76 (d, 1 H, J = 8.0 Hz), 7.68 (d, 1 H, J = 6.4 Hz), 7.62 (dd, 1 H, J = 8.0 Hz), 7.39 (dd, 1 H, J = 1.2, 7.6 Hz), 7.25 (dt, 1 H, J = 1.2, 8.0 Hz), 7.15 (dd, 1 H, J = 2.0, 8.0 Hz), 7.01 (dt, 1 H, J = 1.6, 8.0 Hz), 3.64 - 3.69 (m, 4 H), 3.32 - 3.36 (m, 4 H), LC-MS: rt 3.73 min., m / z 339 (M+1).

[0353] [Example 43] Synthesis of 3-(4-(2-chlorophenyl)piperazin-1-yl)benzo[d]isoxazole-4-carboxamide (compound 431) [ka]

[0354] 3-(4-(2-chlorophenyl)piperazin-1-yl)-4-cyanobenzo[d]isoxazole (the compound of Example 42, 37.8 mg, 0.11 mmol) was dissolved in a mixed solution of 1,4-dioxane (2 mL) and ethanol (2 mL), and a saturated lithium hydroxide aqueous solution (1 mL) was added and reacted in a microwave reactor at 150° C. for 2 hours. The mixture was neutralized with an aqueous hydrochloric acid solution and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by distillation with 100% ethyl acetate using silica gel column chromatography, followed by distillation with 5% methanol / ethyl acetate to obtain a mixture containing the title compound. The mixture was dissolved in ethyl acetate and washed three times with saturated sodium bicarbonate water. The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (27.9 mg). 1H NMR (CDCl3, 400 MHz)δ8.27(bs, 1 H,), 8.04 (dd, 1 H, J = 0.8, 7.6 Hz), 7.69 (dd, 1 H, J =1.2, 8.4 Hz), 7.64 (dd, 1 H, J = 7.2, 8.4 Hz), 7.38 (dd, 1 H, J = 1.2, 7.6 Hz), 7.25 (dt, 1 H, J = 1.6, 7.6 Hz), 7.08 (dd, 1 H, J = 1.2, 7.6 Hz), 7.02 (dt, 1 H, J = 1.2, 7.6 Hz), 6.17 (bs, 1 H)3.52 - 3.57 (m, 4H), 3.23 - 3.29 (m, 4H), LC-MS: rt 3.00 min., m / z 357 (M+1). (L-0003)

[0355] [Test Example 1] Calcium assay using HEK293 cells transiently expressing TRPC channels 1. Introduction and expression of TRPC channels into cells The TRPC6 gene was introduced into HEK293 cells (human fetal kidney-derived cells) by lipofection, and the TRPC6 channel was expressed in the cell membrane. Specifically, the TRPC6 plasmid DNA (pCI-neo (Promega)) was introduced into HEK293 cells using a lipofection agent, and the cells were cultured at 37°C for 24 to 48 hours to express the TRPC6 channel in the cell membrane. Similarly, the TRPC3 gene-introduced HEK293 cells were cultured to express the TRPC3 channel in the cell membrane.

[0356] 2. Measurement of calcium ion concentration changes in TRPC-expressing cells The cultured cells were detached with trypsin, re-seeded on a cover glass, and then cultured again at 37°C for 3 hours. The calcium indicator Fura-2 AM was added to the medium and cultured at 37°C for 30 minutes to allow it to be taken up by the cells. The extracellular solution contained Ca 2+ Containing solution and Ca 2+ A free solution was prepared.

[0357] Ca 2+Containing solution: (2 mM CaCl2, 132 mM NaCl, 4 mM KCl, 1 mM MgCl2, 5 mM glucose, 5 mM HEPES (pH 7.4)) Ca 2+ Free solution: (132 mM NaCl, 4 mM KCl, 1 mM MgCl2, 5 mM glucose, 5 mM HEPES (pH 7.4))

[0358] Ca 2+ After the cells were placed in the solution, the following operations were carried out while measuring the fluorescence intensity (510 nm) of Fura-2 over time at room temperature using an ARGUS CA-20 (Hamamatsu Photonics).

[0359] 0 minutes:Ca 2+ Place TRPC3- or TRPC6-expressing cells in the measurement chamber containing the solution. After 30 seconds: Ca 2+ Ca-containing solution 2+ Replace with free solution After 1 minute: Ca 2+ Add a given amount of test compound to the free solution. 3 minutes later: Ca 2+ Add carbachol (100 μM) to the free solution. After 7 minutes: Ca 2+ Ca-free solution containing test compounds and carbachol (100 μM) 2+ Replace with a solution containing After 15 minutes: Measurement completed

[0360] Compound 011 was used as the test compound, and the amount added was 0.01, 0.1, 0.5, 1.0, 5.0, 10, or 50 μM. In addition, 0.1% DMSO was used as a control instead of the test compound. Carbachol (cch) is a TRPC channel activator, and when it is applied to cells, it opens the TRPC channel and activates Ca in the extracellular solution. 2+In addition, Fura-2 AM has high cell membrane permeability due to the presence of the AM group (acetoxymethyl group), and is easily taken up into cells. In the cells, the AM group is hydrolyzed to become Fura-2, resulting in the Ca 2+ This enables chelation, and the loss of the AM group makes it less likely for the protein to leak out of the cell.

[0361] The results of calcium imaging in TRPC6-expressing cells and TRPC3-expressing cells are shown in Figures 1 and 2, respectively. 2+ The concentration of the control (DMSO) increased from about 100nM to about 280nM (TRPC6, Figure 1) or from about 100nM to about 350nM (TRPC3, Figure 2) by adding carbachol (cch), whereas the concentration of the test compound (compound 011) increased from about 100nM to about 140nM (TRPC6, Figure 1) or from about 100nM to about 180nM (TRPC3, Figure 2), confirming the inhibition of activation of TRPC6 and TRPC3 channels. In addition, concentration-response curves were created from the measurement results, and the IC 50 were 4.6 μM (TRPC6) and 0.7 μM (TRPC3).

[0362] [Test Example 2] Calcium assay using HEK293 cells transiently expressing TRPC6 channels. TRPC6-expressing cells were prepared in the same manner as in Test Example 1. Except for using 10 μM Pyr 4 and 10 μM compounds 011, 031, 041, and 191 as test compounds, the same procedure as in Test Example 1 was used from 7 minutes after the start of measurement (i.e., Ca 2+The maximum calcium ion concentration was measured in the 100-well plate (after replacement with the calcium ion-containing solution). The average calcium ion concentration up to 30 seconds after the start of measurement (initial calcium ion concentration) was subtracted from this maximum calcium ion concentration to calculate the calcium ion increase. The results are shown in Figure 3. In Figure 3, the calcium ion increase is expressed as a relative value, with the calcium ion increase in the control (DMSO) taken as 100%. The addition of the test compound reduced the amount of calcium ions flowing into the cells, confirming the inhibition of TRPC6 channel activation.

[0363] [Test Example 2-1] Calcium assay using HEK293 cells transiently expressing TRPC6 channel Calcium ion concentration was measured and calcium ion increase was calculated in the same manner as in Test Example 2, except that 10 μM of compounds 011, 361, 362(E), 362(Z), 371, 372(Z), 381, and 401 were used as test compounds and Pyr 4 was not used. The calcium ion increase of each test compound is shown in Table 2 as a relative value with the calcium ion increase in the control (DMSO) taken as 100%. [Table 2]

[0364] Addition of the test compound reduced calcium ions flowing into the cells, confirming inhibition of TRPC6 channel activation.

[0365] [Test Example 3] Calcium assay using HEK293 cells transiently expressing TRPC6 channel Calcium ion concentration was measured and calcium ion increase was calculated in the same manner as in Test Example 2, except that 10 μM Pyr 4 and 10 μM compounds 202(E), 061, and 071 were used as test compounds, and ATP was used instead of carbachol as a TRPC channel activator. The results are shown in Figure 4. In Figure 4, the calcium ion increase is expressed as a relative value with the calcium ion increase in the control (DMSO) taken as 100%. The addition of the test compound reduced the amount of calcium ions flowing into the cells, confirming the inhibition of TRPC6 channel activation.

[0366] [Test Example 4] Electrophysiological evaluation using HEK293 cells transiently expressing TRPC6 channels Evaluation was performed using TRPC6 expressing cells cultured under the same treatment as in Test Example 1. The transfected cells were placed in a chamber installed in a microscope, and TRPC6 current was measured in whole cell mode using a patch glass electrode (5-10 MΩ). The extracellular and intracellular solutions used here are as follows.

[0367] Extracellular solution: (140mM NaCl, 5mM KCl, 1mM CaCl2, 1.2mM MgCl2, 10mM Glucose, 10mM HEPES (pH7.4)) Intracellular solution: (120mM CsOH, 120mM Aspartate, 20mM CsCl, 2mM MgCl2, 1.5mM CaCl2, 5mM EGTA, 10mM Glucose, 10mM HEPES, 2mM ATP-Na, 0.1mM GTP (pH7.4))

[0368] The holding potential was fixed at -50 mV. TRPC current was induced by adding carbachol (100 μM) to the cells. 20 seconds after the addition of carbachol, 30 μM of a test compound (compound 011) was added to the cells for 30 seconds, and the change in current was evaluated.

[0369] The results of Test Example 4 (effect of compound 011 on TRPC6 current induced by carbachol (cch)) are shown in Figure 5. The left figure in Figure 5 shows a trace at -50 mV. The right figure in Figure 5 shows a current-voltage characteristic curve measured by applying a ramp wave (linear voltage of -100 to +100 mV) for about 1 second at two time points a and b in the left figure. Since a significant decrease in the amount of current was observed after the addition of the test compound, an inhibitory effect on TRPC6 channel activation was observed by the addition of the test compound.

[0370] [Test Example 5] Fibrosis inhibition evaluation experiment 1 (Western blotting and cell morphology observation) The expression of α-smooth muscle actin (α-SMA) in fibroblasts was evaluated by Western blot. Dermal fibroblasts were isolated from 1-3 day old mice and 2.5x10 5Cells were seeded onto a 12-well plate. After 24 hours, the medium was replaced with one lacking fetal bovine serum and cultured for another 24 hours. After that, 10 ng / ml transforming growth factor β1 (TGFβ1) was added and cultured for 48 hours. At the same time as adding TGFβ1, a test compound (compound 011) at a specified concentration (0.1 μM, 1 μM, 10 μM), 10 μM Pyr 2, or DMSO (solvent control) was also added. After culture, the morphology of the cells was observed using an all-in-one fluorescence microscope (Keyence BZ-X700) (magnification 20x). After incubation, the cells were lysed in lysis buffer (140 mM NaCl, 20 mM Tris-HCl pH7.8, 1% Triton-X100, 0.05% sodium deoxycholate, 0.1% SDS, 2 mM EDTA, proteinase inhibitor cocktail) and separated by SDS-PAGE. α-SMA was detected using anti-α-SMA antibody (Sigma) as the primary antibody and anti-mouse IgG antibody fused with horse radish peroxidase (Cell signaling) as the secondary antibody.

[0371] The results of the Western blot are shown in Figure 6. Figure 6 shows that the test compounds (especially 10 μM) and Pyr 2 caused the color development of the α-SMA antibody to be weaker compared to the control (DMSO TGFβ1+), confirming that the test compounds strongly inhibited the expression of α-SMA induced by TGFβ1.

[0372] Furthermore, microscopic observation revealed that the addition of Pyr 2 induced cell elongation, whereas the addition of the test compound did not result in any change in cell morphology or cytotoxicity.

[0373] [Test Example 6] Fibrosis inhibition evaluation experiment 2 (immunofluorescence staining method) Dermal fibroblasts were isolated from mice in the same manner as in Test Example 5, and sterilized cover glasses with a diameter of 12 mm were placed in a 12-well plate. 5Cells were seeded and grown on cover slips. After 24 hours, the medium was replaced with one lacking fetal bovine serum and cultured for another 24 hours. Cardiac fibroblasts were also isolated from 1-2 day old rats and treated in the same manner as for skin fibroblasts. Then, 10 ng / ml of TGFβ1 was added to the skin fibroblasts, and 2 ng / ml of TGFβ2 was added to the cardiac fibroblasts, and the cells were cultured for 48 hours. At the same time as the addition of TGFβ, 10 μM of the test compound (compound 011), 10 μM of Pyr 2 (conventional inhibitor) or DMSO (solvent control) were also added. Separately, cells were prepared by adding phosphate buffered saline (PBS) without TGFβ to the cultured cells. After the culture, the cells were fixed with 4% paraformaldehyde and permeabilized with Tris buffered saline pH 7.4 (TBS) containing 0.5% Triton-X100. After blocking with 1% bovine serum albumin, α-SMA was detected using anti-α-SMA antibody (Sigma) as the primary antibody and anti-mouse IgG antibody fused with Alexa488 (Molecular probe) as the secondary antibody, and images were taken using a fluorescence microscope (Keyence) with a 20x objective lens. The average fluorescence intensity per cell area (fluorescence intensity / pixel) was calculated and analyzed using Image J software.

[0374] The results of fluorescent staining are shown in Figure 7 (skin fibroblasts) and Figure 8 (cardiac fibroblasts). In both cells, TGFβ treatment enhanced the expression of fibrous α-SMA. Compound 011, similar to Pyr2, almost completely suppressed the expression of α-SMA induced by TGFβ.

[0375] [Test Example 7] Creation of an animal model of drug-induced hearing loss Cisplatin injection solution (Nichi-Iko, 0.5 mg / ml) was intraperitoneally administered at 12 mg / kg to 5-8 week-old male CBA / N mice purchased from Japan SLC Co., Ltd., and the hearing levels of the mice were tested by auditory brainstem response (ABR) measurement 7 and 14 days later. It was confirmed that intraperitoneal administration of cisplatin (CDDP) reduced hearing levels in a wide frequency range from 5 to 36 kHz.

[0376] Auditory brainstem response (ABR) measurement Mice were intraperitoneally administered a triple anesthesia mixture (medetomidine hydrochloride 0.3 mg / kg, midazolam 4 mg / kg, butorphanol tartrate 5 mg / kg), and sufficient anesthesia was confirmed by toe pinch or corneal reflex. First, stainless steel needle electrodes (Terumo 26 gauge) for measuring electroencephalograms were inserted subcutaneously on the top of the head, behind the ears, and on the back, and the output port of a speaker (TD-250D; Fostex, Japan) was inserted into the left ear canal of the mouse. Tone bursts with five frequencies (5, 10, 16, 24, and 36 kHz) and 0.5 ms rising and falling phases and a 2 ms steady phase were presented as sound stimuli. The potential changes in the neurons in the auditory pathway induced by the sound stimulus were amplified 5000-fold using a signal amplifier (EX-1 Differential amplifier; Dagan Corporation, MN, USA), and band-pass filtered at 0.3-2 kHz to obtain ABR data. Each data was integrated and averaged for 800 stimuli and used for analysis. The hearing threshold for each frequency was determined as the lowest sound pressure level at which ABR waves II and III were clearly observed when the sound pressure was changed in 10 dB increments. The voltage-sound pressure characteristics of the speaker were calibrated in advance using a microphone (Sokolich G-II Ultrasonic Probe Microphone System; WGS / Associates, CA, USA), and the stimulus sounds of each frequency were generated accordingly. After the measurements, the mice were promptly awakened by intraperitoneal administration of 0.3 mg / kg of antisedan.

[0377] Evaluation of sample (compound 011) Compound 011 was suspended in PBS (Fujifilm, Japan; phosphate buffer) at 2 mg / ml to prepare a sample. This sample was orally administered to 5-8 week old male CBA / N mice at 10 mg / kg once a day from the day before cisplatin administration until 14 days after cisplatin administration, and the inhibitory effect of compound 011 on hearing loss was evaluated. The mice used for the measurement were divided into the following three groups. Group 1: Group receiving intraperitoneal administration of cisplatin and oral administration of PBS (control) (n=12) Group 2: Group receiving intraperitoneal administration of cisplatin and oral administration of Compound 011 (n=12) Group 3: A group receiving intraperitoneal administration of saline as a control for cisplatin administration and oral administration of compound 011 (n=10) For each group, hearing levels were determined immediately before cisplatin administration, and 7 and 14 days after administration by auditory brainstem response (ABR) measurement. The results are shown in Figures 9 and 10. The results from Group 1 show that cisplatin administration caused an increase in the hearing threshold. The results of the second group show that administration of compound 011 significantly inhibited the increase in the hearing threshold. The results of the third group show that administration of Compound 011 does not significantly alter the hearing thresholds of mice under normal conditions. From the above, it was confirmed that compound 011 can suppress hearing loss by simple oral administration.

[0378] [Test Example 8] Effect of intraperitoneal administration of compound 011 on plasma cisplatin kinetics Cisplatin injection solution (Nichi-Iko, 0.5 mg / ml) was intraperitoneally administered at 12 mg / kg to male CBA / N mice aged 5 to 8 weeks purchased from Japan SLC Co., Ltd., and blood was collected from the tail vein one and two days later. The blood was centrifuged at 4°C and 1000 g for 5 minutes, and the supernatant was used as a plasma sample. The plasma sample was analyzed by Shimadzu Techno Research's high-frequency inductively coupled plasma (ICP) mass spectrometry to evaluate the plasma platinum (plasma Pt) concentration, which reflects the plasma cisplatin concentration. PBS (Fujifilm, Japan; phosphate buffer solution) or a solution obtained by suspending compound 011 in PBS at 2 mg / ml was orally administered at 10 mg / kg once a day from the day before cisplatin administration to two days after cisplatin administration, and the mice were classified as a control group (n=5) and a compound administration group (n=5), respectively. As a pretreatment for ICP mass spectrometry, 0.5 ml of nitric acid was added to the plasma sample, the container was sealed, and then it was subjected to microwave digestion (ETHOS-TC, Milestone General) at 180 °C for 5 minutes. After cooling, 0.5 ml of hydrochloric acid was added, and the volume was adjusted to 5 ml with water, and then it was subjected to ICP mass spectrometry using an Agilent 7700x ICP-MS (Agilent technologies, CA, USA) (PF output 1550 W, plasma gas 15.0 L / min, auxiliary gas 0.90 L / min, carrier gas 1.0 L / min, sampling depth 10 mm). Each sample was measured three times under the conditions of an integration time of 1 second and 100 sweeps. The measured mass numbers were 195 for the analyte Pt and 103 for the internal standard Rh. The results are shown in Figure 11.

[0379] No significant change in plasma Pt concentration was observed with or without compound 011 one day or two days after administration of cisplatin. In other words, it was suggested that administration of compound 011 does not affect the blood kinetics of cisplatin. Considering this together with the results of the hearing test using a cisplatin-induced hearing loss model (Test Example 7), it was suggested that the hearing protection effect of compound 011 is not simply a result of lowering the concentration of cisplatin in the body, but a result of protecting cells involved in hearing from the toxicity of cisplatin.

[0380] [Test Example 9] Protective effect of 1-(4-(4-methyl-1,2,3-thiadiazole-5-carboxamido)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (ethyl Pyr4) on the inner ear (evaluation of hair cell death using zebrafish neuromasts)

[0381] Pyr4 is known to have TRPC3 and TRPC6 inhibitory effects.

[0382] Hair cell death is known to be a common factor in progressive hearing impairment caused by various environmental factors (excessive noise, drugs (chemotherapeutic agents such as aminoglycoside antibiotics and cisplatin, aging, etc.)). Screening evaluation based on hair cell death is used to develop drugs to treat hearing loss. Zebrafish neuromasts are used for this screening (C. Ton and C. Parng, The use of zebrafish for assessing ototoxic and otoprotective agents. Hearing research, 208, 79-88 (2005)). Zebrafish have a lateral line on the body surface that consists of neuromasts composed of hair cells, and these hair cells are morphologically and functionally similar to the hair cells in the mammalian inner ear, making neuromasts useful for evaluating mammalian hair cell death. Because neuromasts develop in defined locations along the head and body of the zebrafish, fluorescence imaging can be used to easily identify hair cell loss and hair cell death due to drug sample application and to quantify the effect of drug samples on hair cells.

[0383] Ten embryos (zebrafish larvae, 5 embryos per well in 2 wells) were used for each test. Test substances were 1.5 μM and 3 μM Pyr4. As a vehicle control group, untreated embryos were used in rearing medium (0.16 mM MgSO4, 0.4 mM CaCl2, 0.17 mM KCl, 5 mM NaCl, 10 mM Hepes (pH 7.2 - 7.6) + 0.5% DMSO). Embryos treated with 1000 μM D-methionine in the rearing medium served as a positive control group. Embryos treated with 20 μM cisplatin in the rearing medium were used as the ototoxicity induction group (cisplatin treatment group). Embryos (fry on the 5th day after fertilization) were pretreated with the test substance, D-methionine, or vehicle control for 1 hour at 28.5°C, and then exposed to cisplatin. After that, they were reared at 28.5°C for 24 hours and then stained as follows. The medium was replaced with 0.01% DASPEI (2-(4-(dimethylamino)styryl)-N-ethylpyridinium iodide) and the plates were incubated in the dark for 15 min at room temperature, after which they were washed three times for 5 min with culture medium. After staining, embryos were anesthetized with 0.003% tricaine, placed on their lateral side in methylcellulose, and images were acquired using a Leica stereoscope and LAS AF software. Images were used to quantify the number of neuromasts present in the lateral line of each embryo. In addition, embryos were classified into three different categories based on neuromast fluorescence intensity (i: bright, ii: dim, iii: barely or no detect). The percentage of embryos belonging to each category was determined for each experimental group. After all photographs were taken, embryos were euthanized.

[0384] The number of neuromasts is shown in Figure 12, and the percentage of each category based on fluorescence intensity is shown in Table 3. In Table 3, CISP and CISPL stand for cisplatin, and Met stands for methionine. [Table 3]

[0385] The experiment was considered valid because the percentage of intact embryos in the untreated control group was over 80%. Furthermore, the number of neuromasts in cisplatin-treated embryos was statistically significantly lower than that in the vehicle control group. Exposure to D-methionine alone caused a slight decrease in the number of neuromasts, probably due to normal variations in staining and unrelated to any specific effect. D-methionine inhibited the decline in neuromast number caused by cisplatin treatment. Treatment with Pyr4 did not affect neuromast viability at any of the concentrations evaluated and inhibited the neuromast loss induced by cisplatin treatment. Similar effects were seen at both 1.5 and 3 μM concentrations, which may indicate that a plateau was reached.

Claims

1. A pharmaceutical composition for preventing and / or treating hearing loss, comprising 5-chloro-6-(4-(4-(trifluoromethyl)benzo[d]isoxazol-3-yl)piperazin-1-yl)nicotinic acid or a salt thereof.

2. 2. The pharmaceutical composition according to claim 1, which is for oral administration.

3. The pharmaceutical composition according to claim 1 or 2, wherein the hearing loss is sensorineural hearing loss.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the hearing loss is caused by a platinum preparation.

Citation Information

Patent Citations

  • Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds

    JP1996506094A

  • Di-t-butylphenyl piperazines as calcium channel blockers

    US20090270413A1

  • Inhibitors of TRPC6

    US20190169168A1

  • Benzisoxazole compound

    WO2019208812A1

  • Cyclopentane compounds

    WO2019215268A1